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Abstract  
Objective 
To study the clinicopathological features of cutaneous lymphomas and the role of TCR gene 
rearrangement in the diagnosis ofpatch/plaque (Stage I/IIA) mycosis fungoides where the 
histological diagnosis of mycosis fungoides could not be excluded or the diagnosis was 
suggestive but not confirmatory. 
Method 
 Ahospital based cross sectional study was conducted from November 2012 to August 
2014 where in patients with a diagnosis of cutaneous lymphoma (CL)were included. 
Diagnosis was established by histology and immunohistochemistry and classified based on 
WHO-EORTC classification. TCR gamma gene rearrangement assay was done by PCR in 
patch/plaque (Stage I/IIA) mycosis fungoides (MF) where the histological diagnosis of 
mycosis fungoides could not be excluded or the diagnosis was suggestive but not 
confirmatory. Routine laboratory tests; lymph node, bone marrow biopsies and imaging were 
done when indicated for staging based on the ISCL/EORTC proposal.  
Results 
There were 54 patients (M/F-1.25) with CL.This included primary cutaneous T-cell 
lymphomas (CTCL) (48), secondary CTCL (4), primary cutaneous B-cell lymphoma (CBCL) 
(1)and secondary CBCL (1). Among CTCL there were 27 cases of MF, LyP (lymphomatoid 
papulosis) (8), SPTL (subcutaneous panniculitis like T-cell lymphoma) (6), ALCL 
(Anaplastic large cell lymphoma) (3), PTCL, NOS (peripheral T-cell lymphoma, not 
otherwise specified) (3) and HVLL (hydroa vacciniforme like T-cell lymphoma) (1). Mean 
age at diagnosis of MF, CD30+ LPD, SPTL and PTCL, NOS were 41.1±18.8 years, 
33.8±17.1 years, 33.6±17.3 years and 56.3±18.9 years respectively.Paediatric CL accounted 
for 16.7% of cases. The most common type of CTCL in the paediatric age group (≤20 years) 
was MF (n=4, 44.4%) followed by LyP (n=2, 22.2%), SPTL (n=2, 22.2%) and HVLL (n=1, 
11.1%). Male preponderance was noted in all subtypes of cutaneous lymphoma except SPTL. 
Unusual clinical types of MF in our study included hypopigmented MF and dyshidrosiform 
MF. MF with palmoplantar involvement was seen in 14.8% patients. Among the unusual 
types of CTCL (other than MF) seen in our study were one case each of erythrodermic 
ALCL, LyP type D and HVLL. Clonality detection rate among early stage MF in our study 
was 61.5%. Statistical significance of clonal detection with histological grading and 
immunohistochemistry findings was not found in our study. 
Conclusion 
CTCL was the most common subtype as reported in earlier studies from Asian 
countries and the West. However the proportion of CBCL was lower than that reported from 
other countries. Female preponderance was noted in SPTL and rest of the subtypes showed a 
male preponderance.MF was the commonest among CTCL comprising 56.25% of all CTCLs. 
Monoclonality detection in early stage MF was slightly lower than the detection rate in 
various studies across Europe using a similar protocol. Though the statistical significance of 
clonality detection with histopathological grading of MF could not be demonstrated it was 
evident that in patients with histopathological diagnosis suggestive of MF had increased 
clonal detection rate.Usefulness of TCR clonal rearrangement studies in early MF has to be 
further evaluated with large population studies. 
Keywords 
Cutaneous lymphoma, TCR gene rearrangement study, mycosis fungoides 
INTRODUCTION 
 
In 1865, Samual Wilks coined the term Hodgkin‟s disease to represent the 
cancers of lymphatic system. It was narrowed down over many years and eventually a 
large group of lymphoma was made into a separate entity termed non-Hodgkin‟s 
lymphoma (1). Hodgkin‟s lymphoma (HL) and non-Hodgkin‟s lymphoma (NHL) were 
the two kinds of lymphoma recognized initially. There has been further progress in the 
classification of NHL with the introduction of genetics, molecular biology, and 
immunology. The term “cutaneous T-cell lymphoma” (CTCL) was used first in 1975 to 
include mycosis fungoides (MF) and its variants. The other types including CD30+ 
lymphoproliferative disorders, primary subcutaneous panniculitis-like T-cell 
lymphomas, nasal-type NK/T-cell primary cutaneous lymphoma, and non-classifiable 
T-cell PCL were included subsequently (2,3). 
Mycosis fungoides was first described in 1806 in France by Alibert, who named 
it in 1814 as “Pian fongoide”. The  term “mycosis fungoides” was only adopted by 
Alibert  in 1832 (4). It was Bazin, a student of Alibert who described its evolution 
according to the natural history of the disease and defined its stages as patch, plaque, 
tumoral and systemic dissemination in 1870. In 1938, Sezary and Bouvrain first 
described the Sezary syndrome (SS).  
Considering all NHLs, B-cell NHLs are far more common than T-cell NHLs, 
(85% versus 15%), the reason being unknown. In cutaneous lymphomas the incidence 
is reversed. B-cell lymphomas are far less common than T-cell lymphomas (20-25% 
versus 75-80%) (5). This suggests that the development of cutaneous lymphomas is 
distinct from that of other lymphomas. Men are more commonly affected than women, 
with no identifiable risk factors or causes. NHLs are more common in adults and the 
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average age of diagnosis is in the early-to-mid 60s. Most of the cutaneous lymphomas 
are indolent (non -aggressive and slow growing). Most of the studies on cutaneous 
lymphomas are from the West, or countries like South Korea and Japan (6–9).  
 
Well established cutaneous lymphomas are diagnosed by histopathological 
examination and immunohistochemical marker studies without much ambiguity. 
Molecular study (TCR gene rearrangement) plays an additional role in early lesions 
where the diagnosis of cutaneous lymphomas cannot be established confidently by the 
above modalities (10). Various studies around the world had demonstrated a wide range 
of clonality detection (40-90%) in CTCLs (11–15). Though the detection of clonality in 
early MF does not have any prognostic significance it has a significant role in diagnosis 
of early MF. 
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AIMS AND OBJECTIVES 
 
Primary objective:  
To study the clinicopathological features of primary and secondary cutaneous 
lymphomas. 
 
Secondary objective:  
To study the role of T-cell receptor gene rearrangement studies in the diagnosis 
of patch/plaque (Stage I/IIA) mycosis fungoides where in the histological diagnosis of 
mycosis fungoides could not be excluded or the diagnosis was suggestive but not 
confirmatory. 
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REVIEW OF LITERATURE 
 
Cutaneous lymphomas (CL) are extranodal non-Hodgkin lymphoma of 
malignant, mature T and B lymphocytes that target the skin and have various distinct 
clinicopathological entities with varied natural histories, clinical presentations and 
treatment options (16). Owing to the rarity and heterogeneous presentation, it poses a 
great challenge in accurate diagnosis and subsequent treatment modalities. Cutaneous 
lymphomas may be primary or secondary. Of all the extranodal lymphomas, CL 
represent 19%, with mycosis fungoides being the commonest among them (6). Primary 
cutaneous lymphomas refer to those cutaneous T-cell lymphomas (CTCL) and 
cutaneous B-cell lymphomas (CBCL) without any extracutaneous disease at the time of 
diagnosis. Secondary CL represents infiltrates of a disseminated nodal or extranodal 
lymphoma into the skin. As aids to clinical management and prognostic evaluation, 
modern classifications tend to be based on clinicopathological entities (7). Based on 
clinicopathological findings, immunophenotyping is done for delineation and accurate 
diagnosis of variants of cutaneous lymphomas.  
Cutaneous lymphomas with primary cutaneous manifestations were listed into 3 
broad categories as follows based on World Health Organization–European 
Organization for the Research and Treatment of Cancer (WHO-EORTC) joint 
classification system [Table 1] which was updated in 2008 (7,17). 
1) Cutaneous T-cell and NK cell lymphomas 
2) Cutaneous B-cell lymphomas 
3) Precursor hematologic neoplasm.  
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Table 1. WHO-EORTC classification of cutaneous lymphomas 
WHO - EORTC CLASSIFICATION OF CUTANEOUS LYMPHOMAS (7) 
Cutaneous T-cell and NK-cell lymphomas 
Mycosis fungoides (MF) 
Subtypes of MF 
Pagetoid reticulosis 
Granulomatous slack skin 
Folliculotropic MF 
Sezary syndrome 
Adult T-cell leukemia/lymphoma 
Primary cutaneous CD30+ lymphoproliferative disorders (CD30+ LPD) 
Lymphomatoid papulosis 
Primary cutaneous anaplastic large cell lymphoma 
Subcutaneous panniculitis-like T-cell lymphoma* (SPTL) 
Extranodal NK/T-cell lymphoma, nasal type (Extranodal NKTL) 
Primary cutaneous peripheral T-cell lymphoma, unspecified (PTCL, NOS) 
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (provisional) 
Cutaneous δ/γ T-cell lymphoma (provisional) 
Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma(provisional) 
Cutaneous B-cell lymphomas (CBCL) 
Primary cutaneous marginal zone B-cell lymphoma (PCMZL) 
Primary cutaneous immunocytoma 
Primary cutaneous plasmacytoma 
Follicular hyperplasia with monotypic plasma cells 
Primary cutaneous follicle center lymphoma (PCFCL) 
Growth patterns: follicular, follicular and diffuse, diffuse 
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL) 
Primary cutaneous diffuse large B-cell lymphoma, other 
Intravascular large B-cell lymphoma (IVLBCL) 
Precursor haematological neoplasm 
CD4+ ⁄ CD56+ haematodermic neoplasm (formerly blastic NK cell lymphoma) 
*By definition phenotype is T-cell receptor α/β chain positive 
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Epidemiology 
The estimated annual incidence of cutaneous lymphoma (CL) is 1:100,000 
according to the WHO (7). Most of the epidemiological studies on CL have been done 
in USA, Europe, Germany, Japan and Korea (6–9,18). A large population based study 
from US showed an increased incidence rate from 5.0/1000000 person-years during 
1980-1982 to 12.7 in 2004-05 (6). Epidemiology of CL in Asia differs from the West 
with an increased incidence of extranodal NK/T-cell lymphoma, hydroa vacciniforme 
like lymphoma (HVLL), subcutaneous panniculitis like T-cell lymphoma (SPTL) and 
adult T-cell leukemia/lymphoma and low incidence rates of cutaneous B-cell 
lymphomas (19–21) [Table 2]. 
In Europe and USA, CTCLs constitute 75%–80% and CBCLs constitute 20%–
25% of all cutaneous lymphomas (6,7). In Asia, the prevalence of CTCLs is higher than 
that reported from USA (6,8). A study from Japan showed a prevalence of mature T- 
and natural killer cell neoplasms of 85.7%, B-cell neoplasms were 12.9% and blastic 
plasmacytoid dendritic cell neoplasm was 1.4% (8). Another study from Korea showed 
a prevalence of primary and secondary cutaneous lymphomas of 74.2% and 17.9% 
respectively (9). Hospital based retrospective studies from India have shown the 
prevalence of CTCL to vary from 69% - 94% (22,23). Epidemiological data from 
multicentre studies are shown in Table 2 (6–9,18). 
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Table 2. Cutaneous lymphomas incidence pattern in various countries 
STUDY GROUP DACLG SEER JSCS KOREA DDG 
COUNTRY 
NL+A 
(2005) 
USA 
(2009) 
JAPAN 
(2014) 
KOREA 
(2014) 
GER 
(2007) 
Total no. of patients 1905 3884 1733 517 998 
 Freq% Freq% Freq% Freq% Freq% 
MATURE T-CELL AND NK-CELL 
NEOPLASMS 
77 71.3 85.7 74.2 85 
Mycosis fungoides (MF) 47 38.3 43.3 29.1 61 
Sezary syndrome (SS) 3 0.8 1.9 0.3 2 
Primary cutaneous CD30+ T-cell 
lymphoproliferative disorders 
NA 10.2 12.0 NA NA 
Primary cutaneous anaplastic large-
cell lymphoma (PCALCL) 
8 NA 7.8 8.2 7 
Lymphomatoid papulosis (LyP) 12 NA 3.8 8.5 7 
Subcutaneous panniculitis-like T-
cell lymphoma (SPTL) 
1 0.6 2.0 8.2 NA 
Peripheral T-cell lymphoma, Not 
otherwise specified (PTCL, NOS) 
2 20.8 5.8 13.5 NA 
Primary cutaneous CD4+ 
small/medium T-cell lymphoma 
2 NA 1.4 1.3 5 
Primary cutaneous δ/γ T-cell 
lymphoma 
<1 NA 0.3 2.1 NA 
Extranodal NK/T-cell lymphoma, 
nasal type (NKTL) 
<1 0.3 2.3 7.1 NA 
Adult T-cell leukemia/ lymphoma NA 0.1 16.7 0.2 NA 
MATURE B-CELL NEOPLASMS 23 28.5 12.9 17.9 15 
Extranodal marginal zone 
lymphoma of mucosa associated 
lymphoid tissue (PCMZL) 
7 7.1 4.2 5.0 7 
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Primary cutaneous follicle center 
lymphoma (PCFCL) 
11 8.5 2.1 1.1 4 
Primary cutaneous diffuse large-cell 
lymphoma, leg type (PCLBCL, leg) 
4 2.6 5.5 1.6 <2 
Primary cutaneous diffuse large-cell 
lymphoma, other 
NA NA NA NA- NA 
IMMATURE HEMATOLOGICAL 
NEOPLASMS 
NA 0.3 1.4 NA NA 
CD4+ ⁄ CD56+ haematodermic 
neoplasm (Blastic plasmacytoid 
dendritic cell neoplasm) (BPDCN) 
NA 0.2 1.4 2.1 NA 
Freq, Frequency; Figures in %; CL, Cutaneous lymphoma; DACLG, Dutch and Austrian Cutaneous Lymphoma 
Group; EORTC, European Organization for Research and Treatment of Cancer; DDG – German Society of 
Dermatology; JSCS – Japanese Skin Cancer Society; MF, mycosis fungoides; SS, Sezary syndrome; PCL, primary 
cutaneous lymphoma; PTL, peripheral T-cell lymphoma; SEER, Surveillance, Epidemiology, and End Results; 
WHO, World Health Organization; PCL, primary cutaneous lymphoma; MF, mycosis fungoides; SS, Sezary 
syndrome; NL+A, Netherlands and Austria; USA, United states of America; GER, Germany. 
 
Gender distribution [Table 3] 
Majority of studies have reported male preponderance in all subtypes of 
cutaneous lymphomas except SPTL (7–9). Equal gender distribution is noted in a study 
from Europe while rest of the studies had reported female preponderance in SPTL 
[Table 3]. A study from Japan has reported a female preponderance in NKTL and LyP 
(8). Male preponderance in cutaneous lymphomas has been reported in hospital based 
Indian studies also (22,23) [Table 4]. 
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Table 3. Gender distribution, mean age at diagnosis and 5 year survival rate 
of cutaneous lymphomas in various countries 
STUDY GROUP DACLG (7) SEER (6) JSCS (8) 
KOREA 
(9) 
 M/F AD 5 yr M/F AD 5 yr M/F AD 5 yr M/F 
MF 1.8 57.5 88 1.66 NA 90.9 1.41 62 NA 1.1 
SS NA NA 24 2.11 NA 39.5 3.71 68 NA NA 
cALCL 2.5 NA 95 1.73 NA 73.1 1.62 67.5 NA 1.3 
LyP 1.5 45 100 NA NA NA 0.83 53.5 NA NA 
SPTL 1 NA 82 NA NA NA 0.55 55 NA 0.5 
PTL NA NA 16 1.82 NA 79.1 1.09 68 NA 1.1 
NK/T NA NA NA NA NA NA 0.62 66 NA 1.5 
PCMZL NA NA 99 1.28 NA 93.1 1.00 63 NA 1.9 
PCFCL NA NA 95 1.84 NA 96.2 2.08 64 NA NA 
PCLBCL NA NA 55 1.70 NA 46.3 0.90 77 NA 1.9 
NA – Not available; M/F – Male:Female ratio; AD – Age at diagnosis; 5yr – 5 year survival rate; MF, Mycosis 
fungoides; SS, Sezary syndrome; cALCL, Primary cutaneous anaplastic large cell lymphoma; LyP,  
Lymphomatoid papulosis; SPTL, subcutaneous panniculitis like T cell lymphoma; NKTL, Natural killer/T cell 
lymphoma; PTL, Peripheral T cell lymphoma unspecified; PCMZL – Primary cutaneous marginal zone 
lymphoma; PCFCL- Primary cutaneous follicular cell lymphoma; PCLBCL – Primary cutaneous diffuse large B 
cell lymphoma, leg type 
Age distribution 
A multicentre study from US has reported that the age incidence for MF, 
cutaneous CD30+ LPD and PTCL, NOS are similar among males and females at 
younger age (<30 years), but notably higher among males at older ages (6). Age at 
diagnosis of MF varies from 55-70 years in various studies while the same for CD30+ 
LPD varies from 40-55 years (6,8,9). Most of the cutaneous lymphomas are diagnosed 
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around 6
th
 to 7
th
 decade [Table 3]. Indian studies have shown a wide range of age 
distribution in MF (20-70 years) while the range of age distribution in CBCL was 35 -
70 years [Table 4]. SPTL occurs approximately 2 decades earlier than other types of 
primary cutaneous lymphoma and predominantly affects young adults (24). 
Epidemiological  and demographical data from Indian studies are tabulated as follows 
(22,23,25) [Table 4]: 
Table 4. Frequency, age and gender distribution of cutaneous lymphomas in 
Indian studies 
CL subtypes 
George et al, 1999* Doshi et al, 2011 Burad et al, 2014# 
F % Age 
range 
M/F F% Age 
range 
M/F F % 
Age 
range 
M/F 
MF/SS 39.4% 36-70 5.5:1 74.4% 20-39 3:2 36% ~ ~ 
PCALCL 3.03% NA 1:0 2.12% NA 2:1 8.2% ~ ~ 
LYP NA NA NA 17% 41-60 2:1 8.2% ~ ~ 
SPTL 9.09% NA NA NA NA NA 24.5% ~ ~ 
NKTL NA NA NA 0.7% NA 1:0 -NA ~ ~ 
PTL 9.09% NA NA NA NA NA 19.6% ~ ~ 
AITL 3.03% NA NA NA NA NA NA ~ ~ 
CBCL 21.1% 35-70 5:1 5.67% 41-60 1.6:1 NA ~ ~ 
* Based on R.E.A.L classification; # Study included only peripheral T cell lymphomas; NA- Not 
available 
 
Cutaneous lymphomas in children 
Cutaneous lymphomas are uncommon in children. It accounts for around 6% of 
all malignant neoplasms in children. Two large studies on cutaneous lymphomas in 
children have been published from Europe and Korea (26,27). Proportion of paediatric 
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CTCLs in both studies were about 82% while that of CBCLs‟ proportion varied from 
3% to 13% (26,27). MF was the commonest CTCL in Europe and LyP was the 
commonest in Korea (26,27). Median age at diagnosis of MF varies from 14–17 years 
while the same for LyP and SPTL varies from 8-14 years and 7-20 years respectively 
(26,27). The risk of developing lymphoid malignancies in children with LyP is similar 
to that of adults (28). Long term follow up is needed in children irrespective of its 
favourable prognosis. Primary cutaneous ALCL is rare in children however systemic 
ALCL can occur in approximately 15% of childhood NHLs. Secondary cutaneous 
involvement in systemic ALCL can occur in 18-25% children (29). 
Cutaneous T-cell lymphomas 
Mycosis fungoides 
Mycosis fungoides (MF) is the most common CTCL subtype, with prevalence 
rate of 54% in US, 40-60% in Europe, 43% in Japan and 29% in Korea (6–9,18) 
[Table 2]. A recent retrospective study from India showed a prevalence of 34% of all 
CTCLs (25). Mycosis fungoides has a male predilection with  M/F ratio between 1.6 
and 2.1 (6–8). MF occurs more frequently in older individuals (>50 years) but recent 
studies had reported an increased incidence of MF in children and adolescents (16,30). 
 
Risk factors 
Male gender, black race and old age are the risk factors for the development of 
MF (6). 
Anatomical distribution 
Classical Alibert-Bazin type of MF presents with mild erythematous scaly 
annular or arcuate patches which classically involve sun-shielded areas (“bathing suit 
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distribution”). Though the early patches have predilection over unexposed areas, later 
they may become eczematous, hypopigmented or hyperpigmented. In a few patients 
erythroderma may arise de novo or from progression of patch/plaque MF. Patients who 
develop erythroderma and do not meet hematologic criteria for SS are considered as 
“erythrodermic MF” (EMF) (31).  
Subtypes and variants 
Subtypes and variants of MF include folliculotropic MF, pagetoid reticulosis 
and granulomatous slack skin. Other atypical variants including syringotropic, 
bullous/vesicular, hyperpigmented, hypopigmented, unilesional, palmoplantar, 
hyperkeratotic/verrucous, vegetating/papillomatous, ichthyosiform, pigmented purpura-
like and pustular variants had been reported in literature. Few atypical variants 
including hypopigmented, pityriasis lichenoides-like, and ichthyosiform mycosis 
fungoides are more prevalent in Asians compared to the West (20). In particular 
hypopigmented MF which mimics pityriasis versicolor, pityriasis alba, vitiligo, leprosy 
and post inflammatory hypopigmentation had increasingly been reported in Asians 
(20). 
Histopathology 
Diagnosis of MF was supported by the following histopathologic findings which 
includes superficial lymphoid infiltrate, epidermotropism without spongiosis 
(intercellular edema of the epidermis), and atypical lymphoid infiltrate which is defined 
as cells with enlarged, hyperchromatic nuclei and irregular or cerebriform nuclear 
contours. The hallmark of MF and SS is epidermotropism, but in fact well-formed 
Pautrier microabscesses are seen in only a minority of patients (19%) and in most skin 
biopsies the diagnosis of early MF rests on other histological and clinical criteria (32). 
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The lymphoid infiltrate increases in density and invade the deeper reticular dermis, and 
subsequently nuclear atypia becomes more apparent as the disease progresses from 
early stage to advanced stages. Histological, immunological and molecular biology data 
as a criterion may be of interest for the dermatologist to differentiate early MF and 
other dermatoses. Presence of epidermal lymphocytes with extremely convoluted, 
medium–large (7-9μm) nuclei aids the correct diagnosis of MF which has 100% 
sensitivity and 92% specificity (33). In 1996, Muche et al was the first to demonstrate 
circulating neoplastic lymphoid cells in early stage MF, proving the molecular basis 
and systemic nature of the early MF (34). Guitart et al in 2001 proposed a criterion for 
diagnosis of MF (35). Major criteria included: 
(1) Assessment of density of infiltrate at low power (mild perivascular, 
moderately dense perivascular or band like infiltrates and dense superficial 
infiltrate with widening of papillary dermis or involvement of deep reticular 
dermis) 
(2) Epidermotropism at medium power (focal basal epidermotropism with or 
without Pautrier‟s microabscess, basal epidermotropism with 2 or more 
Pautrier‟s microabscess and extensive epidermotropism)  
(3) Cellular atypia at high power (mild, moderate and uniform atypia).  
Minor criteria included reticular fibroplasia of papillary dermis, intraepidermal atypical 
lymphocytes and lymphocytic infiltrate without inflammatory features. Based on the 
above criteria the diagnosis was classified into: 
1. Mycosis fungoides 
2. Atypical lymphocytic infiltrates suggestive of MF 
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3. Atypical lymphocytic infiltrates where the diagnosis of MF cannot be excluded 
and 
4. Perivascular/interface dermatitis 
Immunohistochemistry 
Expression of CD4 which is a marker of mature helper T-cells is a hallmark 
finding of MF. Immunophenotypical markers which are commonly observed in MF 
includes CD2+, CD3+, CD4+, CD5+, CD45RO+, CLA+ (cutaneous lymphoid 
antigen), CD8- (cytotoxic T-cell marker) and CD30- (7). Low levels of CD7 expression 
(<10%) has a sensitivity of 40% and specificity of 80% to 100% which helps to 
distinguish early MF from benign mimics (41). 
Course of the disease 
Several studies had demonstrated that early MF patients with limited patches or 
plaques who have received skin-directed treatment have median survival similar to that 
of matched control populations (36–38). MF has an indolent clinical course with slow 
progression over years or sometimes decades, from patches to more infiltrated plaques 
and eventually to tumors. As MF progresses into advanced stages there is progressive 
growth of the neoplastic infiltrate into the dermis and subcutaneous fat. 25–33% of 
patient‟s progress to late-stage disease characterized by cutaneous tumours or 
erythroderma over months or years and nodal involvement may occur (36,39).  
Approximately one-third of patients present with advanced disease, which is associated 
with a poor prognosis (36,38). Around 6-28% of patients who had bone marrow 
involvement during the initial staging were associated with advanced skin and nodal 
disease (36,39). 
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Prognostic markers 
Determination of prognosis is an essential step in the management of primary 
cutaneous lymphomas. The prognosis of patients with MF is dependent on few clinical 
markers such as male sex and increasing age, haematological markers such as LDH, 
histological features such as folliculotropism and genetic abnormalities apart from 
clinical staging, and in particular the type and extent of skin lesions and the presence of 
extracutaneous disease (7,39). Early stage disease has a favourable prognosis (5 year 
survival – 49-100%) while the advanced stage disease with tumours or erythroderma is 
associated with worse prognosis (5 year survival – 0-39%) (38–40). Variants like 
hypopigmented MF, MF with lymphomatoid papulosis, poikilodermatous MF and 
increased numbers of CD8+ T cells in histology of the skin are favourable prognostic 
factors and associated with reduced risk of disease progression (31,40).  
Staging of MF 
Staging guidelines was published in 2007 by ISCL/EORTC for MF/SS (Olsen 
et al) based on morphology of skin lesions, extent of involvement, nodal involvement, 
extracutaneous dissemination and blood involvement (41). (Annexure IA & IB) 
„T‟ stage was divided into 4 stages (T1-T4) based on type of skin lesions and 
extent of involvement. T1 and T2 stages are further subdivided into „a‟ and „b‟ in 
respect to patch stage and plaque stage respectively. Patch stage disease has an 
improved survival than plaque stage MF (39,40). As the T stage of disease advances, 
prognosis of the disease proportionately becomes worse (40). 
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Clinical stage as defined by TNMB classification (IA-IVB) has prognostic 
implications and varied treatment approaches (39). Staging of the disease at 
presentation is a useful measure of tumour burden. 
Mycosis fungoides in children 
MF in children constitutes <5% of all MF cases (42). Male predominance is 
noted in children with MF similar to adults. In a study comprising 46 children with MF 
mean age at diagnosis was 10.3 years while the mean duration of symptoms prior to 
diagnosis was 24 months (30).  Hypopigmented lesions are common in children than 
adults (30). Distinguishing MF from benign dermatoses particularly in hypopigmented 
lesions is a challenging task (30).  Histological examination with immunohistochemical 
and molecular analysis may be helpful in such situation. The overall prognosis of MF 
in children is excellent with treatment (30). 
Sezary syndrome (SS) 
Sezary syndrome (SS), a triad of erythroderma, generalized lymphadenopathy, 
and the presence of neoplastic T cells (Sezary cells) in skin, lymph nodes, and 
peripheral blood has a poor prognosis (7).  
Clinical features 
SS usually occurs in a short time period de novo and progresses rapidly. 
Though it was considered separate from MF, rarely SS may follow classic MF (10).  
Patients with SS usually present with generalized exfoliative erythroderma with 
keratoderma and fissures on the palms and soles which may be associated with 
electrolyte imbalance, hypothermia, hair loss, and eyelid changes/ectropion (7). 
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Generalized seborrheic dermatitis, psoriasis, cutaneous drug reactions, infections and 
chronic photosensitivity reactions may mimic SS. 
Diagnostic criteria 
Only patients with SS will have susbstantial leukemic T-cell burden in the 
blood which helps to distinguish it from erythrodermic MF (43). The International 
Society for Cutaneous Lymphoma (ISCL) proposed these patients as „„SS preceded by 
MF‟‟ to distinguish them from classic SS. 
International Society for Cutaneous Lymphomas (ISCL) recommended criteria for 
diagnosis of SS include one or more of the following (43): 
1) Absolute Sezary cell count of 1000 cells/cubic mm or more 
2) Specific immunophenotypical abnormalities (CD4/CD8 ratio more than 10, loss 
of any or all of the T-cell antigens CD2, CD3, CD4, and CD5, or both) 
3) Demonstration of a T-cell clone in the peripheral blood by molecular or 
cytogenetic methods. 
 
Histopathology and immunohistochemistry 
Classical histopathological features including epidermotropism, Pautrier 
microabscesses are variable and less prominent in SS. Traditional determination of 
Sezary cells quantification was largely replaced by flow cytometry analysis which 
identifies neoplastic T cells, which are characterized as CD4+ CD7- and/or CD4+ 
CD26- (44). 
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Prognosis 
SS is an aggressive disease with a median survival of 2–4 years and an overall 
survival rate at 5 years of between 11 and 20% (7). Transformation into a large-cell 
lymphoma may also occur in the course of SS as in classical MF (43).  
Primary cutaneous CD30+ lymphoproliferative disorders (CD30+ LPD) 
The primary cutaneous CD30+ lymphoproliferative disorders (LPD) are the 
second most common form of CTCL  contributing around 25% of all CTCLs‟(45). 
Lymphomatoid papulosis (LyP) and cutaneous anaplastic large cell lymphoma (C-
ALCL) form a spectrum of CD30+ lymphoproliferative disorders which is usually 
differentiated by clinical appearance, course and histological criteria. In India, the 
prevalence of cutaneous CD30+ lymphomas was reported to be around 16% of all 
CTCLs (25). 
Lymphomatoid papulosis (LyP) 
Clinical profile 
LyP generally occurs in adults with male predominance but may occur in 
children as well.  Median duration of skin lesions before first diagnosis was 18 months 
(range - 1 to 117 months) (45). Clinically, LyP is usually characterized by a chronic 
course of self-healing skin eruption of erythematous papules and nodules that may 
become haemorrhagic, necrotic, and/or ulcerative lesions each of which undergoes 
spontaneous regression after weeks or months (45). Conditions that resemble LyP are 
arthropod bites, pityriasis lichenoides et varioliformis acuta (PLEVA), prurigo 
nodularis, folliculitis and various other cutaneous lymphomas. 
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Histopathology 
The three well recognized histological subtypes of LyP are (45) 
i) Type A, characterized by a mixed infiltrate containing large atypical CD30+ 
cells intermingled with small lymphocytes, histiocytes, neutrophils and or 
eosinophils 
ii) Type B, characterized by mycosis fungoides (MF) like histologic picture 
iii) Type C, characterized by large CD30+ cells with relatively few admixed 
inflammatory cells which mimics anaplastic large T-cell lymphomas but has 
an indolent clinical course 
Recently two new histological variants have been described. They include LyP 
type D in which the histology simulates an aggressive epidermotropic CD8 positive 
cytotoxic T-cell lymphoma but clinically follows an indolent course and type E, 
characterized by angioinvasive infiltrate of small to large atypical lymphoid cells which 
are CD30+, CD8+ and TIA-1+ which also follows an indolent course with an excellent 
prognosis (46,47). 
 
Prognosis 
It usually follows an indolent course and has an excellent prognosis (7). 
However, a cohort study has shown that 4% of patients develop systemic lymphoma 
and 2% of patients die of systemic disease over a median follow up period of 77 
months (45). Twenty percent of patients LyP may be preceded by, associated with or 
followed by another type of malignant lymphoma, cutaneous ALCL or Hodgkin 
lymphoma (7). 
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Primary cutaneous anaplastic large cell lymphoma (primary cALCL) 
Clinical picture 
Primary cALCL manifests in majority of patients as a solitary or grouped, 
rapidly growing and ulcerating large tumors or thick plaques with associated 
extracutaneous spread in 10% (7). Rare presentation of erythrodermic cALCL has been 
reported (48). Median age at diagnosis has been reported to be 60 years in a study 
comprising 219 patients with CD30+ LPD (45). Male preponderance is noted in the 
same study. Nodules/tumors are the common morphological skin lesions in cALCL 
occurring in 88% of patients (45). 
Histology 
Histological picture of cALCL show a diffuse, non epidermotropic infiltrate 
with cohesive proliferations of large CD30+ lymphocytes. Neoplastic cells show 
anaplastic features in majority of patients and less commonly, they might have a 
pleomorphic or immunoblastic appearance (49). LyP, cALCL and secondary infiltrates 
of systemic ALCL as well as tumor stage of MF and transformation in SS show 
overlapping histological and phenotypical features and it exemplifies that 
differentiation can be achieved only by clinicopathological correlation and staging 
examinations (17). According to the latest WHO-EORTC classification, cALCL is 
classified by the expression of CD30 in more than 75% of large atypical cells (7). The 
atypical cells usually show an activated CD4+ T-helper cell phenotype with variable 
loss of T-cell markers and frequent expression of cytotoxic proteins. Borderline 
patients can also occur which include patients with the clinical presentation of a CD30+ 
cALCL but histologic features suggestive of LyP and conversely, patients with clinical 
picture of LyP that shows histologic features characteristic of a CD30+ cALCL (45). 
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The clinical presentation and the course of disease over time are used as decisive 
criteria for the definitive diagnosis and choice of treatment (49). 
Prognosis 
Primary cALCL has a favourable prognosis with 5-year survival rates between 
76% and 96%. Spontaneous complete or partial regression of the tumor is reported in 
up to 44% of the patients (45,50). 
 
Subcutaneous panniculitis like T - cell lymphoma (SPTL) 
Subcutaneous panniculitis-like T-cell lymphoma (SPTL) which accounts for 1% 
of all CL‟s is defined based on new WHO/EORTC classification as a cytotoxic T-cell 
lymphoma showing an α/β+, CD3+, CD4-, CD8+ phenotype which is primarily limited 
to subcutaneous infiltrates with an indolent clinical course (7). Frequency of SPTL was 
reported to be around 8% among all peripheral T cell lymphomas in a study from an 
Indian tertiary referral centre (25). Only few other patient reports and a small patient 
series were reported from India till date (51–55). 
In recent WHO-EORTC classification, SPTL and primary cutaneous γδ T cell 
lymphoma were distinguished as 2 groups in regards to distinct histology, phenotype 
and prognosis as tabulated below (7,56) [Table 5]. 
Clinical profile 
The median age at diagnosis was 36 years (range 9-79 years) (56). Clinically 
SPTL occurs as  nodular skin lesions or deeply seated plaques, which varies in sizes 
from 1 to 20 cm. Extremities are more commonly involved than trunk and face (56).  
The duration of skin lesions prior to the diagnosis ranged from 1 month to more than 10 
years (56).  
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Table 5. Distinction between SPTL and PCGD-TCL 
 SPTL PCGD - TCL 
IMMUNOHISTOCHEMISTRY 
βF1+, TCR-γ1-, CD3+, 
CD4–, CD8+, CD56– 
βF1-, TCR-γ1+, CD3+, CD4–, 
CD8–, CD56+ 
ARCHITECTURE Subcutaneous 
Subcutaneous and/or 
epidermal/dermal 
HPS Uncommon Common 
5 YR SURVIVAL 
91% (without HPS) vs 
46% (with HPS) 
11% 
TREATMENT Systemic steroids Systemic chemotherapy 
HPS – Haemophagocytosis; TCR – T-cell receptor;  
Histopathology 
Typically all patients show a histological picture with predominant 
subcutaneous atypical lymphoid infiltrate, showing a typical adipotropism and 
characteristically involving the fat lobules resembling a lobular panniculitis (56,57). 
Septal involvement may be absent or appear as secondary changes. Mild to moderate 
extension of the atypical infiltrate into the reticular dermis and periappendageal 
infiltration was often observed (57).  
Prognosis 
Studies had shown CD56+, cytopenia with haemophagocytic syndrome, 
angioinvasion, skin ulcers, liver dysfunction, elevated LDH and EBER (EBV encoded 
RNA) oligonucleotides as unfavourable prognostic factors (56–58). When complicated 
by hemophagocytic syndrome (HPS), SPTL has an aggressive clinical course, and 
should therefore be treated with aggressive multiagent chemotherapy (56,58). 
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Extranodal NK/T – cell lymphoma (Extranodal NKTL) 
Extranodal NK/T-cell lymphoma, nasal type, usually an EBV+ lymphoma of 
small, medium, or large cells with an NK-cell, or more rarely a cytotoxic T-cell, 
phenotype. After nasal cavity/nasopharynx, most common site involved is skin which 
may be a primary or secondary manifestation of the disease. Presence of extra nasal 
involvement is an important poor prognostic factor (59). Biopsy of the tumor usually 
shows a diffuse proliferation of lymphoid cells harboring a surface CD3–, cytoplasmic 
CD3e+, CD56+/– phenotype, and a cytotoxic profile (positive for TIA-1, perforin, or 
granzyme B). Demonstration of EBV-encoded RNA [EBER] or immunohistochemistry 
for latent membrane protein 1 (LMP-1) is mandatory for diagnosis (60).  
Hydroa vacciniforme like T – cell lymphoma (HVLL) 
Clinical profile 
Hydroa vacciniforme (HV) is a rare condition of childhood, clinically 
characterized by necrotic papulovesicular eruption with scarring on sun-exposed areas 
which is considered to be associated with hypersensitivity to ultraviolet light. HVLL is 
an EBV+ lymphoproliferative disorder which has clinical similarities to HV was 
recognized by the 2008 WHO classification as HVLL (61). There are increased reports 
of this condition from Asia, Central and South America (62–64). Recurrent skin lesions 
may be indolent for even up to 15 years before it progresses to involve visceral organs 
which usually manifest as fever, asthenia, lymphadenopathy, and hepatosplenomegaly 
(65). 
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Histopathology 
Histological findings are similar to chronic EBV infection which is 
characterized by NK-cell or T-cell infiltrates extending from epidermis to the subcutis, 
showing necrosis, angiocentricity, and angioinvasion. CD56 is positive only in the NK 
cell–derived lesions. Demonstration of EBER in situ hybridization is a definite criterion 
for diagnosis (62). Clonal T-cell rearrangement favours the diagnosis of HVLL (65).  
Prognosis 
Poor prognostic factors include presence of photosensitivity and symptoms 
indicating chronic active EBV infection, such as high viral load in the peripheral blood, 
clonality of EBV or T cells, deeper dermal infiltration and cellular atypia (66). 
Peripheral T- cell lymphoma, not otherwise specified (PTCL, NOS) [Table 6] 
All patients that do not belong to MF, SS, CD30+ LPD, SPTL or extranodal NK ⁄ 
T-cell lymphoma are assigned to the group of peripheral T-cell lymphoma, unspecified 
(PTL, NOS) according to the WHO ⁄ EORTC and WHO classifications (7,17). Male 
preponderance has been reported and median age at diagnosis is 68 years (range, 8-87 
years). Median duration of skin lesions prior to diagnosis was 6 months in a study of 82 
patients with PTCL, NOS (67). Most common morphological skin lesions were nodular 
or tumorous skin lesions. The skin lesions may occur as solitary skin lesions (26%) or 
localised (13%) or multifocal (61%) (67). Accounting for less than 10% of all primary 
cutaneous T-cell lymphomas, this was sub classified (provisional entities) (7) into: 
1) Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma 
2) Primary cutaneous γ/δ T-cell lymphoma 
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3) Primary cutaneous CD4+ small/medium-sized/large pleomorphic T-cell 
lymphoma 
4) Peripheral T-cell lymphoma, not otherwise specified 
Table 6. Distinction between subtypes of PTCL, NOS based on 
immunohistochemistry 
PTCL, NOS subtype 
IMMUNOHISTOCHEMISTRY 
CD4 CD8 TCR α/β CM 
Epidermotropic CD8+ T-
cell lymphoma 
+ or - + + + 
Cutaneous γ/δ T-cell 
lymphoma 
- - or + - + 
Cutaneous α/β 
pleomorphic T-cell 
lymphoma 
+ or - - + + 
Cutaneous medium/large 
pleomorphic T-cell 
lymphoma, not otherwise 
specified 
+ + or - _ + 
CM - cytotoxic molecule; TCR - T-cell receptor 
Primary cutaneous γδ T cell lymphoma (PCGD-TCL) [Table 5] 
Clinical picture 
PCGD–TCL usually present with disseminated plaques and/or ulceronecrotic 
nodules or tumors with frequent involvement of mucosal and other extranodal sites. But 
lymph nodes or bone marrow involvement is uncommon.  
Histopathology 
The neoplastic infiltrates in PCGD-TCL are not confined only to the 
subcutaneous tissue, but generally involve the epidermis and/or dermis as well, which 
is in contrast to SPTL where the neoplastic infiltrates are confined to subcutaneous 
tissue (7). The neoplastic cells characteristically have a TCR γ/δ+, βF1–, CD3+, CD2+, 
CD5–, CD4–, CD8–, CD56+/– phenotype with strong expression of cytotoxic proteins. 
Commercially available TCR-γ antibodies have been extremely helpful in 
differentiating between PCGD-TCL and SPTL (60) [Table 5] 
Prognosis 
Hemophagocytic syndrome (HPS), characterized by an aggressive clinical 
course may occur particularly in patients with panniculitis-like tumors (60). PCGD-
TCL has a poor prognosis and resistant to multiagent chemotherapy (60). 
 
Primary Cutaneous CD8+ aggressive epidermotropic cytotoxic T-Cell 
Lymphoma 
Clinical profile 
Clinically these lymphomas are characterized by eruptive papules, nodules, and 
tumors with central ulceration and necrosis or superficial, hyperkeratotic patches and 
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plaques which tend to disseminate to mucosal and other extranodal sites (lung, testis, 
central nervous system, and oral mucosa), but lymph nodes are often spared (60).  
Histopathology 
Ranging from a lichenoid pattern with marked, pagetoid epidermotropism in 
early patch-like lesions to diffuse dermal infiltrates in nodular and tumorous lesions in 
which epidermotropism and folliculotropism are marked, histological picture is 
variable (67). Tumor cells may be small medium or medium-large with pleomorphic or 
blastic nuclei. They have a βF1+, CD3+, CD8+, granzyme B+, perforin+, TIA-1+, 
CD45RA+, CD45RO–, CD2–, CD4–, CD5–, CD7–/+ T-cell phenotype (67). 
Prognosis 
It expresses an aggressive clinical behaviour and poor prognosis. 
Angiocentricity and angioinvasion may be present (67).  
Cutaneous small/medium sized pleomorphic T-cell lymphoma, not 
otherwise specified (CD4+ PCSM-TCL) 
Clinical picture 
CD4+ PCSM-TCL, characterized by predominance of small to medium-sized 
CD4+ pleomorphic T cells occurs without prior or concurrent patches and plaques 
typical of MF (7). It usually present with a solitary plaque or tumor localized to the 
head or neck. The prognosis of such patients are excellent (60).  
Histopathology 
Histologically, these lymphomas show nodular to diffuse infiltrates, which often 
extend into the subcutaneous fat. IHC shows a predominance of CD3+, CD4+, CD8–, 
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CD30– small to medium pleomorphic T cells and fewer than 30% large CD4+ 
pleomorphic T cells (7). In most of the patients small reactive CD8+ T-cells are 
admixed with CD20+ B-cells, including some centroblasts and histiocytes and in some 
patients with multinucleated giant cells and/or granulomatous changes. The clinical 
presentation, architecture, and cellular composition of PCSM-TCL are similar to 
pseudo-T-cell lymphomas (60). 
Cutaneous B-cell lymphomas (CBCL) 
Cutaneous B cell lymphomas always remain a great challenge for the clinicians 
and pathologists in terms of definitive diagnosis and treatment. The different types of 
cutaneous B cell lymphomas include primary cutaneous marginal zone B cell 
lymphoma (PCMZL), primary cutaneous follicle centre lymphoma (PCFCL), primary 
cutaneous diffuse large B cell lymphoma leg type (PCLBCL–LT), primary cutaneous 
diffuse large B-cell lymphoma, other and intravascular large B-cell lymphoma (7). 
Primary cutaneous follicle centre lymphomas are the most common among CBCLs‟ 
(68). Studies have shown that B-cell lymphomas are rare in Asia compared to the West 
(6,7,69). Data about cutaneous B cell lymphomas reported from India are very sparse 
except few case reports (68,70–72). Three essential steps in diagnosis of cutaneous B- 
cell lymphomas include the determination of infiltrates (benign or malignant), 
identification of cell lineage and the final step is classification of B- cell lymphoma 
(73). Evidence of absence of extracutaneous disease for 6 months after diagnosis is 
required to classify as primary cutaneous B cell lymphomas (7). 
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Primary cutaneous follicle center lymphoma (PCFCL) 
Clinical picture 
PCFCL usually presents as solitary or grouped papules, plaques, or nodules 
with scalp, forehead, neck, and trunk being the more common sites of involvement and 
rarely occurs on lower extremities. Median age at diagnosis is 60 years and men are 
affected 1.05 times more than women (74). Incidence of PCFCL is around 9-11% of all 
cutaneous lymphomas (6,7). Benign inflammatory conditions including rosacea, 
folliculitis, acne, lupus miliaris, epidermal inclusion cysts, arthropod bites, benign 
cutaneous neoplasms and malignant neoplasms including basal cell carcinoma, Merkel 
cell carcinoma, and other non B-cell cutaneous lymphomas or folliculotropic MF can 
mimic PCFCL. 
Histopathology 
Histological patterns include follicular, nodular, diffuse, and mixed patterns 
which do not differ much in terms of prognosis (73,74). Histopathological examination 
of PCFCL usually shows dermal and subcutaneous proliferation of cleaved follicle 
center cells (centrocytes) admixed in variable proportions with large transformed cells 
(centroblasts). Immunophenotyping of follicle center cells generally express CD20+, 
CD79a+, Bcl-6+, Bcl-2- and variable expression of CD43 and CD10 (73).  
Prognosis 
Five-year survival rate of PCFCL is up to 95% and 5-10% of patients can 
disseminate to extracutaneous sites (7,73). Leg lesions carry a poor prognosis (68).  
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Primary cutaneous marginal zone lymphoma (PCMZL) 
(Extranodal MZL of MALT lymphoma – WHO 2008 classification) 
Clinical picture 
PCMZL‟s are indolent lymphomas which commonly present as plaques and 
nodules with cutaneous recurrences but rare extracutaneous dissemination. PCMZL 
contributes 2-7% of primary CL and can present as solitary or localized lesions which 
affect multiple anatomical sites simultaneously or rarely be generalized (75). Most 
common anatomical sites to be involved are extremities and trunk rather than head and 
neck. Median age at diagnosis is 55 years with an excellent prognosis and a 5-year 
survival of 90-100% (7).  
Histopathology 
Prominent histological features include dermal and subcutaneous proliferation 
of marginal zone B-cells, lymphoplasmacytoid mononuclear cells, and plasma cells 
admixed with a minor number of centroblast- or immunoblast-like cells and many 
reactive T-cells. In patients with abundant plasmacytoid cells, PAS positive, 
immunoglobulin containing intranuclear Dutcher bodies and intracytoplasmic Russell 
bodies may be present (75). IHC usually shows CD20+, CD43+, CD10- , CD5-, bcl-2+, 
and bcl-6-. Multiple myeloma-1/interferon regulatory factor-4 (MUM1/IRF4) and 
CD138 positivity may be noted reflecting the plasma cell component of the infiltrate 
(75). 
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Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) 
Clinical picture 
PCLBCL-LT constitutes about 10-20% of all PCBCL‟s and presents as multiple 
red or bluish red nodules or tumors and infrequently as solitary lesions. It occurs more 
common in women and elderly, with a median age of onset of 76 years (73). Presence 
of multiple lesions at diagnosis is a poor prognostic indicator. 5 year disease specific 
survival is about 50% (7,76). 
Histopathology 
Histology of PCLBCL-LT shows a diffuse dermal infiltrate of centroblasts and 
immunoblasts in monotonous or confluent sheets. IHC usually displays CD20+, 
CD79a+, CD10-, Bcl-2+ and Bcl-6+/-. Expression of Bcl-2, MUM1/IRF4, and FOX-P1 
are strong in contrast to PCFCL (75). 
The term “PCLBCL, other,” refers to rare patients of large B-cell lymphomas 
that lack the typical clinical, histological and immunophenotypical features of 
PCLBCL-LT (17). Unlike their nodal counterparts, they appear to have an excellent 
prognosis (76).  
Intravascular large B- cell lymphoma, characterized by an accumulation of 
large neoplastic B cells within blood vessels carries a poor prognosis. Central nervous 
system, lungs and skin are preferentially affected. Pure cutaneous involvement has 
relatively a better prognosis (77). 
B-cell lymphomas associated with EBV infection are diffuse large B-cell 
lymphomas, plasmablastic lymphoma and plasmacytic marginal zone lymphoma which 
are usually related to immunosuppression (78). 
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Precursor hematologic neoplasm 
CD4+/CD56+hematodermic neoplasm (formerly blastic NK-cell lymphoma) 
Commonly presents as solitary or multiple nodules or tumours with or without 
concurrent extracutaneous localizations which exhibits an aggressive course with a 
poor prognosis. Median survival is around 14 months. Bone marrow, peripheral blood, 
lymph nodes, and extranodal sites can be rapidly involved in patients presenting with 
cutaneous lesions (7,79,80). 
Secondary cutaneous lymphomas 
B- Cell lymphomas 
In contrast to primary cutaneous lymphoma, B-cell predominance (65.8%) is 
seen in secondary cutaneous lymphomas. It represents 25% of all cutaneous 
lymphomas (69). In one study, it contributes about 50% of cutaneous lymphomas other 
than MF. Clear distinction between primary and secondary lymphomas can be difficult 
because of incomplete clinical evaluation in most of the situations. Based on published 
literature most common secondary cutaneous B- cell lymphoma is diffuse large B-cell 
lymphoma which accounts for 26.8%, next being follicular lymphoma (21.4%) in 
which combined expression of bcl-2, bcl-6 and CD10 appears to a much strong 
predictor of secondary disease (68). Though primary and secondary diffuse large B cell 
lymphomas commonly involve the head and neck regions or the extremities, trunk 
involvement may be more characteristic of secondary disease (81). Clinical behaviour 
and gene expression profiling are much helpful in distinction between primary and 
secondary types (73). Expression of CD10 or t (14;18) warrants a systemic evaluation 
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(73). In patient of marginal zone lymphomas, secondary disease appears to be more 
commonly associated with multifocal skin disease when compared to primary marginal 
zone lymphomas (74). 
T and NK cell lymphomas 
19-55% of PTCL, NOS patients can have secondary cutaneous involvement at 
the time of diagnosis. Most common among secondary T and NK cell lymphomas is 
PTCL, NOS which is clinically aggressive than primary cutaneous PTCL. Study from 
India had reported a frequency of 34% patients of PTCL, NOS with cutaneous 
involvement (25). 
Secondary CD30+ lymphoproliferative disorders accounts for 5% of all CD30+ 
LPD with median age of 55 years at diagnosis and bimodal age distribution (45). 
Anaplastic large cell lymphoma which accounts for around 9.1% has worse prognosis 
compared to its primary counterpart which is relatively indolent (45). In contrast to 
systemic anaplastic large-cell lymphoma (ALCL), primary CD30+ cALCL rarely 
carries the t(2;5) translocation and is usually ALCL kinase protein (ALK) negative 
(45).  
Around 8 to 20% of NK/T cell lymphomas of the nasal type can have secondary 
cutaneous involvement (82). As in any other sites, infiltrate is composed of medium to 
large irregular cells along with angioinvasion and necrosis. Cells usually express 
CD2+, cytoplasmic CD3+, CD56+ and EBV positive. Skin lesions commonly occur in 
angioimmunoblastic T cell lymphoma (AITL), maculopapular eruptions resembling 
viral exanthem being the commonest presentation (82–84). Histologically the skin 
lesions may have sparse infiltrate with fairly nonspecific perivascular lymphocytes and 
eosinophils and associated capillary hyperplasia, with or without obvious abnormalities 
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of the lymphocytes. Most of the patients have enlarged, atypical lymphoid cells with 
loss of aberrant T- cell antigens. 
Among HTLV-1 associated lymphomas most common is adult T-cell 
leukemia/lymphoma with life time risk being 1-4% and latent period for development 
of disease is estimated to be 30-50% (85). Histopathologically poor prognosis is noted 
in patients with nodules diffuse infiltration of medium sized to large lymphoma cells. 
TCR gamma gene rearrangement 
Well established cutaneous lymphomas are diagnosed by histopathological 
examination and immunohistochemical marker studies without much ambiguity. 
Molecular study (TCR gene rearrangement) plays an additional role in early lesions 
where the diagnosis of cutaneous lymphomas cannot be established confidently by 
above modalities (10). Various studies around the world had demonstrated a wide range 
of clonality detection (40-90%) in CTCLs‟ (11–13,86). But the difference is attributed 
to the usage of different PCR protocols for the detection of clonal cells. One study from 
Italy which had used multiplex PCR ⁄HD analysis of PAGE on fresh frozen sections 
had demonstrated clonality in 83.5% of CTCLs in a large series of patients (12).  
Clonality detection rate proportionately increased with „T‟ score of the disease (12). 
Ponti et al demonstrated a clonality percentage of 83.5% in all CTCLs and 73.75% in 
T1/T2 stages of MF (87). Tok et al had demonstrated clonal TCR gamma gene 
rearrangements in 73% of the specimen‟s non diagnostic for CTCL, 71% of those 
suggestive of CTCL, and 74% of those diagnostic of CTCL (87). Another study from 
China had demonstrated clonal detection of 80% and 100% in cases of suspected MF 
and typical MF respectively (88). 
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Though the detection of clonality in early MF does not have any prognostic 
significance, it has significant role in diagnosis of early MF (89). False negativity in 
detection of clonality can occur due to low density of infiltrated tumour cells in biopsy 
specimens of early MF, partial or incomplete rearrangement of the TCR, somatic 
hypermutation or TCR region translocation (86,90). There are no studies on clonality 
(TCR gamma gene rearrangement) of early stage mycosis fungoides from India till 
date. 
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MATERIALS AND METHODS 
 
 
Setting  
The study was conducted at the Department of Dermatology, Venereology and 
Leprosy, Christian Medical College and Hospital (CMCH). Patients with cutaneous 
lymphoma who presented to Dermatology OPD and patients referred mainly from the 
adult and paediatric Haematoncology and Medicine departments were included in the 
study. 
 
Study design 
A hospital based cross-sectional study was conducted where in patients 
fulfilling the inclusion criteria were recruited into the study.  
 
Study duration 
The study was conducted from November 2012 to August 2014 (22 months) 
 
Inclusion criteria  
Any patient with cutaneous lymphoma diagnosed by histopathological 
examination and immunohistochemistry as per standard criteria. 
 
Exclusion criteria 
 Patients who were not willing to be included in the study. 
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METHODS 
Patients who fulfilled the inclusion criteria were included in the study. All 
patients who were diagnosed to have cutaneous lymphomas by histopathology and 
immunophenotyping seen during the study period were included in the study. All the 
subjects and the parents/legal guardian of the subjects were informed about the purpose 
of the study (Annexure IV-VI) as well as informed consent was obtained (Annexure 
VII-IX)  
All the patients were examined by the principal investigator and the details 
obtained from the patient or parent/legal guardian were entered in a proforma 
(Annexure XIIA). The details were collected and subsequently entered in an electronic 
database. Epidata (version 3.1), a data management software was used for the data 
entry and evaluation. 
 
Demographic details 
Socio-demographic data including age at recruitment into the study, gender, 
place of stay, duration of symptoms and age of onset were recorded. Age of onset was 
defined as the age at which the patient first noticed the skin lesions. 
 
History pertaining to the disease 
1. Presenting cutaneous complaints (including skin lesions, pruritus and other 
complaints) and duration of the same were recorded. 
2. Systemic complaints (including history of fever, night sweats and weight loss) 
associated with the primary complaints were recorded. 
3. Past treatment of the patient (if any) including systemic and topical medications 
were recorded. 
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Clinical Examination 
Each patient was examined by the principal investigator and the findings were 
confirmed by the guide. Morphology of skin lesions, area of involvement and the extent 
of involvement were recorded. The diagnosis of the lesions was based on clinical 
features and confirmed by skin biopsy in all patients. The systemic examination 
including presence of pallor, lymph node assessment, organomegaly and ascites (if 
present) were recorded. 
Investigations 
Histopathological examination 
Skin Biopsy 
Skin biopsy from the most advanced lesion was done and in those with varied 
morphology the most common representative lesion was chosen for biopsy. Wedge and 
elliptical biopsies were done from ulcers and subcutaneous nodules and plaques. 
 
Haematoxylin and eosin stain 
The biopsy sample obtained was fixed, processed in an automated processor for 
thirteen hours and embedded in paraffin wax, and each tissue specimen was serially 
sliced into sections of 4 μm for routine haematoxylin and eosin staining.In each biopsy 
the following parameters were analysed;  
(1) Epidermal changes (hyperplasia, ulceration, etc.) 
(2) Epidermotropism  
(3) Pattern and thickness of the lymphoid infiltrate 
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(4) Presence of Pautrier‟s microabscess 
(5) Papillary dermis thickening 
(6) Presence of spongiosis 
(7) Presence of an inflammatory component (plasma cells, histiocytes, eosinophils, 
etc) 
(8) Presence of mitoses.  
Percentage of large T-lymphocytes was also analysed (>25% was considered as 
significant). 
Diagnosis of MF 
The diagnosis of mycosis fungoides was based on the histologic criteria 
proposed by Guitart et al (35) (Annexure II). Major criteria included assessment of 
density of infiltrate at low power, epidermotropism at medium power and cellular 
atypia at high power. Minor criteria included reticular fibroplasia of papillary dermis, 
intraepidermal atypical lymphocytes and lymphocytic infiltrate without inflammatory 
features. Based on the above criteria the diagnosis was classified into: 
1. Mycosis fungoides 
2. Atypical lymphocytic infiltrates suggestive of MF 
3. Atypical lymphocytic infiltrates where diagnosis of MF cannot be excluded and 
4. Perivascular/interface dermatitis. 
Diagnosis of cutaneous lymphomas other than MF/SS 
Cutaneous lymphomas other than MF/SS diagnosed by the distinct 
histopathological features and immunohistochemistry markers were classified based on 
WHO-EORTC classification (updated in 2008) (7,17). 
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Immunohistochemistry studies 
Immunohistochemistry was done manually using the Envision technique 
developed with diaminobenzidine for all patients on formalin fixed paraffin embedded 
tissue sections. A primary panel of one pan T-cell marker (CD3), one pan B-cell 
marker (CD20) and proliferation marker (MIB1) was used. In CD3 positive patients 
other markers were done for sub typing depending on the morphology which included 
pan T-cell antigens CD5 and CD7 and subset markers CD4 (helper T cell antigen) and 
CD8 (cytotoxic T cell  antigen). NK cell antigen CD56 and EBV antigen LMP-1 were 
done for patients with clinical and morphological findings suggestive of NK/T cell 
lymphoma. In patients with morphology and clinical background of CD30+LPD, 
activation marker CD30 and ALK epithelial membrane antigen (EMA) were done. The 
details of the antibody panels used including their clones, source, dilution and pre-
treatment have been shown in annexure X (A). Procedure of immunohistochemistry has 
been shown in annexure X (B). 
TCR gene rearrangement studies (Annexure XI) 
TCR gamma gene rearrangement study was done in patch/plaque (Stage I/IIA) 
mycosis fungoides where in the histological diagnosis of mycosis fungoides could not 
be excluded or the diagnosis was suggestive but not confirmatory. Additionally the test 
was done in other stages of MF and few subtypes of cutaneous lymphoma if requested 
by the referring physician of the patient.  
DNA was extracted using the Qiagen DNA Mini kit (Qiagen, Hilden, 
Germany). Three- four 5µ thick paraffin embedded sections were used. The 260/280 
ratio was determined using the nanodrop (Nanodrop technologies, USA). Fifty ng of 
DNA was amplified to determine the quality of DNA using the „amplification control‟ 
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provided along with the T cell receptor gamma chain gene rearrangement assay (In 
Vivo Scribe, USA). Further, mixes 1 and 2 were amplified as per manufacturer‟s 
instructions. The products were detected on a 2% agarose gel before processing them 
for fragment analysis. Fragment analysis was performed using 1μl of the PCR product 
that was denatured with formamide and finally detected using the 3130 genetic analyser 
(Applied Biosystems, USA). 
Other biopsies 
Bone marrow biopsies, lymph node biopsies and extracutaneous organ biopsies 
were done in patients whenever indicated as per ISCL/EORTC staging protocol 
(Annexure IA & IIIB). 
Laboratory tests 
It included a complete haemogram, liver function test, creatinine, urinary 
analysis and serum level of lactate dehydrogenase. Blood borne virus screening 
(optional) included the screening for hepatitis-B, hepatitis-C and HIV. 
Imaging studies 
Imaging studies included chest X-ray, ultrasonography of abdomen and pelvis, 
computed tomography, magnetic resonance imaging and positron emission 
tomography. Imaging studies were done whenever indicated as per staging protocol. 
Staging 
All the patients were classified based on WHO-EORTC classification of 
cutaneous lymphomas (2005). Complete staging was done wherever possible based on 
the International Society for Cutaneous Lymphomas (ISCL)/European Organisation of 
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Research and Treatment of Cancer (EORTC) revised clinical staging and classification 
of mycosis fungoides and Sezary syndrome (41) (Annexure IA & B). Patients other 
than MF/SS were staged based on ISCL/EORTC proposal on TNM classification of 
cutaneous lymphoma other than MF/SS (91). (Annexure IIIA) 
Sample size 
As it is a descriptive study all consecutive consenting patients with a diagnosis 
of cutaneous lymphomas during the study period between November 2012 and August 
2014 attending Dermatology unit I out-patient department and referred from other 
departments were recruited in the study. TCR gene rearrangement was done on patients 
with early stage MF (I/IIA) in whom the diagnosis of MF was not confirmatory. 
Statistical analysis 
All numerical variables were described using mean and standard deviation. 
Categorical variables were summarized using frequencies and percentages. P value was 
calculated using Fisher‟s exact test and Kruskal-Wallis equality-of-populations rank 
test wherever applicable. 
Study approval 
The study was approved by Institutional Review Board (Research and Ethics 
committee) [IRB no 8050]. 
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RESULTS 
Demographic profile 
 
Figure 1.Demographic profile of cutaneous lymphomas 
Fifty-four patients with diagnosis of cutaneous lymphomas were included in the study 
between November 2012 and August 2014 (22 months) [Figure 1]. 
Geographical location 
The patients were from Tamilnadu (n=16, 29.6%), West Bengal (n=9, 16.6%), 
Kerala (n=6, 11.1%). Remaining patients were from Andhra Pradesh (n=5, 9.25%), 
Jharkhand (n=5, 9.25%), Chhattisgarh (n=4, 7.4%), North Eastern states (n=3, 5.55%), 
other states (n=5, 9.25%) and the neighbouring country Bangladesh (n=1, 1.85%). 
 
Age and gender distribution 
The patients included in the study ranged from 2-77 years (median, 40.7 years). 
Mean age at diagnosis of cutaneous lymphomas was 39.9±18.3 years (range 2-77 
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years).There were 30 males and 24 females (M/F ratio, 1.25). M/F ratio of primary CL 
and secondary CL were 1.33 and 0.5 respectively [Figure 1]. Six (11.1%) patients 
belonged to paediatric age group (age≤16 years) (M/F 2:1).  
 
Subtypes of cutaneous lymphomas 
There were 49 patients (90.7%) of primary CL and 5 patients (9.26%) of 
secondary CL. The primary CL included 48 patients (88.9%) of primary CTCL and one 
patient (1.85%) of primary CBCL. The secondary CL included 4 patients (7.4%) of 
secondary cutaneous T-cell lymphoma and one patient (1.85%) of secondary CBCL 
[Figure 2]. 
 
 
Figure 2.Relative frequency of cutaneous lymphomas (primary and secondary) 
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Primary cutaneous T-cell lymphomas 
Forty-eight patients had primary CTCL, of which MF (n=27, 56.25%) was the 
most common type. Other subtypes in decreasing order were CD30+ 
lymphoproliferative disorders (CD30+ LPD) (n=11, 22.9%), SPTL (n=6, 12.5%), 
peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) (n=3, 6.25%) and 
hydroa vacciniforme like T-cell lymphoma (HVLL) (n=1, 2.08%). There were 27 
males and 21 females (M/F ratio - 1.28). Male predominance was noted in all subtypes 
of primary CTCLs except SPTL [Figure 3]. 
 
Figure 3. Gender distribution in primary CTCL 
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Table 7. Primary CTCL –Age at diagnosis and duration of disease prior to diagnosis 
Primary CTCL 
(n=48) 
MF 
(n=27) 
CD30+ 
LPD 
(n=11) 
SPTL 
(n=6) 
PTCL, 
NOS 
(n=3) 
HVLL 
(n=1) 
P 
Age at 
diagnosis 
Mean 41.1±18.8 33.8±17.1 33.6±17.3 56.3±18.9 14 ~ 
Median 43 39 27.5 52 ~ ~ 
Range 5-74 2-67 19-60 40-77 ~ ~ 
Duration of 
disease (in 
months) 
Mean 92.7±94 35±58.5 17.8±32.5 4.6±1.5 12 ~ 
Median 72 12 6 6 ~ < .001 
Range 6-400 4-204 0.5-84 3-6 ~ ~ 
 
Age at diagnosis and duration of disease [Table 7] 
Mean age at diagnosis of primary CTCL was 38.9±18.7 years (range 2-77 
years). SPTL was diagnosed at a younger age (median – 27.5 years) while PTCL, NOS 
was diagnosed at a later age (median- 52 years). Mean duration of skin lesions prior to 
diagnosis was 64 months (range 0.5 – 400 months, median - 24 months). Duration of 
the disease prior to the diagnosis of MF (median-72 months) was much longer than 
other subtypes of CTCL (P < .001). Median duration of disease prior to diagnosis of 
SPTL and PTCL, NOS was 6 months. 
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Table 8. Primary CTCL - Comparative clinical profile of each subtype of primary 
CTCL 
Primary CTCL (n=48) 
MF 
(n=27) 
CD30+ 
LPD 
(n=11) 
SPTL 
(n=6) 
PTCL, 
NOS 
(n=3) 
HVLL 
(n=1) 
Morphology 
(n, %) 
Papules 
0 9/11, 
81.8% 
~ ~ 1, 100% 
Patches 
23/27, 
85.2% 
~ ~ ~ ~ 
Plaques 
11/27, 
40.7% 
~ 1/6, 
16.7% 
2/3, 
66.7% 
~ 
Nodules/tumors 
5/27, 
18.5% 
3/11, 
27.3%  
6/6, 
100% 
3/3, 
100% 
~ 
Erythroderma 
2/27, 
7.4% 
1/11, 
9.1% 
~ ~ ~ 
Polymorphic 
9/27, 
33.3% 
2/11, 
18.2% 
2/6, 
33.3% 
2/3, 
66.7% 
~ 
Area of 
involvement  
Head and neck 
4/27, 
14.8% 
1/11, 
9.1% 
~ 3/3, 
100% 
1, 100% 
Trunk 
25/27, 
92.6% 
7/11, 
63.6% 
6/6, 
100% 
2/3, 
66.7% 
 
UL 
25/27, 
92.6% 
8/11, 
72.7% 
3/6, 
50% 
2/3, 
66.7% 
1, 100% 
LL 
27/27, 
100% 
7/11, 
63.6% 
4/6, 
66.7% 
2/3, 
66.7% 
1, 100% 
Multifocal 
27/27, 
100% 
4/11, 
36.4% 
4/6, 
66.7% 
2/3, 
66.7% 
1, 100% 
B-symptoms (n, %) 
2 (7.4%) 1/11 
(9.1%) 
4/6, 
(66.7%) 
1/3 
(33.3%) 
1 
(100%) 
Extracutaneous involvement 
(n, %) 
4 
(14.8%) 
0 0 0 0 
H- Head and neck; T- Trunk; UL- Upper limbs; LL- Lower limbs; Duration of disease was calculated 
in months; 
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Type of skin lesions and area of involvement [Table 8] 
Majority of the patients with CD30+ LPD presented with papules (81.8%) while 
patches and nodules were the most common morphological skin lesions in MF and 
SPTL respectively. Three patients presented with erythroderma, of whom 2 had MF 
and one had cutaneous anaplastic large cell lymphoma. Most common area of 
involvement in MF was the lower limbs while trunk was the most area of involvement 
in SPTL. All three patients with PTCL, NOS had involvement of head and neck region.  
Mycosis Fungoides 
Frequency, gender and age distribution 
MF was the most common CTCL and accounted for 56.25% patients (n=27). 
MF was more common in males (M/F ratio 1.25). Four patients (14.8%) belonged to 
paediatric age group (M/F ratio 3:1). Mean age at presentation in the adult age group 
(>16 years) was 47.5 ± 15.5 years (range 22-74 years) while the same in paediatric age 
group (≤16 years) it was 11.5 ± 3.8 years (range 6-14 years). 
 
Duration of disease prior to the diagnosis 
Mean duration of skin lesions prior to diagnosis of the disease was 92.7 ± 93.9 
months (range 6-400 months, median 72 months) [Table 7] 
Mean duration of skin lesions after excluding the two extreme variables (400 & 
300 months) from the data was 72.2 ± 58.3 months (range 6-220 months, median 72 
months).  
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Types of skin lesions 
Patches were the most common morphological type of skin lesion accounting 
for 85.2% (n=23) followed by plaques (11, 40.7%), tumours (5, 18.5%) and 
erythroderma in two patients (7.4%) while ulceration of existing skin lesions was noted 
in 3 patients (11.1%) [Table 8] 
Hypopigmented skin lesions were noted in 5/27 (18.5%) patients. One patient 
(3.7%) had vesicular lesions on palms and soles. Poikilodermatous MF was noted in 7 
patients (25.9%). Patches and plaques coexisted in 4 patients (14.8%) and all three 
lesions (patches, plaques and tumours) coexisted in 5 patients (18.5%). [Figure 4] 
In the paediatric age group 3/4 children (75%) presented with patches, 1/3 
children had hypopigmented patches and 1/4 children (25%) presented with plaques. 
 
Figure 4. Morphology of skin lesions in MF 
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Anatomical distribution of skin lesions [Table 8] 
All patients had more than one anatomical area of involvement. The lower limbs 
were involved in all patients. Skin lesions on trunk and upper limbs were noted in 
92.6% (n=25) patients and involvement of head and neck was noted in 51.8% (n=14) 
patients [Figure 5]. Palms and soles were involved in 4 patients (14.8%). Extent of 
involvement varies from 5% to > 90% of body surface area. 
All patients in the paediatric age group had skin lesions involving >1 anatomical area 
except one patient who had skin lesions only in one area. Most common anatomical 
area of involvement in the paediatric age group were lower limbs (4, 100%) followed 
by face (3, 75%), upper limbs (3, 75%) and trunk (2, 50%). Body surface involvement 
of skin lesions in children varied from 5% - 50%. 
 
 
Figure 5. Anatomical area of involvement in MF 
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‘T’ stage of skin lesions 
Most of the patients presented in T2a stage (14, 51.8%) followed by T2b (5, 
18.5%), T3 (4, 14.8%) and T4 (2, 7.4%). [Figure 6] In the paediatric age group 3 
patients (75%) were in T2a stage and one patient (25%) was in T1b stage. 
 
 
Figure 6. Frequency of patients at different stages of MF 
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Histopathological features [Table 9] 
Epidermotropism was noted in 25 patients (92.6%) and Pautrier‟s 
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25.9% (n=7) patients. Atypical lymphoid infiltrates extended to deep dermis in 5 
patients (18.5%) among which 60% (n=3) patients belonged to stage T3 and T4. 
Involvement of subcutis was noted in 2 patients (7.4%) of T3 stage of MF. Large cell 
transformation was noted in 2 patients (7.4%) among which one patient belonged to T3 
stage and the other patient belonged to T4 stage. Other features like lymphocyte 
tagging at dermoepidermal junction was seen in 18 patients (66.6%), mild to moderate 
spongiosis in 9 patients (33.3%) and eosinophilia in 2 patients (7.4%).  
 
Table 9.  Relative frequency of salient histological features of MF 
T stage Epidermotropism 
Pautrier’s 
microabscess 
Extension of 
atypical infiltrates 
to deep dermis and 
subcutis 
Large cell 
transformation 
T1a (n=1) 1/1(100) 0 0 ~ 
T1b (n=1) 0 1/1(100) 0 ~ 
T2a (n=14) 14/14(100) 3/14(21.4) 1/14 (7.1) ~ 
T2b (n=5) 4/5 (80) 2/5(40) 1/5 (20) ~ 
T3 (n=4) 4/4(100) 2/4(50) 4/4 (100) 1/5 (20) 
T4 (n=2) 2/2(100) 1/2(50) 1/2 (50) 1/2 (50) 
Total 
(n=27) 
25/27 (92.6) 9/27(33.3) 7/27 (26) 2/27 (7.4) 
( ) In percentage; ‘T’ staging based on ISCL/EORTC revised clinical staging and classification 
of mycosis fungoides and Sezary syndrome 
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Immunohistochemistry [Table 10] 
Pan T-cell marker CD3 was positive in all patients of MF. CD4 positivity was 
noted in 100% patients (n=27). CD8>CD4 was noted in 3/27 patients (stage T2a). Two 
adults and one child were the three patients with predominant CD8 positivity. Aberrant 
loss of CD7 antigen was noted in 25 patients (92.5%) and CD30 positivity in 2 patients 
(7.4%). Mib-1 index was done in 8/27 patients (1/14 patient in stage T2a, 2/5 patients 
in stage T2b, 3/4 patients in stage T3 and 2/2 patients in stage T4) among which 50% 
(n=4) (2 patients in stage T3 and one each in stage T4 and stage T2b) had index more 
than 30%.  
Table 10. Immunohistochemical features of MF (n=27) 
T stage CD3+ CD4+ CD7- CD30+ CD8>CD4 
MIB index 
<30% >30% 
T1a (n=1) 1/1 1/1 1/1 0 ~ ND ND 
T1b (n=1) 1/1 1/1 1/1 0 0 ND ND 
T2a (n=14) 14/14 14/14 14/14 0 3/14 1 ~ 
T2b (n=5) 5/5 5/5 4/5 0 0 1 1 
T3 (n=4) 4/4 4/4 3/4 2/4 0 1 2 
T4 (n=2) 2/2 2/2 2/2 0 0 1 1 
Total (n=27) 27/27 27/27 25/27 2/27 3/27 4 4 
ND – Not done 
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Bone marrow biopsies [Table 11] 
Bone marrow biopsy was done in 9/27 patients (33.3%). This included 2/14 
patients in stage T2a, 2/5 in stage T2b, 3/4 patients in stage T3 and 2 in stage T4. 3/9 
patients (1 each in stage T2b, T3 and T4) (33.3%) had involvement of the bone 
marrow.  
Lymph node biopsies [Table 11] 
Five patients (18.5%) had lymph node enlargement. Lymph node biopsy was 
done in 3/27 patients (11.1%) (2 patients were in stage T4 and one patient in stage T2a) 
who had significant enlargement of lymph nodes. One patient (33.3%) in stage T4 had 
involvement of lymphoma in the lymph node. 
Laboratory parameters [Table 11] 
ESR was done in 11/27 patients (40.7%) of whom 2 patients (18.1%) had 
elevation of ESR. One patient (3.7%) had Sezary cells in the peripheral smear. 
Hypoalbuminemia (serum albumin < 3.5 gm/dl) was noted in 1/23 patients (4.34%) and 
there was elevation of transaminases in 1/23 patients (4.35%). Serum alkaline 
phosphatase was elevated in 4/23 patients (17.3%) among whom one was a child and 
three were adults.  
Serum lactate dehydrogenase (Normal range 0-460 IU/l) was done in 23 
(85.2%) patients of which 10/23 patients (43.5%) had elevated LDH. A patient in stage 
IIIB had LDH level more than 1000 IU/l.  
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Viral markers 
Viral markers including HIV, hepatitis-B and hepatitis-C were done in 12 
patients (44.4%) and all of them were negative for the same. HTLV-1 antibody was 
found positive in an erythrodermic MF patient. 
Table 11. Primary CTCL - Laboratory parameters, imaging studies, bone marrow, 
lymph node biopsy and organ biopsy 
Primary 
CTCL 
(47) 
LDH CXR 
Abnormality 
in USG 
Other 
imaging 
BM 
involvement 
Abnormal 
LN Bx 
Misc 
Bx 
MF 
(27) 
10/23 
(43.5%) 
0/20 0/17 
1/8 
(12.5%) 
2/9 (22.2%) 
1/3 
(33.3%) 
0/1 
cALCL 
(3) 
2/3 
(66.7%) 
0/3 0/2 0/1 0/3 0 0 
LyP (8) 
2/7 
(28.6%) 
0/7 0/7 0 0/1 0 0 
SPTL 
(6) 
5/6 
(83.3%) 
0/6 0/5 0/3 0/6 0 0/1 
PTCL, 
NOS (3) 
2/3 
(66.7%) 
0/3 0/2 0/1 0/2 0 0 
HVLL 
(1) 
1/1 
(100%) 
1/1 
(100%) 
1/1 (100%) 0/1 0/1 0/1 0/1 
Total 
43 (22, 
51.1%) 
1/40 
(2.5%) 
1/34 2.9%) 
1/14 
(7.14%) 
2/22 (9.1%) 1/4 (25%) 0/3 
LDH - Lactate dehydrogenase; CXR – Chest X-ray; USG- Ultrasonography of abdomen and pelvis; 
BM – Bone marrow; LN Bx – Lymph node biopsy; Misc Bx – Miscellaneous organ biopsy; Other 
imaging includes CT scan, MR imaging and PET- CT scan; Denominator indicates the number of 
patients in whom the test was done 
 
56 
 
Imaging studies [Table 11] 
Chest X-ray 
Chest X-ray was done in 20 patients (74.1%) and none of them were detected 
with disease specific abnormalities.  
Ultrasonography 
Ultrasound imaging of the abdomen and pelvis was done in 17 patients (63%) 
and none of them were detected with any disease specific abnormality.  
 
Computed tomography imaging (CT scan) 
Computed tomography imaging of thorax was done in 6 patients (7.4%) and CT 
imaging of the abdomen was done in 4 patients (14.8%). None of them were detected 
with disease specific changes. 
Positron emission tomography 
Two patients (7.4%) underwent positron emission tomography imaging of 
whole body; one patient (50%) had extracutaneous (nodal) involvement the disease. 
Extra-cutaneous involvement 
Among 4/27 (14.8%) patients with extracutaneous involvement, 2 (50%) were 
in T4 stage while one (25%) was in T3 stage and one (25%) was in T2b stage. 3/4 
(75%) patients had bone marrow involvement and 1/4 (25%) patients had 
extracutaneous nodal involvement. 
TNM staging 
Complete staging was done in 22/27 patients who were screened by either of the 
imaging studies (22/27) (Ultrasonography, CT scan, MRI scan or PET scan), lymph 
node biopsies (3/27) and bone marrow biopsies (9/27). As 5/27 patients had only 
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limited skin involvement (4 patients in stage T2a and 1 patient in stage T1b) and 
normal physical examination, neither imaging studies nor organ biopsies were done in 
them. Most of the patients belonged to stage IB (18, 66%) followed by 3 patients (11%) 
in stage IA, 3 patients (11%) in stage IIB and each in stage II, stage IIIB and IVA2 
[Table 12]. 
Table 12. TNM staging of MF 
TNM staging No of patients Frequency (%) 
IA 3/27 11.1 
IB 18/27 66.7 
II 1/27 3.7 
IIB 3/27 11.1 
IIIB 1/27 3.7 
IVA2 1/27 3.7 
 
CD8 positive MF 
Three patients (2 adults and 1 child)showed predominant CD8 positivity in skin. 
All three patients presented with hypopigmented macules on the trunk and lower limbs. 
None of the patients had any systemic or laboratory abnormalities. All three patients 
belonged to „T2a‟ stage of the disease.  
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Molecular study (TCR gene rearrangement assay) 
In 22 patients with patch/plaque (Stage I/IIA) mycosis fungoides, the 
histological diagnosis of mycosis fungoides could not be excluded or the diagnosis was 
suggestive but not confirmatory in 14 patients. TCR gene rearrangement assay was 
done in 13/14 patients. Among them, 11/13 patients (84.6%) belonged to T1a/T2a stage 
of MF and 2/13 patients (15.4%) belonged to T2b stage. One patient belonged to T3 
stage of disease. Monoclonality was detected in 63.6% (7/11) patients of patch stage 
MF (T1a/T2a), 50% (1/2) patients of T2b stage. Monoclonality was detected in the 
patient with T3 stage. [Table 13] 
Table 13. Clonal detection rate in MF 
MF stage 
TCR gene rearrangement assay 
Monoclonal (n=9) Polyclonal (n=5) 
No Frequency (%) No  Frequency (%) 
T1a/T2a (11) 7 63.6% 4 36.4% 
T2b (2) 1 50% 1 50% 
T3 (1) 1 100% 0  
Total (14) 9 64.3% 5 35.7% 
( ) No. of patients in each ‘T’ stage of MF 
Histopathological features in monoclonal and polyclonal patients 
Histological diagnosis of MF was classified based on histological criteria for 
diagnosis of MF proposed by Guitart et al (35). Histological diagnosis of early stage 
MF (I/IIA) was compared with clonal detection rate [Table 14]. Monoclonality was 
detected in 80% (n=4) of patients in whom the histology was categorised as 
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probable/suggestive of MF versus 50% (n=4) of patients in whom it was categorised as 
MF cannot be excluded. Loss of lineage of T-cell differentiation antigens in early MF 
was found in 6/8 (75%) patients in monoclonal group while 2/5 (40%) showed the 
same in polyclonal group [Table 14]. One patient with CD8 positivity showed 
monoclonality and the other patient with CD8 positivity showed polyclonal pattern. 
Table 14. Relationship between histopathological diagnosis and clonality in early 
stage (I/IIA) MF 
Histological and 
immunohistochemical diagnosis of 
MF [Categorised as per grading 
protocol proposed by Guitart et al] 
(35) 
Monoclonal 
(n=8) 
Polyclonal 
(n=5) 
P 
Number % Number % 
MF cannot be excluded (n=8) 4/8 50% 4/8 50% 
0.564 
Probable/suggestive of MF (n=5) 4/5 80% 1/5 20% 
CD3+ , CD4+ and CD7- 6/8 75% 2/5 40% 0.2929 
CD8>CD4 1/8 12.5% 1/5 20% 
 
 
CD30 positive lymphoproliferative disorders (CD30+ LPD) 
Frequency and gender distribution 
Eleven patients (7 males, 4 females) had CD30+ LPD of whom 8 patients had 
lymphomatoid papulosis (72.7%) and 3 patients (27.3%) had primary cutaneous ALCL 
(cALCL). The M/F ratio was 1.75 [Figure 7].  
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Figure 7. Relative frequency and gender distribution in primary CD30+ LPD 
 
Age distribution 
Mean age of presentation was 34.6 ± 17.9 years (range 2-70 years). One patient 
was a female child aged 2 years and rest were adults (>16 years).  
 
Age at diagnosis 
Mean age at diagnosis of the disease was 33.8 ± 17.1 years (range 2-67 years) 
 
Duration of disease [Table 7] 
Mean age at which the patients noticed the skin lesions prior to the diagnosis 
was 30.9 ± 17.9 years (range 1-65 years). Median duration of skin lesions prior to the 
diagnosis of the disease was 12 months (range 4-204 months, mean 35 ± 58.5 months). 
 
  
0
1
2
3
4
5
6
7
8
Lyp
ALCL
5 
2 
3 
1 N
o
 o
f 
p
a
ti
en
ts
 
Male Female
61 
 
Types of skin lesions [Table 8] 
Papules were the most common morphological skin lesion noted in 9 patients 
(81.8%), followed by plaques in 2 patients (18.2%) and nodules in 2 patients (18.2%). 
One patient (9.1%) each presented with erythroderma and noduloulcerative skin 
lesions. 
 
Anatomical distribution [Table 8] 
Upper limbs were the most common anatomical area of involvement followed 
by lower limbs and trunk. 72.7 % (n=8) had involvement of upper limbs while 63.6 % 
(n=7) had skin lesions on trunk and lower limbs. Involvement of head and neck was 
seen in one patient (9.1%). Seven patients (63.6%) had skin lesions in more than one 
anatomical area and four patients (36.4%) had skin lesions only in one anatomical area. 
Except one patient who presented with erythroderma rest of the patients had less than 
10% of body surface involvement.  
 
Past treatment 
2/9 (22.2%) patients in the past were treated with systemic chemotherapy.  
 
Lymphomatoid papulosis (LyP) 
Frequency and gender distribution 
Eight patients (72.7%) had LyP among which 5 were males and 3 were females 
(M/F 1.66) 
 
Age at diagnosis [Table 7] 
Mean age at diagnosis of disease was 28.25±14.7 years (range 2-44 years) and 
all the patients were newly diagnosed during the study period.  
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Duration of disease [Table 7] 
Median duration of skin lesions prior to the diagnosis was 12 months. Mean 
duration of skin lesions prior to the diagnosis was 43.1±67.7 months (range 6-36 
months). 
 
Types of skin lesions [Table 8] 
All the patients presented with papules while one patient had coexistent 
noduloulcerative skin lesions.  
 
Anatomical distribution [Table 8] 
37.5 % (n=3) of patients had skin lesions on trunk and both extremities while 
25% (n=2) had involvement of upper and lower limbs. 37.5% (n=3) of patients had 
single anatomical area of involvement. None of the patients had skin lesions on head 
and neck. Extent of involvement was less than 10% in all patients.  
 
Systemic involvement 
One patient presented with fever for more than a month. None of the other 
patients presented with any systemic symptoms. Neither of the patients presented with 
lymph node enlargement nor with extracutaneous organ involvement. 
 
Laboratory investigations [Table 11] 
LDH level was elevated in 2/7 patients. None of the patients had anaemia or 
other cytopenia.  
 
Histopathological features [Table 15] 
All 7 patients were classified from Type A-D based on histological features. 
The most common type was LyP type A (5, 62.5%). One patient had an unusual pattern 
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(Type D) which histologically simulates an aggressive cytotoxic lymphoma but 
clinically indolent in nature. Epidermotropism was noted in 2/8 patients (25%) and 
tagging of lymphocytes along dermoepidermal junction was noted in 3/8 patients 
(37.5%). Atypical lymphocytic infiltrates extended upto subcutis in 1/8 (12.5%) 
patients while it extended upto deep dermis in 4/8 patients (50%). Mixed inflammatory 
infiltrates in dermis was noted in 5 patients and increased mitotic activity was evident 
in 5 patients. 
Table 15. Histological types of LyP 
Histological types 
LyP (n=8) 
No Freq 
Type A 5/8 62.5% 
Type B 2/8 25% 
Type C 0/8 0 
Type D 1/8 12.5% 
No - Number of patients; Freq - Frequency 
Immunohistochemical profile [Table 16] 
Diffuse CD30 positivity was noted in 3/8 patients (37.5%)and CD30 was 
focally positive in 5/8 patients (62.5%). Pan T-cell marker (CD3) was positive in 6 
patients while CD4 was positive in 5 patients and CD8 was positive in 2 patients. One 
patient showed positivity of granzyme B and TIA-1 antigen. CD56 marker was done in 
2 patients of whom one showed positivity of the same. Mib-1 index was done in 5 
patients (62.5%) and it was <10% in 3 patients, 10-30% in 1 patient and >30% in 1 
patient. 
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Table 16. Immunohistochemical markers pattern in CD30+ LPD 
IHC markers 
LyP (n=8) cALCL (n=3) 
Number of 
patients 
Frequency 
(%) 
Number of 
patients 
Frequency 
(%) 
CD30+ 
(n=8) 
Focal 5/8 62.5 0/3 ~ 
Diffuse 3/8 37.5 3/3 100 
CD3+ 6/8 75 3/3 100 
CD4+ 5/8 62.5 2/3 66.7 
CD8+ 2/8 25 0/3 ~ 
CD7- 4/8 50 ~ ~ 
ALK negative 1/1 100 3/3 100% 
Mib-1 
index 
<10% 3/5 60 1/2 50 
>10% 2/5 40 1/2 50 
ALK – Anaplastic lymphoma kinase;  
Bone marrow biopsy 
Bone marrow biopsy done in 1/8 patient (14.3%) (Stage IIB) was normal. 
Imaging studies [Table 11] 
Chest X-ray and ultrasound imaging of abdomen was done in all 8 patients and 
none of them had any disease specific abnormalities.  
 
Molecular study (TCR gamma gene rearrangement study) 
TCR gamma gene rearrangement was done in one patient (Type B LyP) who 
showed a dominant T-cell clone. 
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Staging of lymphomatoid papulosis [Table 17] 
Based on „T‟ stage of skin lesions, four patients (50%) belonged to stage T3b 
while 1 patient each belonged to stage T1a, T2a, T2b and T3a respectively. Based on 
TNM classification, 5 patients belonged to stage IIB while 2 patients belonged to stage 
IB and 1 patient belonged to stage IA. [Table 17] 
Table 17. TNM staging in LyP and cALCL 
TNM stage 
LyP (n=8) cALCL (n=3) 
No of 
patients 
Frequency 
No of 
patients 
Frequency 
IA 
1 12.5% 0 ~ 
IB 
2 25% 2 66.7 
IIB 
5 62.5% 1 33.3 
 
Primary cutaneous anaplastic large cell lymphoma (cALCL) 
Frequency and Gender distribution 
Three patients (2 males and 1 female) had primary cutaneous anaplastic large 
cell lymphoma.  
Age distribution 
All the patients were adults more than 40 years of age. Mean age at presentation 
was 51.7±15.9 years (range 41-70 years). 
Duration of skin lesions 
Mean duration of skin lesions prior to the diagnosis was 13.3±10.1 months. 
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Course of disease 
Two patients presented with relapse of the disease after completion of treatment 
with systemic chemotherapy (Cyclophosphamide, doxorubicin, vincristine and 
prednisone based chemotherapy). In one patient the disease had relapsed 4 years after 
completion of treatment and in another patient the disease relapsed within a year after 
treatment. 
 
Morphology of skin lesions 
The patients presented with papulonodular lesions (1, 33.3%), noduloulcerative 
skin lesions (1, 33.3%) and erythroderma (1, 33.3%).  
 
Anatomical distribution and extent of involvement 
The lesions were confined to trunk in 1 patient (33.3%) and both trunk and 
upper limbs were involved in 1 patient (33.3%). Extent of involvement was < 10 % in 2 
patients and one patient had >80% involvement. 
Systemic involvement 
One patient each had peripheral lymph node enlargement (axillary and inguinal 
groups) and mild hepatosplenomegaly. 
Laboratory investigations 
Mild anaemia and hypoalbuminemia was noted in one patient (33.3%).LDH 
level was elevated in 2 patients (66.7%). LDH level was >1000 IU/L in the patient with 
erythrodermic ALCL. The same patient also had atypical lymphocytes (13%) in the 
peripheral blood. 
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Histopathological features in primary cALCL [Table 18] 
Increased mitotic activity was noted in 2/3 patients (66.7%) and mixed 
inflammatory infiltrates in 2/3 patients (66.7%). Multinucleated cells and extensive 
neutrophilic infiltrates were noted in 1 patient (33.3%)  
Bone marrow biopsy 
Bone marrow biopsy did not show any evidence of involvement with lymphoma 
in all three patients. 
Table 18. Histological features in primary cALCL 
Histological features in 
ALCL 
Patient 1 Patient 2 Patient 3 
Size of atypical cells 
Medium to 
large 
Large Medium 
Depth of atypical cell 
infiltrates 
Superficial 
dermis 
Deep dermis Superficial dermis 
Inflammatory infiltrates Absent Present Present 
Mitoses Present Absent Present 
Multinucleated cells Absent Present Absent 
Bone marrow biopsy Normal Normal Normal 
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Immunohistochemical features [Table 16] 
Diffuse CD30 positivity was noted in all three patients while ALK was negative 
in all three patients. Pan T-cell marker CD3 was positive in all patients and B-cell 
marker CD20 was negative. CD4 positivity was seen in 2 patients (66.7%) while none 
of them showed CD8 positivity. Mib-1 index was <10% in 1 patient and >30% in 1 
patient. 
Imaging studies 
Chest X-ray and ultrasound imaging of abdomen did not show any disease 
specific abnormality. 
 
Staging of primary cALCL [Table 17] 
One patient had extracutaneous nodal involvement. Based on extent of 
involvement of skin lesions the patients were staged as T3b, T2b and T2a each. As per 
TNM classification the patients were staged as T3bN1M0 (IIB), T2bN0M0 (IB) and 
T2aN0M0 (IB) [Table 17]. 
 
Subcutaneous panniculitis like T-cell lymphoma (SPTL) 
Age and gender distribution 
All patients diagnosed with SPTL were >16 years. There were 5 females and a 
male. (M/F 1:5). 
Age at diagnosis 
Mean age at diagnosis of the disease was 33.7±17.2 years (range 19-60 years, 
median 27.5 years). 
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Duration of skin lesions [Table 7] 
Median duration of skin lesions prior to the diagnosis of the disease was 6 
months (Mean – 17.8 ± 32.5 months, range – 0.5-84 months). 
While 4 patients (66.7%) were newly diagnosed, one patient was in remission 
after treatment and one patient presented with relapse of the disease. Relapse of the 
disease occurred 3 years after the completion of systemic chemotherapy. 
Types of skin lesions [Table 8] 
All six patients (100%) presented with subcutaneous nodules and one patient 
presented with large purpuric macules overlying the subcutaneous indurated nodules. In 
one patient (16.6%) plaques coexisted with nodular skin lesions.  
Anatomical distribution [Table 8] 
Most common area of involvement was trunk (5, 83.3%) followed by lower 
limbs (4, 66.6%) and then upper limbs (3, 50%). Involvement of face was noted in 2 
patients (33.3%). Four patients (66.7%) had involvement of >1 anatomical area. Total 
body surface area involvement of skin lesions was <10% in 5 patients (83.3%) and one 
patient had involvement of >10%. 
 
Systemic involvement 
Four patients (66.7%) presented with systemic symptoms including fever, 
weight loss and pedal edema. 50% (n=3) patients had peripheral lymph node 
enlargement. Two patients (33.3%) had hepatomegaly among which one patient had 
ascites. 
 
Laboratory investigations [Table 11] 
Four patients (66.7%) had anaemia (Haemoglobin <12 gm/dl); one patient 
(16.6%) had mild thrombocytopenia (<1 lakh cu.mm) and one patient had elevated 
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ESR. Hypoalbuminemia was noted in 3 patients (60%) and elevated transaminases 
were noted in 2 patients (40%). LDH level was elevated in 5 patients (83.3%) and it 
was more than 1000 IU/l in 3 patients (50%). Viral markers (HIV, hepatitis-B and 
hepatitis- C) done in all patients were negative. EBV PCR done in a patient was 
negative. 
Histopathological features [Table 19] 
Unique histopathological features noted in all patients of SPTL were atypical 
lymphoid infiltrates involving subcutis and rimming of adipocytes by atypical 
lymphocytes. Predominant lobular panniculitis was noted in all patients while septal 
involvement was noted in one patient (16.7%). Fat necrosis was noted in 2 patients 
(33.3%) and haemophagocytosis was noted in 1 patient (16.7%). 
 
Immunohistochemical features [Table 19] 
Pan T-cell marker (CD3) and cytotoxic T-cell marker (CD8) were positive in all 
patients. Three patients showed focal positivity of CD4. Granzyme B done in 4/6 
(66.7%) patients showed positivity of the same and CD56 done in 5/6 (83.3%) patients 
was negative. TIA-1 antigen done in 3/6 (50%) showed positivity of the same. Mib-1 
index was 11-30% in 4/6 patients (66.7%) and >30% in 2/6 patients (33.3%). 
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Table 19. Histological and immunohistochemical features of SPTL 
Subcutaneous panniculitis like T-cell 
lymphoma 
Number of 
patients (n=6) 
Frequency 
Panniculitis 
Lobular 6/6 100% 
Septal 1/6 16.7% 
Fat necrosis 2/6 33.3% 
Haemophagocytosis 1/6 16.7% 
CD4+ 3/6 50% 
Granzyme B 4/6 66.7% 
CD56 negativity 5/6 83.3% 
TIA-1 antigen positivity 3/6 50% 
Mib-1 index 
<50% 4/6 66.7% 
>50% 2/6 33.3% 
TIA-1 – T-cell intracellular antigen -1 
 
 
Bone marrow biopsy 
Bone marrow biopsy was done in all six patients and there was no evidence of 
lymphoma involvement in bone marrow. 
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Imaging studies [Table 11] 
Chest X-ray 
Chest X-ray was normal in all patients.  
Ultrasonography 
Ultrasound imaging of abdomen was done in 5/6 (83.3%) patients and none of 
them showed any disease specific abnormalities.  
CT scan 
CT scan of thorax and abdomen done in 3 patients did not show any disease 
specific abnormality.  
PET-CT scan 
PET-CT scan done in a patient did not show any features of extra cutaneous 
involvement. 
Extracutaneous involvement 
None of the patients had extracutaneous involvement at the time of presentation. 
Staging of SPTL [Table 20] 
Three patients were in stage T3b while 2 patients were in stage T3a and 1 
patient was in stage T2b. Based on TNM staging, four patients (80%) were in stage IIB 
while two patients were in stage IB. 
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Table 20. ‘T’ stage and TNM stage in SPTL patients 
Staging 
Number of patients 
(n=6) 
Frequency 
T staging 
T2b 1/6 16.7% 
T3a 2/6 33.3% 
T3b 3/6 50% 
TNM 
staging 
IB 2/6 33.3% 
IIB 4/6 66.7% 
 
Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) 
Frequency and gender distribution 
PTCL, NOS constituted 6.25% (n=3) of all primary CTCLs. All the three 
patients were males and were newly diagnosed during the study period. 
 
Age distribution and duration of skin lesions [Table 6] 
All 3 patients were adults (>16 years). Mean duration of skin lesions prior to the 
diagnosis was 4.7±1.5 months (range 3-6 months). 
 
Age at diagnosis 
Mean age at diagnosis of the disease was 56.3 ± 18.9 years (range 40-77 years). 
 
Types of skin lesions [Table 8] 
All 3 patients presented with nodules, in 1 patient they were ulcerated. Two 
patients (66.7%) had plaques coexisted with nodules 
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Anatomical distribution [Table 8] 
One patient (33.3%) had a solitary nodular skin lesion on face and rest (2, 
66.7%) had skin lesions involving face, trunk and both extremities 
 
Systemic symptoms 
None of the patients had any significant systemic symptoms at the time of 
presentation. One patient had peripheral lymph node enlargement. 
 
Laboratory investigations [Table 11] 
One patient (33.3%) had thrombocytopenia and 2 patients (66.7%) had elevated 
ESR values. Hypoalbuminemia was noted in one patient. All the patients had normal 
liver enzymes. LDH was elevated in 2 patients (66.7%). Viral markers (HIV, hepatitis-
B and hepatitis- C) done in all patients were negative.  
 
Histopathological features 
Two patients (66.7%) had atypical lymphoid infiltrates involving the whole 
dermis (pandermal) and one patient (33.3%) had atypical lymphoid infiltrates extending 
to the mid dermis. One patient (33.3%) displayed epidermotropism and another patient 
showed lymphocyte tagging along the dermoepidermal junction.  
Immunohistochemical markers [Table 21] 
Pan T-cell marker (CD3) and helper T-cell marker (CD4) were positive in all 
three patients while cytotoxic T-cell marker was positive in 2 patients (66.7%). In all 
three patients ratio of CD4 positive cells were more than CD8 positive cells. Aberrant 
loss of CD7 antigen is noted in all three patients. Other immunological markers 
including granzyme B, TIA-1and CD56 were negative in 2 patients. CD30 was 
negative in all 3 patients. Mib-1 index was <10% in 1 patient, >30% in the rest of the 2 
patients. EBV marker done in 1 patient was negative. 
75 
 
Bone marrow biopsy 
Bone marrow biopsy was done in two patients and none of them showed 
involvement of bone marrow. 
 
Imaging studies [Table 11] 
Chest X-ray 
Chest X-ray was normal in all 3 patients.  
Ultrasonography 
Ultrasound imaging of abdomen was done in 2 patients (66.7%) who did not 
show any involvement of other organs or central lymph nodes.  
 
PET scan 
PET scan done in a patient did not show features of any extracutaneous 
involvement. 
 
Staging of PTCL, NOS 
None of the patients had extracutaneous involvement at the time of 
presentation. Two patients were in stage T3b and one patient was in stage T1a. Based 
on TNM staging, 1 patient was in stage IA and two were in stage IIB. 
Clinical, histological and immunological features of all three patients of PTCL, 
NOS are summarised in Table 21. 
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Table 21. Clinical, histological and immunohistochemical pattern in PTCL, NOS 
Features Patient 1 Patient 2 Patient 3 
Sex Male Male Male 
Age at diagnosis 
(in years) 
52 40 77 
‘T’stage T1a T3b T3b 
Stage IA IIB IIB 
Skin lesions N P, N, U P, N 
Area involved H H, T, UL, LL H, T, UL, LL 
Extent of 
involvement 
1% >50% 30-50% 
Extracutaneous 
involvement 
No No No 
LDH (IU/L) 385 700 733 
Immunological 
markers 
CD3+, CD4+, 
CD8+, CD7-, 
CD56-, CD30- 
grB- and TIA1- 
CD3+, CD4+, 
CD8+, CD7-, 
CD56-, CD30- 
grB- and TIA1- 
CD3+, CD4+, 
CD8-, CD7- and 
CD30- 
P- Plaque; N-Nodule; T- Trunk; U-Ulcer; H- Head and neck; T-Trunk; UL-Upper limbs; LL- Lower 
limbs; grB- Granzyme B; TIA-1- T-cell intracellular antigen-1; Staging was done based on 
ISCL/EORTC proposal on TNM classification of cutaneous lymphoma other than MF/SS 
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Hydroa vacciniforme like T-cell lymphoma (HVLL) 
Hydroa vacciniforme like T-cell lymphoma, an EBV+ T-cell 
lymphoproliferative disorder of childhood occurred in a male child aged 14 years. 
Frequency of HVLL of all primary CTCL was 2.08%. Skin lesions were noticed since 
1 year before the diagnosis was made. 
Type of skin lesions and duration of disease 
The patient had papulovesicular skin lesions of 1 year duration. Face, upper 
limbs and lower limbs were involved. Extent of involvement was <10% of total body 
surface area. He presented with facial edema of 1 year duration. 
 
Systemic symptoms 
The patient had low grade fever for 1 year. He also had weight loss for more 
than 6 months.  
 
Laboratory investigations 
Patient had hypoalbuminemia along with elevation of liver enzymes and 
alkaline phosphatase. LDH level was more than 1000 IU/L. Viral markers (HIV, 
hepatitis-B and hepatitis- C) were negative. Qualitative EBV PCR done was positive. 
 
Histopathological and immunohistochemical features 
Skin biopsy showed atypical lymphoid infiltrates which extended unto the 
underlying skeletal muscle. Immunohistochemistry profile was consistent with the 
diagnosis of hydroa vacciniforme like T-cell lymphoma. Atypical lymphoid infiltrates 
showed diffuse positivity for CD3, CD8, CD56 and granzyme B while it showed a 
focal positivity of TIA-1 antigen, CD30 and EBV LMP-1. CD20 marker was negative 
and there was aberrant loss of CD7 antigen. 
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Molecular study 
TCR gamma gene rearrangement assay was done which showed dominant T-
cell clonal population of cells. 
Bone marrow, lymph node and liver biopsy 
Bone marrow, lymph node and liver biopsies done did not show any features of 
systemic involvement. 
Imaging studies 
Ultrasound imaging of abdomen and pelvis revealed hepatosplenomegaly.  
Staging of HVLL 
„T‟ stage of the patient was T3b while the final TNM staging was T3bN0M0 
(IIB). 
Primary cutaneous B-cell lymphoma 
Diffuse large B-cell lymphoma, other 
Clinical profile 
A 65 year old male was diagnosed to have primary cutaneous B-cell lymphoma 
who presented with multiple erythematous annular plaques and underlying induration 
on the left forearm. Two years after onset of symptoms he had bone marrow 
involvement. Extent of involvement of skin lesions of the total body surface area was 
<5%. At presentation he did not have any systemic symptoms.  
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Laboratory investigations 
All relevant investigations including haemoglobin, WBC count, platelets and 
ESR were normal. LDH level was normal (314 IU/L). Viral markers (HIV, hepatitis-B 
and hepatitis- C) done in the patient were negative. 
Histopathological and immunohistochemical features 
Skin biopsy from the plaque showed atypical lymphoid infiltrates extended till 
subcutis. Immunohistochemical profile was consistent with the diagnosis of T-cell rich 
diffuse large B-cell lymphoma. Both T-cell marker (CD3) and B-cell marker (CD20) 
were positive while CD30 marker was negative. 
Bone marrow biopsy 
Bone marrow biopsy done during initial diagnosis did not show any 
involvement. But it was found to be involved when the patient presented with a relapse 
involving the skin two years later. 
Imaging studies 
Chest X-ray done was normal. Ultrasound imaging of the abdomen and pelvis 
did not show any disease specific abnormality. Computed tomography imaging of the 
thorax was done which was normal. 
Staging of PCLBCL, other 
„T‟ stage of the patient was „T2b‟. As the patient had developed extracutaneous 
bone marrow involvement of lymphoma final staging at the time of diagnosis of relapse 
was IVB. 
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Secondary cutaneous lymphomas  
Frequency and gender distribution 
Among 54 patients whom were included in the study, 5 patients (9.25%) (2 
males, 3 females; M: F ratio 0.66) were diagnosed to have secondary cutaneous 
lymphomas. Four (80%) were of T-cell origin and one (20%) was of B-cell origin 
[Figure 8]. 
 
Figure 8. Various subtypes of secondary cutaneous lymphomas 
 
Age distribution 
All patients with secondary CL were adults (>16 years) [Table 22]  
 
Age at diagnosis [Table 22] 
Mean age at diagnosis of secondary cutaneous lymphomas was 45.2 ± 12.5 
years (range, 32-59 years, median-46 years) while the mean age of diagnosis of the 
extracutaneous involvement was 44.6 ± 12.05 years (range, 32-58 years). 
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Duration of skin lesions 
In 3 patients (60%) diagnosis of cutaneous and systemic involvement were 
made concurrently while in 1 patient (20%) cutaneous involvement was found after 6 
months of systemic diagnosis and in another patient cutaneous involvement was found 
within 6 months of systemic diagnosis. 
Types of skin lesions [Table 22] 
Most common type of skin lesion noted among patients with secondary 
cutaneous lymphomas was nodules (4, 80%) followed by plaques (3, 60%). In two 
patients (28.6%) plaques coexisted with nodular skin lesions. One patient (16.7%) 
presented with bullous and ulcerative skin lesions. 
Anatomical distribution of skin lesions [Table 22] 
Common area of involvement of skin lesions in decreasing order of frequency 
was trunk (5, 100%) followed by lower limbs (3, 60%), upper limbs (2, 40%) and head 
and neck (2, 50%). 3/5 (60%) patients had more than one anatomical area of 
involvement. One patient had body surface area involvement of more than 50% and 
another patient had 11-30% of body surface area involvement and the rest of the 
patients (3, 60%) had involvement less than 10% of body surface area. 
Systemic symptoms [Table 22] 
4/5 patients (80%) presented with systemic B-symptoms including fever, weight 
loss, cough and pedal edema. Four patients (80%) had peripheral lymph node 
enlargement at the time of presentation and 3 patients (60%) had hepatosplenomegaly 
on clinical examination. One patient (20%) presented with ascites. 
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Table 22. Demographic and clinical profile of secondary cutaneous lymphomas 
No Diagnosis AD Gender 
Skin 
lesion 
Anatomical 
area 
B-
symptoms 
T-
stage 
1 ALCL 58 F P, NU H, T Absent T3b 
2 ALCL 45 M N T Present T3a 
3 PTCL, NOS 55 F P, N T, UL, LL Present T3b 
4 PTCL, NOS 32 M P, B, U H, T, UL, LL Present T3b 
5 
Plasmablastic 
lymphoma 
33 F N T Present T3a 
F – Female; M- male; P- Plaque; N –nodule; B- Bullous; NU-Noduloulcerative; U-Ulcer; H- Head and 
neck; T- Trunk; UL- Upper limbs; LL- Lower limbs; ‘T’ staging based on ISCL/EORTC proposal on 
TNM classification of cutaneous lymphoma other than MF/SS; AD – Age at diagnosis;  
 
Laboratory investigations 
Anaemia was noted in 3 patients (60%) but none had thrombocytopenia or 
leukopenia at the time of presentation. One patient (20%) had hypoalbuminemia. LDH 
level was elevated in 4 patients in whom the test was done. Two patients (50%) had 
LDH level more than 1000 IU/L. One patient was detected to have human 
immunodeficiency virus (HIV) infection. Viral markers in other patients were negative. 
 
Histopathological and immunohistochemical features [Table 23&Table 24] 
Epidermotropism was noted in 1 patient (20%) of secondary PTCL, NOS. 
Atypical lymphoid infiltrates extended into the subcutis in 2 patients (40%), deep 
dermis in 2 patients (40%) and superficial dermis in 1 patient (20%). Increased mitotic 
83 
 
activity was noted in 3 patients (60%) while angioinvasion was noted in 1 patient 
(20%). 
Histopathological and immunohistochemical features of secondary cutaneous T-
cell and B-cell lymphoma were summarised in [Table 23 & Table 24]. 
 
Table 23. Histological features in various subtypes of secondary cutaneous 
lymphoma 
 
Diagnosis Stage 
Epidermot-
ropism 
Depth of 
infiltrates 
Angioinva-
sion 
Patient 
1 
ALCL T3b Absent Subcutis Absent 
Patient 
2 
ALCL T3a Absent Subcutis Absent 
Patient 
3 
PTCL, NOS T3b Present Deep dermis Absent 
Patient 
4 
PTCL, NOS T3b Absent 
Superficial 
dermis 
Present 
Patient 
5 
Plasmablastic 
lymphoma 
T3a Absent Deep dermis ~ 
 
Bone marrow and lymph node biopsy 
Bone marrow involvement was found in 4 patients (80%) and lymph node 
involvement was found in 1 (20%) patient. 
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Table 24. Immunohistochemistry pattern in various subtypes of secondary 
cutaneous lymphoma 
 
Diagnosis Stage CD3 CD20 CD30 CD4 CD8 
Other 
markers 
Patient 
1 
ALCL T3b CD3+ CD20- CD30+ CD4+ CD8- 
CD43- 
ALK -  
Patient 
2 
ALCL T3a CD3- CD20- CD30+   
CD43+ 
CD79a- 
ALK - 
Patient 
3 
PTCL, NOS T3b CD3+ CD20- CD30+ CD4+ CD8-  
Patient 
4 
PTCL, NOS T3b CD3+ CD20- CD30- CD4+ CD8- 
CD7+ 
CD56-  
Patient 
5 
Plasmablastic 
lymphoma 
T3a CD3- CD20- ~ ~ ~ 
CD138+ 
EBV+ 
 
Imaging studies 
Ultrasonography 
Ultrasound imaging of abdomen and pelvis was done in all five patients of 
whom two patients showed disease specific abnormality.  
 
CT scan 
CT scan of thorax was done in 2 patients and both of them showed disease 
specific abnormality.  
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PET scan 
Whole body PET scan was done in patient showed features of systemic 
involvement of lymphoma.  
 
Staging of secondary cutaneous lymphomas [Table 22] 
Three patients (60%) belonged to stage T3b and 2 patients (40%) belonged to 
stage T3a. Based on TNM classification all patients belonged to stage IVB. 
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A. Lymphocytes tagging along dermoepidermal junction in early MF [H&E 100x]. B. 
Atypical small to medium sized cells with features of inconspicuous nucleoli and scant 
cytoplasm in early MF [H&E 400x]. CD3 positivity is noted on top left [inset] 
 
 
 
 
 
 
               
A. Hypopigmented MF; B Shows atypical lymphoid infiltrate showing epidermotropism 
[Inset, top right picture shows Pautrier’s microabscess] H&E 100x 
 
 
A B 
A B 
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A. Hypopigmented MF: Atypical infiltrate showing epidermotropism [H&E 400x]. CD8 
positivity of tumor cells [inset picture in top left]; B. Poikilodermic Mycosis Fungoides: 
Shows infiltrate consists of small to medium sized atypical cells with hyperchromatic 
nuclei, inconspicuous nucleoli and scant cytoplasm[H&E 400x]. Inset picture shows the 
tumor cells are positve for CD4 [top left] 
 
 
 
  
A. Mycosis Fungoides in Transformation: Shows atypical lymphoid infiltrates mixed with 
other inflammatory cells.H&E [100x]; B. The atypical lymphoid cells with hyperchromatic 
to coarse chromatin, inconspicuous nucleoli and scant to moderate amount of cytoplasm 
[H&E 400x]. CD4 positivity of atypical infiltrates [inset-top left] and   CD30 large cells [top 
right] 
 
A B 
A B 
88 
 
         
A. Subcutaneous panniculitis like T-cell lymphoma - Erythematous nodules on 
anterior aspect of neck; B. Subcutaenous panniculitis like T cell lymphoma: Shows 
diffuse infiltrates involving predominantly lobules of subcutis [H&E 40x] 
 
 
SPTL - Shows rimming of adipocytes with few histiocytes engulfing nuclear dust forming 
bean bag cells[arrow][H&E 400x]. CD8 positivity of atypical infiltrates [inset] 
 
 
     
A. Tumor on forehead consistent with peripheral T-cell lymphoma, not otherwise 
specified; B. PTCL, NOS - Shows atypical lymphoid cells with hyperchromatic nuclei and 
scant cytoplasm with few admixed large histiocytes [H&E 400x] 
 
A B 
A B 
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A. Erythematous plaque with annular morphology on forearm consistent with diffuse 
large B-cell lymphoma; B. Primary cutaneous diffuse large B cell lymphoma, other: Shows 
medium to large sized cells with centrocytes, few centroblast and few intermixed mature 
lymphocytes [H&E 400x]. CD20 positivity of tumor cells [Inset in top left] 
 
 
 
 
Crusted papulovesicular lesions on face consistent with hydroa vacciniforme like T-cell 
lymphoma 
 
A B 
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A. Chronic erythroderma consistent with anaplastic large cell lymphoma; B. Primary 
cutaneous anaplastic large cell lymphoma: Sheets of large cells with moderate to marked 
pleomorphism including mitotic figures and few large pleomorphic cells [H&E 400x]. 
CD30 positivity of large cells [Inset on top left]  
 
 
Mycosis fungoides – Plaque stage 
 
    
A. Vesicular lesions on both palms – consistent with MF; B- Cell poor intraepidermal bulla 
with focal epidermotropism 
A B 
A B 
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Coalescing papular lesions on both forearms consistent with diagnosis of LyP 
 
 
 
 
 
A. Lymphomatoid papulosis type D – Crusted papular lesions on medial aspect of left foot; 
B. Atypical lymphoid cells in epidermis [epidermotropism] Inset picture on top left corner 
-CD30 immunostaining of atypical lymphoid cells [x400] 
 
 
 
 
 
A B 
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DISCUSSION 
Cutaneous lymphomas accounts for 19% cases of all extranodal lymphomas, 
second most common form of extranodal lymphoma after GI lymphomas (27%) (6).  
There is a paucity of data on cutaneous lymphoma from the Indian subcontinent 
(22,23,25). All published studies on CL are hospital based, so the true prevalence of CL 
in India is not known. Among CL the reported prevalence of primary CTCL was 70 -
80% and CBCL was 20-30% in Europe and West (6,7,18). In Asians the reported 
prevalence of primary CTCL was 75-85% while that of primary CBCL was 12-20% 
(8,9). In our study we found a higher prevalence of CTCL (n=48, 97.9%) while that of 
CBCL was 2.08% (n=1). Among the other CL, the prevalence of CD30 positive LPD 
and SPTL were found to be higher than that reported from the West(6,7,18). The 
comparative profile is shown in Table 25. 
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Table 25. Frequency of subtypes of cutaneous lymphomas in different multicentre 
studies around the world 
Study Group DACLG SEER JSCS KOREA DDG 
Present 
study 
Country NL+A US JAPAN KOREA GER IND 
Year 2005 2009 2014 2014 2007 2014 
Total number of 
patients 
1905 3884 1733 517 998 49 
Mature T-cell and NK-cell 
neoplasms 
77 
(1496) 
71.3 
(2796) 
85.7 
(1485) 
74.2 
(311) 
85 
(848) 
97.9 (48) 
MF 47 38.3 43.3 21.3 61 55.1 
Primary cutaneous 
CD30+LPD 
NA 10.2 12.0 NA NA 22.4 
Anaplastic large-cell 
lymphoma (ALCL) 
8 NA 7.8 6 8 6.1 
Lymphomatoid papulosis 
(LyP) 
12 NA 3.8 6.2 4.4 16.3 
Subcutaneous 
panniculitis-like T-cell 
lymphoma (SPTL) 
1 0.6 2.0 6 <1 12.2 
Peripheral T-cell 
lymphoma, Unspecified 
(PTCL) 
2 20.8 5.8 9.9 ~ 6.1 
Mature B-cell neoplasms 22.5 28.5 12.9 17.7 15 2.08 
Diffuse large B-cell 
lymphoma, other (PCLBCL, 
other) 
0.2 8.8 NA 1.6 ~ 2.04 
CL - Cutaneous lymphoma; DACLG - Dutch and Austrian Cutaneous Lymphoma Group; EORTC - 
European Organization for Research and Treatment of Cancer; MF - mycosis fungoides; SS - Sezary 
syndrome; PCL - primary cutaneous lymphoma; PTL - peripheral T-cell lymphoma; SEER - 
Surveillance, Epidemiology, and End Results; WHO - World Health Organization; PCL - Primary 
cutaneous lymphoma; MF - mycosis fungoides; SS - Sezary syndrome; NL+A - Netherlands and 
Austria; US - United states of America; Ger - Germany 
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It is noteworthy that the frequency of SPTL in our study was much higher than 
in Europe, US, Japan and few single Institutional studies around the world 
(6,8,9,18,92). Among the CD30+ LPD, LyP was the common subtype. The prevalence 
of LyP in Germany and Asian countries varied from 3.5 - 6.5% which is lower than that 
seen in our study (16.3%). The frequency of cutaneous ALCL in our study (6.1%) was 
similar to the multicentre studies from U.S, Japan, Korea and Germany (7–9,18) [Table 
25]. The frequency of PTCL, NOS was almost similar as in Japan but much lower than 
those observed from Korea and U.S (6,8,9). There was one case of HVLL in our series 
which has not been reported from India previously. HVLL is mainly reported from 
Korea, China and central and South American countries (63–65). Hospital based 
studies from India has shown the prevalence of MF to be 36-40% which is relatively 
lower than that observed in our study (56.25%) (23,25) [Table 26]. The frequency of 
SPTL and PTCL, NOS were similar to an Indian study conducted in a similar setting 
(23).  Except a study from Taiwan which showed an increased prevalence of PTCL, 
NOS of 16.1%, most studies including ours have shown a low prevalence of PTCL, 
NOS (92–95). 
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Table 26. Comparison of demographic profile of cutaneous lymphomas with 
various studies done in India 
 
George et al, 
1999*(23) 
Doshi et al, 
2011(22) 
Burad 
et al, 
2014# 
(25) 
Present study 
Type of 
study 
R study R study R study P study 
Duration of 
study 
10 years 5 years 2 years 22 months 
 F AR M/F F AR M/F F F AR M/F 
MF/SS 39.4 36-70 5.5:1 74.4 20-39 3:2 36 56.25 6-74 1.25 
PCALCL 3.03 ~ 1:0 2.12 ~ 2:1 8.2 6.25 41-70 2.0 
LYP ~ ~ ~ 17 41-60 2:1 8.2 16.7 2-44 1.67 
SPTL 9.09 ~ ~ ~ ~ ~ 24.5 12.5 19-60 0.2 
PTL 9.09 ~ ~ ~ ~ ~ 19.6 6.25 40-77 ~ 
HVLL ~ ~ ~ ~ ~ ~ ~ 2.08 ~ 1:0 
CBCL 21.1 35-70 5:1 5.67 41-60 1.6:1 ~ 2.08 ~ 1:0 
* Based on R.E.A.L classification; #Study included all peripheral T cell lymphomas; R-Retrospective 
study; P- Prospective study 
 
Gender distribution 
Like many other studies around the world including Indian studies our study 
also showed male preponderance among primary and secondary cutaneous lymphomas 
with the exception of SPTL which is more common in females(6,8,9,23,92) [Table 27]. 
The reported M/F ratio in CTCL varies from 1.02 to 1.7 and that of CBCL varies from 
1.6 to 2.08 (6,92,93) [Table 28]. 
In our study the M/F ratio of CTCL was 1.28 and that of CBCL was 1:0. 
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Table 27. Comparison of gender distribution and mean age at diagnosis of 
cutaneous lymphomas across different countries 
Study group 
DACLG 
(7) 
SEER (6) JSCS (8) KOREA (9) Present study 
NL+A US Japan S.Korea India 
 M/F AD M/F AD M/F AD M/F AD M/F AD 
MF 1.8 57.5 1.66 ~ 1.41 62 1.1 ~ 1.25 43 
PCALCL 2.5 ~ 1.73 ~ 1.62 67.5 1.3 ~ 2 40 
LyP 1.5 45 ~ ~ 0.83 53.5 ~ ~ 1.67 29 
SPTL 1 ~ ~ ~ 0.55 55 0.5 ~ 0.2 27.5 
PTL ~ ~ 1.82 ~ 1.09 68 1.1 ~ ~ 52 
HVLL ~ ~ ~ ~ ~ ~ ~ ~ 1:0 14 
PCLBCL, 
other 
~ ~ 1.70 ~ 0.90 77 1.9 ~ 1:0 65 
M/F – Male: Female ratio; AD – Age at diagnosis 
 
Age distribution 
Results from our study show that the primary cutaneous T-cell lymphomas 
present earlier as  compared to patients from other studies (7,8,92,93). Studies from 
U.S, Korea, Japan and Switzerland had demonstrated that majority of the MF present in 
the  6
th 
to 7
th 
decade while in our study median age at diagnosis of MF was 43 years 
(6,8,92,93) [Table 27&Table 28]. 
 This was also seen in patients with SPTL where the disease was detected 
around 6
th
 decade of life (median age at diagnosis was 55 years) in a study from Japan 
while in our study the most common  age group affected was 20-30 years of life 
(median age at diagnosis was 27.5 years) (8). 
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Table 28. Comparison of demographic profile of cutaneous lymphomas with 
various Institutions across the world 
Country 
Switzerland 
(92) 
France (95) Korea (94) Taiwan (93) Present study 
Year 2011 2006 2012 2010 2014 
Type of study R study P study R study R study P study 
Duration 20 years 7 years 16 years 16 years 22 months 
Total patients 263 203 96 31 54 
 F (%) M/F F (%) F (%) M/F F (%) M/F F (%) M/F 
CTCL 72 1.3:1 75.9 84.3 1.02:1 74 1.09:1 97.9 1.28 
MF 43 1.5:1 43.3 21.9 ~ 13 1:1 56.25 1.25 
PCALCL 8.4 1:1.2 3.5 13.5 ~ 8 2:1 6.25 2 
LyP 5 1.4:1 7.4 9.4 ~ 6.5 1:1 16.7 1.67 
SPTL ~ ~ <1 10.4 ~ 3 0:1 12.5 0.2 
PTL 2 ~ 0.5 3.1 ~ 16 1:4 6.3 3:0 
HVLL ~ ~ ~ ~ ~ ~ ~ 2.04 1:0 
CBCL 28 1.9:1 24.1 ~ ~ 13.5 1.6:1 2.08 1:0 
PCLBCL 4 1.5:1 0 1 ~ 6 2:0 2.08 1:0 
MF-Mycosis fungoides; PCALCL-Primary cutaneous anaplastic large cell lymphoma; LyP – Lymphomatoid 
papulosis; SPTL- subcutaneous panniculitis like T cell lymphoma; PTL- Peripheral T cell lymphoma 
unspecified; F- Frequency in percentage; M/F – Male:Female ratio; R – Retrospective study; P – Prospective 
study 
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Cutaneous lymphomas in children [Table 29] 
Cutaneous lymphomas are uncommon in children and accounts for 6% of all 
malignant neoplasms in children (<20 years) (96). MF was the commonest among 
CTCL in Europe while LyP was the commonest among CTCL in Korea (26,27). 
Though we considered the paediatric age group in this study as age ≤ 16 years (as per 
Institutional norms), to facilitate the age adjusted comparison between published 
studies we considered the patients who have been diagnosed as cutaneous lymphoma 
before the age of 20 years. In our study, MF was the most common CL which occurred 
in 4/9 patients (age ≤ 20 years). The frequency of MF was similar to the observation 
made in Europe (27) [Table 29] 
SPTL and lymphomatoid papulosis occurred in 2 patients each (n=2, 22.2%). 
Median age of diagnosis of MF and LyP in our study (13 and 9.5 years) was similar to 
the Korean study (13.8 and 8 years) but slightly lower than the  European study (17 and 
14 years) (26,27) [Table 29]. 
Table 29. Demographic profile of paediatric cutaneous lymphomas compared with 
studies across the world 
CTCL 
subtypes 
West (n=69) Korea (n=41) 
Present study 
(n=9) 
R study –  1960-2002 R study – 1990 -2012 P study – 22 months 
Age cut off ≤ 20 years Age cut off ≤ 20 years Age cut off ≤ 20 years 
% M/F AR Med % M/F AR Med % M/F AR Med 
MF 34.7 1:1 3-20 17 27.6 5:4 7-19 13.8 44.4 3:1 5-14 13 
LyP 17.7 5:6 3-19 14 34.5 7:3 
0.4-
17 
8 22.2 0:2 2-17 9.5 
SPTL 1.6 0:1 ~ 20 3.4 1:0 ~ 7 22.2 0:2 ~ 19 
HVLL ~ ~ ~ ~ ~ ~ ~ ~ 11.1 1:0 ~ 14 
M: F Male:Female ratio; R- Retrospective study; P- Prospective study; AR – Age range; Med – 
Median age at diagnosis 
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Mycosis fungoides (MF) 
The median duration of disease prior to diagnosis was about 6 years in our 
study and this was similar to  data from other studies where it was found to be 4-6 years 
(7,36,38,92). A previous Indian study had showed a median duration of 96 months 
which was slightly more than the current observation (23). This might be due to 
increased awareness among the population regarding skin diseases. Various types of 
MF  have been described like poikilodermatous, hypopigmented, ichthyosiform, 
palmaris et plantaris, bullous/vesicular, pustular, pigmented purpura like and 
hyperkeratotic verrucous like MF in the literature (16,97,98). In our study the variants 
seen included poikilodermatous variant, hypopigmented variant and vesicular variant of 
MF were seen. One patient in our study presented with dyshidrotic vesicles on palms 
and soles consistent with the diagnosis of MF, a rare atypical variant reported in 
literature (99,100). Incidence of poikilodermatous MF in a study from U.K was 
reported to be 11% while in our study the poikiloderma was seen in 25.9% (98). 
Hypopigmented MF had been increasingly reported in Asians and Afro- Americans and 
rarely in light skinned people with good response to therapy (97,101,102).  
Hypopigmented skin lesions were reported more commonly in paediatric age group 
than adults (72.4% vs. 1%) (103). In our study 5/27 (18.5%) patients presented with 
hypopigmented skin lesions of which one was a child (3.7%). Involvement of palms 
and soles in the course of MF was reported to be 11.5% while in our study 14.8% 
(4/27) patients had palmoplantar involvement which was confirmed with biopsy in 2 
patients (104). 
Large population studies in MF had shown that most of the MF patients present 
in early stage (I-IIA) (70-75%) than advanced stage (IIB-IVB) (20-25%) of the disease 
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(40,105). In our study 81.5% (n=22) patients presented in early stage (I-IIA) and 18.5% 
(n=5) patients presented in advanced stage (IIB-IVB). 
The reported occurrence of extra cutaneous involvement in MF is 6-7% which 
correlates with type and extent of skin lesions (36,38). In our study extra cutaneous 
involvement was noted in 4/27 patients (14.8%). The reported occurrence of bone 
marrow involvement in MF/SS is 5.6% and is usually seen in advanced stages of 
disease (stage T4) (105). In our study 3% had bone marrow involvement (1 each in 
stage T2b, T3 and T4). Biopsy proven lymph node involvement was seen in 3.7% of 
our patients, while the prevalence of the same in MF was reported to be around 3-7% 
(36,38,40,105). It have been reported that 7% patients have Sezary cells in the 
peripheral smear while in our study we had 1 patient (3.7%) with Sezary cells in the 
peripheral smear (38). 
Frequency of Pautrier‟s microabscesses in patients of MF varied from 4-37% 
and the same in our study was seen in 33% of patients (n=9) which was in conjunction 
with other studies (35). Large cell transformation (>25% of cells) may occur in 8-55% 
patients of MF and reported to be associated with poor prognosis (106). In our study 
the same was noted in 2 patients (7.4%) and each one belonged to T3 and T4 stage 
respectively. 
CD8 positive MF was reported to be as high as 32% in an Indian study 
compared to 25% in an Italian study (22,107). Prognosis of CD8+ mycosis fungoides is 
reportedly better than CD4+ mycosis fungoides (108). In our study CD8 mature T-cell 
positive phenotype was seen in 3/27 (16.7%) patients. All three patients presented with 
hypopigmented macules and belonged to T2a stage. 
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TCR gamma gene rearrangement study 
Gold standard for diagnosing MF is histopathological examination of a skin 
biopsy. Loss of T-cell differentiation antigens (CD2, CD3, CD5 and CD7) diagnosed 
using immunohistochemical studies and detection of clonal T-cell population in skin 
biopsies using PCR aids an additional value in diagnosis of MF (86). Criteria proposed 
by International Society for Cutaneous lymphomas (ISCL) for diagnosis of early MF 
(32) was not implemented in this study due to lack of facilities for quantitative analysis 
of immunohistochemistry markers in our Institution. Clonality detection in CTCLs 
varies from 40-90% and is dependent on the PCR protocol used for the detection of 
clonal cells (11,12,14,15,87,109). Three studies which used Genescan for detection of 
clonality had showed a detection rate of 66-73% in early stage MF. In our study the 
detection rate was slightly lower (61.5%) (14,15,110) [Table 30]. As „T‟ score of the 
disease advanced clonality detection rate proportionately increased (12). Ponti et al 
demonstrated a clonality percentage of 83.5% in all CTCLs and 73.75% in T1/T2 
stages of MF while in our study the clonality detection percentage was 61.5% in T1/T2 
stage of MF (12). 
Table 30. Clonality detection rate in early stage MF (I/IIA) among different studies using 
similar PCR protocol 
Study Country Published year Clonality detection rate 
Klemke et al(14) Germany 2002 8/12 (66.7%) 
Sandberg et al(15) Netherlands 2003 5/8 (63%) 
Goeldel et al(110) France 2010 27/37 (73%) 
Present study India 2014 8/13 (61.5%) 
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Only very few studies are available till date that have studied the association 
between histopathological features and clonality detection (12,87). Tok et al had 
demonstrated clonal TCR gamma gene rearrangements in 73% of the specimens‟ non 
diagnostic for CTCL, 71% of those suggestive of CTCL, and 74% of those diagnostic 
of CTCL (87). He suggested that histology and molecular biology do not necessarily 
correlate which was demonstrated by the clonal persistence in 30–40% of patients with 
CTCL displaying complete clinical and histological response. When we compared the 
clonality detection with histological grading of early MF (stage T1/T2) proposed by 
Guitart et al, we found that the clonality detection was 50% (3/6) in patients where the 
diagnosis of MF could not be excluded by histopathological grading whereas in a study 
done by Ponti et al the clonality detection was 40.6% (13/32) in the same group of 
patients (12) [Table 31]. 
In the same study the clonality detection was 87.6% (64/73) in patients 
suggestive of MF whereas in our study it was found to be 80 % (4/5) [Table 31]. 
Loss of lineage of T-cell differentiation antigens was found in 8/13 (61.5%) of 
which 6/8 (75%) patients had showed monoclonal pattern and 2/5 (40%) patients had 
showed polyclonal pattern. Ponti et al demonstrated higher percentage (93.9%) of loss 
of lineage of T-cell differentiation antigens while our study showed 75% of the same 
(12).  
Though the statistical significance of clonality detection with histopathological 
grading of MF could not be demonstrated it was evident that in patients with 
histopathological diagnosis suggestive of MF had increased clonal detection rate. We 
might need a large population studies on the same prior to any conclusion. False 
negativity in detection of clonality could be attributed to low density of infiltrated 
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tumour cells in biopsy specimens of early MF, partial or incomplete rearrangement of 
the TCR, somatic hypermutation or TCR region translocation (86,90). However the 
patients of both groups (polyclonal and monoclonal) will be followed up in the future 
for the course of disease progression. 
Table 31. Comparison of clonality detection rate based on histology category among 
different studies 
Histological and immunohistochemical 
diagnosis of MF 
Present 
study 
Ponti et al 
(12) 
Tok et 
al*(87) 
MF cannot be excluded  50% (4/8) 
40.6% 
(13/32) 
73% (8/11) 
Probable/suggestive of MF  80% (4/5) 
87.6% 
(64/73) 
71% 
(6.6/9.3) 
* Study included all CTCL specimens and TCR gene rearrangement assay was done using 
PCR/DGGE 
 
Primary cutaneous ALCL 
Two patients (66.7%) in our study presented with nodular skin lesions which is 
the most common morphological skin lesions in most other studies (45,111). The other 
patient in our study presented with erythroderma. Only a few cases of erythrodermic 
anaplastic large cell lymphoma has been reported in literature (48,112). Male 
predominance noted in our study correlated with observation by various authors 
(111,113). While extra cutaneous dissemination can occur is 10% of patients , none of 
the patients in our study had extra cutaneous involvement (111). All three patients in 
our study showed ALK negativity which was consistent with the diagnosis of primary 
cutaneous ALCL as reported in many studies (49,114). 
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Lymphomatoid Papulosis (LyP) 
Male predominance is noted in LyP studies around the world as in our study 
(M: F, 1.67). Most common histologic variant of LyP was type A (79%) followed by 
type C (6.7%) and type B (5.08%) (45). In our study the most common variant of LyP 
was type A (n=5, 62.5%) followed by type B (n=2, 25%). One patient had a newly 
described rare type D (1, 12.5%) variant. In a large study comprising of 219 patients 
with primary and secondary CD30+ LPD, 19% (23/118) patients had associated 
malignant lymphoma either before, after or concurrent with LyP and median follow up 
of the study was 77 months (45).  In our study none of the patients had any evidence of 
concurrent lymphoma at the time of presentation. Longest duration of disease prior to 
diagnosis in our study was 204 months and median duration was 12 months.  
Subcutaneous panniculitis like T-cell lymphoma (SPTL) 
SPTL was included as a distinct entity in WHO-EORTC 2005 classification and 
it is defined as cytotoxic T-cell lymphoma characterized by subcutaneous infiltrates of 
small medium or large pleomorphic T-cells with α/β T-cell phenotype. Our study 
showed a frequency of 12.2% (n=6) of all primary CTCLs. M/F ratio of SPTL reported 
in literature was 0.5 while in our study the M/F ratio was 0.2 (56). The median age at 
diagnosis of SPTL reported in literature was 36 years (range 9-79 years) (56) while in 
our study the median age of diagnosis was 27.5 years. The morphological presentation 
of SPTL was nodules/plaques (100%) and majority of the patients has multifocal 
involvement (78%). Extremities are more commonly involved than trunk and face (56). 
In our study all patients presented with nodules and multifocal involvement was noted 
in 66.7% of patients. Trunk was the most common area of involvement in our study. 
CD56 positivity, hemophagocytic syndrome, angioinvasion, skin ulcers, liver 
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dysfunction and elevated LDH are reported to be associated with an unfavourable 
prognosis. (56–58). Incidence of abnormal laboratory values (anaemia, leucopenia, 
thrombocytopenia, elevated liver function test) have been reported to be 29% and B-
symptoms are reported to occur in 59% of patients (56). In a study comprising 22 cases 
of SPTL incidence of elevated liver enzymes and elevated LDH were reported to be 
59% and 64% respectively(58). In our study B- symptoms were noted in 66.7% patients 
while elevated LDH was noted in 5 patients (83.3%) and abnormal liver transaminases 
were noted in 2 patients (40%). 
Haemophagocytosis was observed in 15% of patients while in our study the 
same was noted in one patient (1/6) (16.6%) which was similar to the observation by 
Willemze et al (56). Though adipocyte rimming by neoplastic T-cells are not specific 
or diagnostic of SPTL it is commonly observed in many patients of SPTL (56,57). This 
feature was also reported in patients of tumour stage MF, aggressive epidermotropic 
CD8+ T-cell lymphoma, extranodal NKTL and few secondary cutaneous B-cell 
lymphomas (115).  
 
Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) 
Patients who do not fit into any of the well-defined entities of CTCL are 
classified under PTCL, NOS (7). Most common morphological lesions reported in 
literature under this entity were generalized nodules or tumours while in our study all 
three patients (100%) presented with nodular skin lesions of which two patients had 
multifocal involvement (BSA>30%). There is no site predilection reported for this 
category of CTCL (67). Prognosis of this entity is poor irrespective of the type and 
extent of skin lesions with 5 year survival rate of less than 20% (7,24,67). Duration of 
skin lesions prior to diagnosis varied from 1 to 100 months (median, 6 months) while in 
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our study median duration of skin lesions prior to diagnosis ranged from 3 to 6 months 
(median, 5 months) (67). CD30 staining & CD56 expression are usually negative which 
was the finding in our study also (67). 
Hydroa vacciniforme like T-cell lymphoma 
Hydroa vacciniforme like T-cell lymphoma, an EBV+ T-cell 
lymphoproliferative disorder of childhood (updated in 2008 WHO classification) had 
been reported increasingly (2-7%) from Central America, South America and Far East 
countries (8,9,61). Our patient presented with systemic B-symptoms as in most other 
patients reported in literature (65). 
Median age at diagnosis reported in literature was 8 years while our patient was 
diagnosed at the age of 14 years (65). A large study on HVLL comprising of 20 
patients showed the involvement of sun exposed areas in all patients (100%). The 
morphology and distribution of lesions of our patient were similar to that reported in 
literature. The presence of concurrent hepatosplenomegaly and lymphadenopathy seen 
in our patient has been reported in literature. The infiltrate was monoclonal and IHC 
pattern of CD3+, CD8+, granzyme B+, T1A-1+ and EBV-LMP positivity was typical 
of HVLL (65). EBV antibody in the serum was positive in our patient. 
 
Secondary cutaneous lymphomas 
Most common lymphoma which present with secondary cutaneous involvement is 
diffuse large B-cell lymphoma (6). In a large population study of cutaneous lymphoma, 
diffuse large B-cell lymphoma with secondary cutaneous involvement was around 27% 
while in our study the most common secondary cutaneous lymphoma were 2 cases of 
ALCL and PTCL, NOS (40%). 
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Anaplastic large cell lymphoma 
Systemic anaplastic large cell lymphomas were distinguished by the expression 
of ALK antigen and negative expression of the same in systemic ALCL correlates with 
poor prognosis (45) although both subtypes warrant treatment with polychemotherapy. 
Involvement of skin in patients of systemic ALCL has been reported to be 12.5% (116). 
Median age at diagnosis is 59.5 years and B-symptoms reportedly to occur in 
27% patients while in our study the mean age at diagnosis was 51.5 years and one 
patient had B-symptoms (45). M/F ratio of secondary cutaneous ALCL was 0.83 while 
in our study the M/F ratio was 1:1. The reported median duration to develop skin 
lesions following the diagnosis of systemic ALCL was 53 months while in our patient 
the same was 6.5 months (45). 
 
Peripheral T-cell lymphoma, not otherwise specified 
Secondary or concurrent involvement of skin in PTCL, NOS ranged from 19-
55% patients as reported in a study (67). Most common skin lesions were multifocal 
erythematous plaques to tumours and nodules (67). As reported in earlier studies our 
patients also presented with multifocal polymorphic skin lesions (plaques and tumours). 
Mean age of diagnosis in our study was 43.5 years while in a study comprising 82 
patients with PTCL, NOS it was reported to be 65 years (range 8-85 years) (67). Most 
common immunohistochemistry observed in the same study was CD4+/CD8- (12/17, 
70.5%) while in our study both patients showed the CD4+/CD8- 
immunohistochemistry pattern (67). 
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Plasmablastic lymphoma (PBL) 
Plasmablastic lymphoma, a rare B-cell non-Hodgkin lymphoma often 
associated with HIV infection and Epstein-Barr virus (EBV) infection (117). PBL 
accounts for 2.6% of all acquired immunodeficiency syndrome related malignant 
lymphomas (118). Male predominance is noted in PBL (77%) and median age at 
diagnosis was 46 years (range - 1.2 to 87 years) (117). Cutaneous involvement is noted 
in 12% patients with plasmablastic lymphoma. Overall survival rate was between 6 to 
12 months (117). In our study a female patient with HIV infection was diagnosed to 
have plasmablastic lymphoma with cutaneous involvement. Both systemic and 
cutaneous involvement was diagnosed concurrently. Age at diagnosis of our patient 
was 33 years. Most common morphological cutaneous presentation of PBL reported in 
literature was nodules which was a finding in our patient also (117,119). 
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CONCLUSIONS 
 CTCL was the most common subtype of CL seen in our study which was 
similar to data from studies reported from Asia and the West. However the 
proportion of CTCL was higher than that reported from other countries. 
 Male preponderance was noted in all subtypes of cutaneous lymphomas except 
SPTL where the males were affected less frequently (M/F -1:5) 
 MF was the commonest among CTCL comprising 56.25% of all CTCLs. 
 Majority of MF patients belonged to stage I & IIA as has been reported from 
other studies. 
 Duration of disease prior to disease in MF was significantly longer than other 
subtypes of CTCLs (P < 0.001). 
 Unusual clinical types of MF seen included hypopigmented MF and 
dyshydrosiform MF. MF with palmoplantar involvement was also seen in 
14.8% patients. 
 Among the unusual variants of CTCL (other than MF) seen in our study were 
one case each of erythrodermic ALCL, LyP type D and HVLL. 
 16.7% of patients with lymphoma were in the paediatric age group (≤ 20 years). 
The most common type of CTCL seen was MF (44.4%). 
 Monoclonality detection in early MF of 61.5% in our study was slightly lower 
than the detection rate in various studies across Europe using a similar protocol. 
 In our study we did not find any significant correlation between the histological 
grades of MF proposed by Guitart et al and clonality detection. However the 
clonality detection rate was higher in patients with histopathological diagnosis 
suggestive of MF than patients in whom the diagnosis of MF could not be 
excluded. 
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 The loss of lineage of T-cell differentiation antigens was higher in early MF 
patients in whom monoclonality was detected; however the difference was not 
statistically significant. 
LIMITATIONS 
 The study is from a single centre and done over a limited period of time (22 
months), so the number of patients studied is small. 
 Clonality pattern was studied only in 13 patients of patch/plaque (Stage I/IIA) 
mycosis fungoides where in the histological diagnosis of mycosis fungoides 
could not be excluded or the diagnosis was suggestive but not confirmatory. 
This is because of the high cost of the procedure. 
RECOMMENDATIONS 
 Multicentre studies are needed to study the prevalence and clinical profile of 
cutaneous lymphomas seen in India.  
 A cutaneous lymphoma registry should be started for the same and all the data 
entry should be facilitated by an electronic database for the convenience of 
physicians across the country. 
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SUMMARY 
 
Background 
Cutaneous lymphoma, an extranodal non-Hodgkin lymphoma on skin is distinct 
from non-cutaneous lymphomas in clinical profile, course, prognosis and treatment. So 
it is important to know the epidemiology of cutaneous lymphomas, frequency, gender 
and age distribution and distinct clinicopathological profile of each subtype. Though 
there are few multicentre studies across the globe, studies from India were sparse. So 
we decided to take up this study to find epidemiological data and clinicopathological 
profile of cutaneous lymphomas in a hospital based setting. 
Moreover diagnosis of mycosis fungoides was always been a challenge to both 
dermatologist and pathologist particularly to differentiate the early stages of mycosis 
fungoides from benign dermatoses. In addition to clinical picture, histopathology and 
immunohistochemistry markers, molecular study aids as a tool in diagnosis of early 
stage of mycosis fungoides. In this background we decided to do look the role of TCR 
gene rearrangement study in early stage of mycosis fungoides to find the role of 
clonality studies in early stage of mycosis fungoides. 
 
Objective 
Our primary objective was to study the clinicopathological profile of cutaneous 
lymphomas in a hospital based setting. Secondary objective was to study the role of 
TCR gene rearrangement study in early stage mycosis fungoides. 
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Methods 
A hospital based cross sectional study was conducted in department of 
Dermatology, Venereology and Leprosy, Christian Medical College, Vellore over 
period of 22 months with approval from the Institution Review Board (IRB.No: 8050). 
Patients with clinical features of cutaneous lymphomas were included in the study after 
confirmation with biopsy. Immunohistochemical markers were done in all patients to 
confirm the diagnosis as a part of standard operating procedures. Patients were 
informed prior to inclusion in the study and a written consent was obtained from the 
patients and guardians in patient of children. Demographic details, clinical data, 
laboratory values, imaging and histopathological findings were recorded in a proforma. 
TCR gamma gene rearrangement study was done in patch/plaque (Stage I/IIA) mycosis 
fungoides where the histological diagnosis of mycosis fungoides could not be excluded 
or the diagnosis was suggestive but not confirmatory. Detection of clonality was 
interpreted in correlation with clinical and histopathological features. Data on clinical 
and pathological features were expressed in numbers and percentages.  
The role of TCR gene rearrangement in detection of monoclonality in early 
stage MF was calculated with 95% confidence interval. P value was calculated using 
Fisher‟s exact test wherever applicable. 
 
Results 
A total of 54 patients with cutaneous lymphomas were included in the study. 
There were a total of 30 males and 24 females (M/F-1.25). The mean age at diagnosis 
of cutaneous lymphoma was 39.9±18.3yrs (range 2-77years). 
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Primary cutaneous T-cell lymphomas were the commonest among all cutaneous 
lymphomas (n=48, 88.9%) followed by secondary CTCL (n=4, 7.4%), primary CBCL 
(n=1, 1.85%) and secondary CBCL (n=1, 1.85%). The most common type of CTCL in 
the paediatric age group (≤ 20 years) was MF (n=4, 44.4%) followed by LyP (n=2, 
22.2%), SPTL (n=2, 22.2%) and HVLL (n=1, 11.1%). 
Among subtypes and its variants, mycosis fungoides was the commonest (27, 
50%) followed by CD30+ LPD (n=11, 20.3%), SPTL (n=6, 11.1%), PTCL, NOS (n=3, 
5.6%), HVLL (n=1, 1.85%) and PCLBCL (n=1, 1.85%). 2 patients (4.2%) of secondary 
ALCL, 2 patients (4.2%) of secondary PTCL, NOS and 1 patient (1.85%) of 
plasmablastic lymphoma were also seen during the study period. 
Mean age at diagnosis of MF, CD30+ LPD, SPTL and PTCL, NOS were 
41.1±18.8 years, 33.8±17.1 years, 33.6±17.3 years and 56.3±18.9years respectively. 
Duration of disease prior to diagnosis of MF was much longer when compared to other 
subtypes of cutaneous lymphomas (median, 72 months) (P < .001). Patches were the 
commonest morphological skin lesions among MF patients while all patients with 
SPTL classically presented with subcutaneous nodular skin lesions and patients with 
LyP presented with papular skin lesions. 
Unusual clinical types of MF in our study included hypopigmented MF and 
dyshidrosiform MF. MF with palmoplantar involvement was also seen in 14.8% 
patients. Among the unusual types of CTCL (other than MF) seen in our study were 
one case each of erythrodermic ALCL, LyP type D and HVLL. 
Clonality detection rate among early stage MF in our study was 61.5%. But 
statistical significance of the same with histological grading and immunohistochemistry 
findings was not found. However we found that the clonality detection was higher in 
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patients in whom the histopathological diagnosis was suggestive of MF than the 
patients in whom the histopathological diagnosis of MF could not be excluded. 
CONCLUSION 
In our study of 54 patients with cutaneous lymphomas, CTCL was the most 
common subtype as reported in earlier studies from Asian countries and the West. 
However the proportion of CBCL was lower than that reported from other countries. 
Female preponderance was noted in SPTL and rest of the subtypes showed a male 
preponderance in occurrence. MF was the commonest among CTCL comprising 
56.25% of all CTCLs. The unusual types of CTCL seen in our study included 
erythrodermic MF, hypopigmented MF, dyshidrosiform MF, LyP type D and HVLL. 
Duration of disease prior to disease in MF was significantly longer than other subtypes 
of CTCLs (P < .001). Monoclonality detection in early MF was slightly lower than the 
detection rate in various studies across Europe using a similar protocol. In our study we 
did not find any statistically significant correlation between the histological grades of 
MF, immunohistochemical studies and clonality detection in early MF. Usefulness of 
TCR clonal rearrangement studies in early MF has to be concluded with large 
population studies. A cutaneous lymphoma registry should be started and all the data 
entry should be facilitated by an electronic database for the convenience of physicians 
across the country. 
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ANNEXURE I 
 
 
 
ANNEXURE I (A): 
 
The International Society for Cutaneous Lymphomas (ISCL)/European 
Organization of Research and Treatment of Cancer (EORTC) revised clinical 
staging and classification of mycosis fungoides and Sezary syndrome 
Tumour stage (skin) 
 T1: limited patches, papules, and/or plaques covering <10% of skin surface 
o T1a: patch only 
o T1b: plaque with or without patch 
 T2: patches, papules, or plaques covering 10% or more of skin surface 
o T2a: patch only 
o T2b: plaque with or without patch 
 T3: one or more tumours equal to or greater than 1 cm diameter 
 T4: confluence of erythema, covering 80% or more of body surface area. 
Nodal stage 
 N0: no clinically abnormal peripheral lymph nodes; biopsy not required 
 N1: clinically abnormal peripheral lymph nodes; histopathological involvement, 
no atypical lymphocytes 
o N1a: clone-negative 
o N1b: clone-positive 
 N2: clinically abnormal peripheral lymph nodes; histopathological involvement, 
aggregates of atypical lymphocytes 
o N2a: clone-negative 
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o N2b: clone-positive 
 N3: clinically abnormal peripheral lymph nodes; histopathological involvement, 
partial or complete effacement of nodal architecture by atypical lymphocytes or 
neoplastic cells; clone-positive or -negative 
 Nx: clinically abnormal peripheral lymph nodes; no confirmed histological 
involvement. 
Metastatic stage (visceral) 
 M0: no visceral disease 
 M1: visceral disease. 
Blood stage 
 B0: No haematological involvement; <5% atypical or Sezary‟s cells in 
peripheral blood 
o B0a: clone-negative 
o B0b: clone-positive 
 B1: Sezary‟s count 5% or more of peripheral blood lymphocytes, but does not 
meet criteria of B2 
o B1a: clone-negative 
o B1b: clone-positive 
                          B2: 1000/microliter or more Sezary‟s cells; clone-positive. 
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ANNEXURE I (B) 
 
ISCL/EORTC revision to the staging of mycosis fungoides and Sezary 
syndrome 
 
  STAGE           T N M      B 
IA 
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 0,1 
 
IB 
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 0,1 
II 
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ANNEXURE I (C) 
 
 
The SS diagnostic criteria were: 
(i) Erythroderma and peripheral lymphadenopathies 
(ii) Peripheral blood involvement by circulating Sezary cells (SC)  
(iii) Cutaneous biopsy-proven CTCL.  
Peripheral blood involvement was defined, according to the criteria recently proposed 
by the International Society for Cutaneous Lymphoma, only in the presence of two 
major criteria: i) An absolute circulating SC count > 1000 mm
3
 ; ii) PCR detection of a 
dominant TCR-γ gene rearrangement in the peripheral blood.  
Adjunctive criteria were: 
 (i) CD4 ⁄CD8 ratio > 10; 
(ii) Circulating CD4+CD7– ‡ 40%;  
(iii) Aberrant expression of T-cell markers; and  
(iv) Chromosomally abnormal T-cell clone. 
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ANNEXURE I (D) 
 
 
Pathological staging for lymph nodes in mycosis fungoides 
 
Updated ISCL/EORTC 
Classification 
Dutch system NCI-VA classification 
N1 Grade 1: dermatopathic 
lymphadenopathy (DL) 
 LN0: no atypical 
lymphocytes 
LN1: occasional and isolated 
atypical lymphocytes (not 
arranged in clusters) 
LN2: many atypical 
lymphocytes or in 3-6 cell 
clusters 
N2 Grade 2: DL; early 
involvement by MF (presence 
of cerebriform nuclei > 7.5 
um) 
 
LN3: aggregates of atypical 
lymphocytes; nodal 
architecture preserved 
N3 Grade 3: partial effacement of 
LN architecture; many 
atypical cerebriform 
mononuclear cells (CMCs) 
Grade 4: complete effacement 
 
LN4: partial/complete 
effacement of nodal 
architecture by atypical 
lymphocytes or frankly 
neoplastic cells 
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ANNEXURE II 
 
Histopathological criteria for diagnosis of MF as proposed by Guitart et al 
 
Major criteria 
  
1) Density of infiltrate at low power 
Grade 0= scant infiltrate 
Grade 1= Mild perivascular superficial infiltrate 
Grade 2= moderately dense perivascular or band like infiltrate without thickening of 
papillary dermis 
Grade 3= Dense confluent infiltrate with thickening of the papillary dermis and 
involvement of the reticular dermis. 
1) Epidermotropism at medium power 
0= None 
1= Local basal epidermotropism and/or single Pautrier microabscesses or a few 
couplets/triplets or scattered lymphocytes without spongiosis 
2= Extensive basal and/or two or more Pautrier microabscesses 
3= Extensive epidermotropism with more lymphocytes than keratinocytes. 
2) Atypia at high power 
0 = No atypia 
1 = Mild atypia 
2= Moderate atypia 
3= uniformly atypical or pleomorphic cells, many mitotic figures, few small round 
reactive lymphocytes 
Minor criteria 
1- Reticular fibroplasias of the papillary dermis around single lymphocytes 
1 or 2- Primarily intraepidermal atypical lymphocytes 
1-Lymphocytic infiltrate without inflammatory features 
 
Scoring for diagnosis 
 
Score Diagnostic category 
0-2 Perivascular/interface dermatitis or other specific dermatoses 
3-4 Atypical lymphocytic infiltrate(MF cannot be excluded) 
5-6 Atypical lymphocytic infiltrate suggestive of MF 
7+ Mycosis fungoides 
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ANNEXURE III (A) 
 
ISCL/EORTC proposal on TNM classification of cutaneous lymphoma other 
than MF/SS 
 
T 
T1: Solitary skin involvement 
T1a: a solitary lesion <5 cm diameter 
T1b: a solitary >5 cm diameter 
T2: Regional skin involvement: multiple lesions limited to 1 body region or 2 
contiguous body regions 
T2a: all-disease-encompassing in a <15-cm-diameter circular area 
T2b: all-disease-encompassing in a >15- and <30-cm-diameter circular area 
T2c: all-disease-encompassing in a >30-cm-diameter circular area 
T3: Generalized skin involvement 
T3a: multiple lesions involving 2 noncontiguous body regions 
T3b: multiple lesions involving >3 body regions 
N 
N0: No clinical or pathologic lymph node involvement 
N1: Involvement of 1 peripheral lymph node region that drains an area of current or 
prior skin involvement 
N2: Involvement of 2 or more peripheral lymph node regions† or involvement of any 
lymph node region that does not drain an area of current or prior skin involvement 
N3: Involvement of central lymph nodes 
M 
M0: No evidence of extracutaneous non–lymph node disease 
M1: Extracutaneous non–lymph node disease present 
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ANNEXURE III (B) 
 
ISCL/EORTC recommendations for staging evaluation in cutaneous 
lymphomas other than MF/SS 
 
Complete history/review of systems and physical examination 
 
Laboratory studies 
Complete blood count, comprehensive serum chemistries, serum LDH 
Whenever indicated, relevant flow cytometric studies of peripheral blood mononuclear 
cells 
Imaging studies* 
CT of chest, abdomen and pelvis with contrast alone or with whole-body PET (18F-
FDG); include CT or ultrasound of neck if clinically indicated 
Whole-body integrated PET/CT (as alternative imaging study to the standard contrast-
enhanced CT) 
Bone marrow biopsy and aspirate 
Required in cutaneous lymphomas with intermediate to aggressive clinical behavior as 
categorized in the WHO-EORTC classification 
Should be considered in cutaneous lymphomas with indolent clinical behavior, but not 
required unless indicated by other staging assessments 
Additional studies as indicated clinically 
*Lymph nodes that are >1.0 cm in short axis and/or have significantly increased PET 
activity should be sampled for tissue examination (an excisional biopsy is preferable 
whenever possible) 
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ANNEXURE IV 
 
Patient Information sheet 
 
 Study Title: 
      Clinicopathological features of cutaneous lymphomas and true prevalence of mycosis 
fungoides by using T-cell receptor gene rearrangement. 
Purpose of research:   
We are going to study the signs and symptoms of cutaneous lymphoma (a cancer that affects 
the skin), the pathology which includes the type of cells in the affected skin with special 
methods which will be helpful in making a decision regarding treatment and the way in which 
the disease will affect you.It is difficult to differentiate early stages of mycosis fungoides from 
common benign dermatoses (non-harmful) by only the signs, symptoms and its pathology. So 
we are also doing a new test called TCR gene rearrangementin those who have patches which 
will help us to differentiate mycosis fungoides from non-harmful benign skin diseases. Thus 
we will be able to make a definite diagnosis and start early treatment. 
Expected duration of the Subject’s participation:  
You will be examined by the doctor only once in the study period. 
Description of the procedures: 
The doctor will do detailed clinical examination and note down the data in a special 
proforma.  Skin biopsy will be done from the skin lesion for diagnostic purpose which is a 
part of routine management. Other blood tests and imaging studies will be done as per 
standard protocol to see if the disease has spread to other extracutaneous sites. TCR gene 
rearrangement will be done in patients with early stage of mycosis fungoides which will 
be done from the earlier biopsied tissue or a fresh biopsy tissue. 
Risks or discomforts to the Subject: 
Skin biopsy will be done for the TCR gene rearrangement. Possible complications 
include 
 
 Pain 
 Bleeding at the biopsy site 
 There is also a slight possibility of infection or fainting. 
 Post procedure scar 
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We are not doing any additional studies except TCR gene rearrangement study apart from 
the standard protocol  
Benefits to the Subject: 
We are going to study the signs and symptoms of the disease, the pathology and also the 
type of cells in the affected skin with special techniques which will be helpful in making a 
decision regarding treatment and the way in which the disease affects you. At present 
histopathology and study of the type of cell in the skin is used to diagnose all cases of 
lymphoma. In this study we are going to an additional genetic testing on the skin biopsies 
of those patients with patches which will help us to differentiate from other skin 
conditions that can be mistaken for mycosis fungoides. 
Benefits to others: 
Overall data about cutaneous lymphomas are sparse in India. This study will provide data on 
prevalence of various types of lymphomas in India and their clinicopathological and 
immunophenotypical correlating features. By this study we may know the usefulness of TCR 
gene rearrangement study in distinction of early stage mycosis fungoides from other benign 
dermatoses. 
 
Confidentiality: 
Patient’s identity will not be revealed in any information or released to third parties or 
published. We will keep your records confidential unless we are required by law to share 
any information. 
 
 
Participation:   
 
Your participation in the study is entirely voluntary and the patient is free to withdraw at 
any time, without giving any reason. Refusal to participate will not involve any penalty or 
loss of benefits to which the subject is otherwise entitled. 
 
Contact person:  
Dr. Venkatraman.M,  
Post Graduate resident,  
Department of Dermatology,  
Christian Medical College and Hospital,  
Vellore. 
Mobile- 9894176756 
Office-04162283527 
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ANNEXURE V 
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ANNEXURE VI 
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ANNEXURE VII 
 
Informed Consent form to participate in a clinical trial 
 
Study Title: Study of clinicopathological features of cutaneous lymphomas and t-cell 
receptor gamma gene rearrangement in patch stage mycosis fungoides 
 
Study Number: 
 
Subject’s Initials: _________   Subject’s Name: ________ 
Date of Birth / Age: _______ 
 
(i) I confirm that I have read and understood the information sheet dated _________ for 
the above study and have had the opportunity to ask questions. [ ] 
 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [ ] 
 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [ ] 
 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
 
(v) I agree to take part in the above study. [ ] 
 
 
 
Signature (or Thumb impression of the Subject/Legally Acceptable Representative: 
Signatory’s Name: ____________________________ Date:                                                                           
 
 
 
Signature of the Investigator: ________________________ Date: ____/____/_____ 
Study Investigator’s Name: _________________________ 
 
 
Signature of the Witness: ___________________________ Date: ____/____/_____ 
Name of the Witness: ______________________________ 
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ANNEXURE VIII 
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ANNEXURE IX 
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ANNEXURE X 
 
X(A).TECHNIQUE OF MANUAL IMMUNOHISTOCHEMISTRY BY ENVISION/2 
STEP POLYMER METHOD. 
 
 
1. Approximately  three  microns  thick  sections  were  cut  and  floated  on  pol
y-lysine  coated  slides and  incubated  37  degrees centigrade  overnight.  An 
appropriate control was used for the antibody tested. 
2. Sections were dewaxed in xylene for 15 minutes and brought to water. 
3. Antigen retrieval was done by heat induced pressure cooking 
a.   Slides depending on the IHC antibody used were placed in the 
containercontaining either citrate buffer at pH 6 or EDTA buffer at pH 9 and placed  in 
the cooker with lid closed for 30seconds at a  temperature of 120 degrees centigrade 
and a pressure of 15 psi 
b.  After  boiling,  the  cooker  was  cooled  by  quenching  in  a  sink  of  cold 
running tap water. 
4. The slides were removed from the cooker, quickly washed in running tap 
water and transferred to TRIS buffered saline {TBS} at pH 7.6 
5. 0.3% Hydrogen peroxide (H2O2) was added to the slide and incubated at 
room temperature for 10 min to block endogenous peroxidase. 
6. The slides were washed in TBS at pH 7.6 
7. The primary antibody was applied and incubated at room temperature for 30 
minutes. 
8. The slides were washed in TBS at pH 7.6 
9. Envision (commercially available secondary antibody + enzyme) was applied 
and incubated at room temperature for 30 minutes. 
10. The slides were washed in TBS at pH 7.6 
11. Chromogen (Diaminobenzidine) along with substrate (hydrogen peroxide) 
was applied. 
12. Slides were washed in running tap water. 
13. The  slides  were  counterstained  with  Harris  haematoxylin  for  10  seconds
  and then dehydrated, cleared and mounted. 
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ANNEXURE X (B)  
PREPARATION OF REAGENTS USED FOR IMMUNOHISTOCHEMISTRY 
 
 
1. TBS {TRIS from Aldrich}. The pH is checked and adjusted to 7.6 
Nacl 80g 
TRIS 6.05g 
1N HCl 40ml 
Distilled H2O 10 litres 
 
2. Hydrogen peroxide – H2O2 is available commercially as 30% 
solution fromQualigens{SQ}.  A 0.3% solution is prepared by adding 1 ml of 
H2O2 to 9 ml of distilled water. 
 
3. DAB solution – Commercially available 5 ml solution from DAKO along with 
250 ml of substrate buffer. Working solution is prepared by mixing DAB 
solution and substrate buffer in a ratio of1:50. 
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ANNEXURE XI 
 
MULTIPLEX POLYMERASE CHAIN REACTION ASSAY FOR T-CELL RECEPTOR 
GAMMA CHAIN GENE REARRANGEMENT 
 
SUMMARY 
 
This test is indicated for the accurate differentiation of malignant vs benign 
lymphoproliferative disorders and for establishing T cell lineage.  Clonal proliferations 
of T lymphocytes can be detected by the identification of specific DNA rearrangements 
in the T-cell gamma chain antigen receptor gene.  The majority of lymphocytic 
leukemias and non-Hodgkin's lymphomas arise from a clonal proliferation of a single 
lymphoid cell that has become aberrant.  T cells normally differentiate from stem 
(precursor) cells in a highly specific and sequential manner.  The malignant 
transformation may take place at any stage in the maturation process and when it 
occurs, the resulting malignant clone bears the characteristics of the originally 
transformed cell and is called monoclonal.  Some of the early events in the maturation 
process of lymphoid cells involve specific nucleic acid rearrangements within the 
gamma chain antigen receptor gene in T-cells. 
 
T-cell gene rearrangement testing can be used to determine the presence of a 
monoclonal T cell population in a submitted sample, indicative of a neoplastic 
lymphoproliferative disorder.  Southern blot testing using genomic probes to the beta 
chain antigen receptor gene has been the method of choice for establishing the 
monoclonal nature of a T lymphoid process. This test, however accurate, requires fresh 
frozen tissue and at least 20 ug of high molecular weight DNA to perform accurately.  
In cases where there is not a sufficient amount of tissue (or the tissue has been poorly 
preserved), the Polymerase Chain Reaction (PCR) can be utilized to detect the clonal 
population.  PCR also does not required fresh or frozen tissue and can be used on fixed 
and paraffin embedded material. 
 
Polymerase Chain Reaction (PCR) refers to in-vitro enzymatic amplification of 
a defined DNA sequence by repeated rounds of heat denaturation, specific DNA primer 
annealing, and DNA polymerase-mediated primer extension.  The use of a thermostable 
DNA polymerase found in the bacteria Thermusaquaticus allows for repeated rounds of 
amplification without further addition of polymerase enzyme at each cycle.  Each cycle 
causes a doubling of the specific sequence circumscribed by the primers so that 
production of specific DNA product ideally approaches 2
n
 where n = the number of 
amplification cycles. 
 
A. PRINCIPLE 
 
To detect T cell gene rearrangements using PCR, a multiple pairs of primers are 
constructed that target multiple exons with in the variable (V) region and the joining (J) 
of the T cell gamma chain antigen receptor gene.  In the germline configuration found 
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in somatic cells, these areas are widely separated (by more than 70KB) making 
amplification across the area impossible.  The sequence alteration brought about by 
gene rearrangement brings these regions into close proximity, making the area of 
amplifiable length.  Each T cell has a single productive V-J rearrangement that is 
unique in both length and sequence. The template-free incorporation of nucleotides (N-
regions) between the spliced V and J gene segments also adds uniqueness to the PCR 
product.  Therefore, when this region is amplified using DNA primers that flank this 
region, a clonal population of cells yields one or two prominent amplified products 
(amplicons) within the expected size range.  Two products are produced in cases when 
the initial rearrangement was non-productive and was followed by rearrangement of the 
other homologous chromosome.  In contrast, DNA from a normal or polyclonal 
population produces a bell-shaped curve (or Gaussian distribution) of amplicon 
products that reflects the heterogeneous population of V-J region rearrangements. 
 
Since the antigen receptor genes are highly polymorphic, it is difficult to 
employ a single set of DNA primer sequences to target all of the conserved flanking 
regions around the V-J rearrangement.  N-region diversity and somatic mutation further 
scramble the DNA sequences in these regions.  Therefore multiplex master mixes, 
which target several regions (Vgamma 1-8,9 + J1/2 consensus for T1 and Alternate V 
gamma + J1/2 for T2), are required to identify the majority of clonal rearrangements.  
As indicated, clonal rearrangements are identified as prominent single-sized products 
within the smear of different sized amplicon products that form a Gaussian distribution 
around a statistically favored, average-sized rearrangement.  As expected, primers that 
amplify from the different gamma chain regions produce correspondingly different size 
ranges of products. 
 
A powerful detection method for the amplicons produced in the multiplex 
reaction involves capillary electrophoresis and differential fluorescence detection of the 
amplified products.  The primers used in the master mixes are labeled with different 
fluorescent dyes, each corresponding to a different target region (V-J combinations).  
This detection system results in unsurpassed sensitivity, single base resolution, 
differential product detection and relative quantitation.   Further, differential detection 
allows accurate, reproducible and objective interpretation of primer-specific products 
and automatic archiving of data.  The limit of detection of this assay has been 
determined to be approximately 1 clonal cell in 100 normal cell.  The inter-assay and 
intra-assay reproducibility in size determination using capillary electrophoresis is 
approximately 1-2 base pairs.  This reproducibility and sensitivity allows monitoring 
and tracking of individual tumors.  The automatic archiving of specimen data allows 
the flexibility to compare data collected at different times. 
 
B. SPECIMEN REQUIREMENTS 
 
1. TYPE 
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Analysis can be performed on a variety of tissues which include whole blood (1 
ml), bone marrow aspirate 0.5 ml) or biopsy (approx. 1 cm), solid tissue (0.1 x 0.1 x 0.1 
cm) or aspirated cells (1x10
6
 minimum), specimens embedded in paraffin (see below).  
Samples for T Cell PCR are forwarded from samples that did not yield conclusive 
results from flow cytometry evaluation (body fluids or tissue) or directly from external 
clients.  Samples may be forwarded to the laboratory in the fresh state, frozen, or as 
paraffin embedded sections. 
 
2. HANDLING AND STORAGE CONDITIONS 
 
All specimens should be handled according to Standard Precautions guidelines 
established by the University (see section on Blood borne Pathogens) Policy & 
Procedure Manual). 
 
a) Whole blood and marrow aspirates should be collected in EDTA or ACD and 
refrigerated, but NOT FROZEN.  Samples collected in Heparin are not suitable for 
PCR analysis. 
b) Bone marrow biopsies should be placed in a container without media and frozen.   
c) Solid tissues should be trimmed free of fat, connective tissue, and excess normal 
tissue and FROZEN at -30
o
C or colder.   
d)  Skin biopsies for the diagnosis of CUTANEOUS LYMPHOMAS  requires a 
minimum of 1 punch biopsy (4 mm) of the area involved.  This should be placed in a 
container without media and frozen.    
e) Cells in suspension should be centrifuged, the supernatant decanted, and frozen as a 
pellet. 
f) Specimens fixed in 95% ethanol may be submitted.   
g) Samples embedded in OTC medium may be submitted. 
f) For specimens embedded in paraffin, sections should be cut and placed dry in a 1.5 
ml PCR screw cap micro centrifuge tube. (see General Policies & Procedure Man., 
Specimen Handling Protocol Sec. A., Clonality Testing by PCR Specimen Handling # 
3-4).  Paraffin embedded tissue is stored at room temperature until DNA is extracted. 
Once DNA is extracted, it can be stored at -20C.  All specimens should be cut using 
PCR cross-contamination precautions.  These include using a new knife for each 
different block being cut and cleaning all contact surfaces with xylene to remove any 
possible contamination from other blocks. 
 
a) If the tissue is 0.5 x 0.5 cm or larger, (five) 5 x 10u sections should be cut and 
placed dry in a 1.5 ml PCR screw cap micro centrifuge tube. 
b) If the tissue is smaller than 0.5 x 0.5 cm, (ten) 10 x 10u sections should be cut 
and placed dry in a 1.5 ml PCR screw cap micro centrifuge tube. 
c) For skin biopsies (3 or 4mm punch bx),  (twenty) 10 x 20u sections should be cut 
and placed dry in a 1.5 ml PCR screw cap micro centrifuge tube. 
d) Specimens fixed in B5 fixative are not suitable for PCR analysis. 
 
3. REJECTION CRITERIA 
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Samples not appropriately labeled with patient name will be rejected and 
returned to the requestor at the discretion of the Lab Director.  Due to the delicate and 
valuable nature of many of the samples, efforts will be made to verify identity and 
integrity. 
 
 
 
C. EQUIPMENT / REAGENTS / MATERIALS 
 
EQUIPMENT 
 
Dubnoff Shaking Water Bath 
Fisher Micro centrifuge Model 59A 
Gilson Pipetman pipettes (P10, P20, P200, P1000) 
Aerosol barrier pipet tips for the Pipetman pipettes 
Perkin Elmer GeneAmp 9600 PCR thermal cycler or ABI GeneAmp PCR System 
9700. 
ABI 3100-Avant Genetic Analyzer and related consumables. 
ABI 3100-Avant Capillary Array (36 cm) 
National Appliance Vacuum Oven 
Screw-cap, 1.5 ml micro centrifuge tubes w/ cap inserts 
500 ulmicrocentrifuge tubes-assorted colors  
MicroAmp tubes with attached caps or strips (8) and related cap strips (ABI or 
compatible)  
Lab-Line Multi-Blok heating block 
 
MATERIALS AND STORAGE REQUIREMENTS 
 
Reagents-General Considerations 
The lot number of all critical reagents used in these procedures (as stated in the 
Validation of Reagents, General Policies & Procedures Manual) should be noted in the 
Molecular Biology Reagent log book when they are put in use.  All reagents should be 
dated when they are received, opened or placed in use, and expiration date noted (if 
applicable).  All laboratory chemicals (salts, solvents, acids, bases, etc.) in original 
manufacturer‟s containers have no applicable expiration date unless otherwise noted on 
the container by the manufacturer.  All reagents must be stored under the specifications 
given by the manufacturer or as otherwise noted below.  All laboratory-prepared 
reagents must be appropriately labeled with name, concentration if applicable, date 
prepared, storage conditions, expiration date, and tech initials. No reagent is used past 
its noted expiration date. 
 
XYLENE 
Xylenes (for de-paraffination of sections). (Mallinckrodt Chemical Co.)   Store 
at room temperature.  Do not use near heat or open flame.  No expiration date. 
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ETHANOL 
100% Absolute ethyl alcohol, 200 proof (Florida Distillers Corp.)  Store at 
room temperature.  Do not use near heat or open flame.  No expiration date. 
 
QIAGEN QIAamp DNA MINI KIT 
QIAGEN Catalogue #51304.Store at room temperature until opening.  Good 
until manufacturer‟s expiration date if properly stored.  The kit contains the following 
components that have their own storage conditions after opening. 
 
Qiagen Buffer ATL 
For tissue lysis.Store at room temperature. Mix thoroughly by shaking before use.  
Good until manufacturer‟s expiration date if properly stored.  
 
Buffer AL 
Mix thoroughly by shaking before use.  Stable for 1 year at room temperature. 
 
Buffer AW1 
Add 25 ml of absolute ethanol to buffer AW1 concentrate before use.  Final volume for 
is 44ml. 
Store closed at room temperature.   Stable for 1 year after reconstitution if appropriately 
stored. 
 
Buffer AW2 
Add 30 ml of absolute ethanol to buffer AW2 concentrate before use.  Final volume for 
is 43ml. 
Store closed at at room temperature.   Stable for 1 year after reconstitution if 
appropriately stored. 
 
QIAamp Spin Columns 
Store at room temperature in sealed plastic bag.  Do not mix lot numbers of columns.  
Good until manufacture‟s expiration date if appropriately stored. 
 
Qiagen Buffer EL 
Purchased separately for lysis of red blood cells.Store at room temperature until 
opening.  Good until manufacturer‟s expiration date if properly stored.  
 
RED CELL LYSIS BUFFER 
10mM Tris (pH 7.5), 5mM MgCl2, 0.32 M Sucrose, 1% Triton X-100.  Add 109.5g 
Sucrose to 500 ml dH2O and stir until dissolved.  Add 1.21g Tris base and either 1.02g 
of MgCl2 crystals or 5ml of 1M MgCl2 solution (Sigma Chem. Co.).  Adjust pH to 7.5 
with HCl, add 10 ml Triton X-100, and QS to 1 liter.   Store at 4
0
C.  Good for 18 
months if properly stored. 
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PROTEINASE K 
Proteinase K MBG (Promega Scientific) stored at -20
0
C.  Working solution is 50mg/ml 
in distilled H2O. Aliquot and store at -20
o
C.  Good for 6 months if appropriately stored. 
 
AMPLITAQ GOLD DNA POLYMERASE 
Recombinant, thermostable, heat activated 94kDa DNA polymerase derived from 
Thermusaquaticus DNA polymerase gene and inserted into E. coli (Perkin Elmer).  
5U/ul, 250U/vial.  Store frozen at -20
0
C in a constant temperature freezer.  Good until 
manufacturer‟s control date on tube if properly stored. 
T CELL RECEPTOR GAMMA GENE REARRANGEMENT ASSAY KIT 
Invivoscribe Technologies, San Diego, CA.Catalogue # 1-207-0011.Contains 
fluorescent-labeled PCR reagents for identification of clonal T cell popluations. Store 
frozen at -20
0
C in a constant temperature freezer.  Good until manufacturer‟s control 
date on individual reagent tubes if properly stored (Invivoscribe Technologies, San 
Diego, CA).  The kit contains the following components that after opening must be 
stored in the manufacturer's recommended storage conditions.  Only the following 
components are used in the Multiplex T Cell Receptor Gamma Gene Rearrangement 
PCR assay: 
 
T Cell Receptor Gamma Master Mix 1 
Catalogue # 2-207-0011.  Contains multiple primer sequences that target the Vgamma 
1-8,9 + J1/2 consensus region of the T gamma chain locus.   All other required 
reactants to ensure robust amplification of the target region (i.e. PCR buffer, salts and 
dNTP bases), excluding the Amplitaq DNA polymerase, are included in the master 
mix.   For undiluted use only.  Store frozen at -20
0
C in a constant temperature freezer.  
Good until manufacturer‟s control date on tube if properly stored. 
 
T Cell Receptor Gamma Master Mix 2 
Catalogue # 2-207-0021.Contains multiple primer sequences that target alternate V 
gamma + J1/2 regions of the T gamma chain locus.   All other required reactants to 
ensure robust amplification of the target region (i.e. PCR buffer, salts and dNTP bases), 
excluding the Amplitaq DNA polymerase, are included in the master mix.   For 
undiluted use only.  Store frozen at -20
0
C in a constant temperature freezer.  Good until 
manufacturer‟s control date on tube if properly stored. 
 
Specimen Control Size Ladder 
Catalogue # 2-096-0021.Contains primers that target multiple human housekeeping 
genes and generates a series of amplicons of 100, 200, 300, 400, and 600 base pairs to 
ensure that the quality and quantity of input sample DNA is adequate to yield a valid 
result.For undiluted use only.  Store frozen at -20
0
C in a constant temperature freezer.  
Good until manufacturer‟s control date on tube if properly stored. 
 
Clonal T Cell DNA (JURKAT) 
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Catalogue # 4-200-0060.  100ul of Positive control Human DNA that contain 
detectable clonal rearrangements in the T gamma chain gene region described at a 
concentration of  200ug/ml.  For undiluted use only.  Store frozen at -20
0
C in a constant 
temperature freezer. Good until manufacturer‟s control date on tube if properly stored. 
 
Human Polyclonal Genomic DNA  
Catalogue # 4-101-0010.  100ul of Negative control Human DNA that does not contain 
detectable clonal rearrangements in the specific T gamma antigen receptor gene regions 
described at a concentration of  200ug/ml.  For undiluted use only.  Store frozen at -
20
0C in a constant temperature freezer. Good until manufacturer‟s control date on tube 
if properly stored. 
HI-DI
 TM
 FORMAMIDE 
Catalogue # 4311320.De-ionized formamide. Store frozen at -20
0
C in a constant 
temperature freezer prior to opening.   After opening, pipet 1 ml aliquots and store in 
screw-cap microcentrifuge tubes.  Store frozen at -20
0
C in a constant temperature 
freezer until use.  Good until manufacturer‟s control date on container if properly 
stored.  Applied Biosystems, Foster City, CA. 
 
GENETIC ANALYZER BUFFER (10X) WITH EDTA 
Catalogue # 402824.  Proprietary buffer for use with ABI 3100-Avant instrument for 
capillary electrophoresis detection of fluorescent labeled DNA sequences.  Store at 2-
8
0C. Good until manufacturer‟s control date on container if properly stored.  Applied 
Biosystems, Foster City, CA. 
 
GENESCAN 400HD
 TM
 (ROX) SIZE STANDARD 
Catalogue # 402985.  Labeled size standards for use with ABI 3100-Avant instrument 
for capillary electrophoresis detection of fluorescent labeled DNA sequences.  Store at 
2-8
0
C. Alternatively, may be dispensed (40ul) into 1 ml aliquots of HI-Di Formamide 
reagent and stored frozen at -20
0C until use.  Good until manufacturer‟s control date on 
container if properly stored.  Applied Biosystems, Foster City, CA. 
 
3100 POP-4
TM
  PERFORMANCE OPTIMIZED POLYMER 
Catalogue # 4316355.  Gel polymer optimized for use in the 3100-Avant Genetic 
Analyzer for capillary electrophoresis detection of fluorescent labeled DNA sequences.  
Store at 2-8
0C. Good until manufacturer‟s control date on container if properly stored.  
Applied Biosystems, Foster City, CA. 
 
D. QUALITY CONTROL 
 
1. CONTROLS FOR REAGENTS 
The lot number of all critical reagents used in these procedures (as stated in the 
Validation of Reagents, General Policies & Procedures Manual) should be noted in the 
Molecular Biology Reagent logbook when they are put in use.  All new critical reagent 
lots (as stated in the Validation of Reagents, General Policies & Procedures Manual) 
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are tested against the lot currently in use to assess functionality prior to use on clinical 
samples.  
 
2. CONTROL OF AMPLIFIABLE DNA (SAMPLE):  SPECIMEN CONTROL SIZE 
LADDER 
All samples are analyzed using the Specimen Control Size Ladder amplification master 
mix (Size Ladder) to determine the presence of „amplifiable DNA‟.  The Size ladder 
amplification reaction will yield amplicons of 89bp, 96bp, 200bp, 300bp, 400bp, and 
600bp with human DNA specimens.  For a patient result to be considered valid, the 
sample DNA must show peaks in the size ladder control larger than the upper size limit 
of the valid size range result for the particular master mix being evaluated. 
 
3. CONTROLS  FOR T CELL CLONALITY 
Each run of multiplex T cell PCR must include a No Template Control (NTC), a 
Negative Control (Human Polyclonal Genomic DNA) and a Positive Control (Clonal T 
Cell (JRUKAT) Positive Control DNA).  To consider the run valid, the No Template 
Control (NTC) must show no major peaks, in the valid size range for each of the master 
mixes used  (Tubes 1 and 2).  To consider the run valid, the Negative Control must 
show a Gaussian distribution of peaks, and no specific monoclonal peaks, in the valid 
size range for each of the master mixes used (Tubes 1 and 2).  To consider the run 
valid, the positive control must show a specific peak or peaks of the correct size in each 
specific master mix tested.   
 
4. CONTROL FOR ACCURACY AND PRECISION 
Each run shall include the Clonal T Cell (JURKAT) Positive Control DNA in the run.  
This control is evaluated by the Lab Director prior to evaluating patient results.  The 
result for the positive control must fall in the expected control range (expected size in 
bp +/- 5bp) to be considered valid.  These results will be plotted and evaluated monthly 
for any size variation trend.  Each run shall include a negative control (Human 
Polyclonal Genomic DNA). This control is evaluated by the Lab Director prior to 
evaluating patient results.          
 
E. PROCEDURE-STEPWISE 
 
DNA SAMPLE PREPARATION (Qiagen kit procedure for blood and body 
fluids) 
 
1. Remove all blood and body fluid samples for analysis from the refrigerator and 
allow to come to room temperature.  Log them into the DMPL specimen log book 
giving each sample a unique, consecutive identifying number.  This number will be 
used to identify the sample throughout the rest of the procedure.  Centrifuge the 
samples at 3000 RPM for 10 minutes. 
 
2. Prepare a water bath at 560 C.  
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3. Prepare two 1.5 ml screw-cap microcentrifuge tubes per sample.  Label each tube 
with the unique sample identifying number (i.e DMPL#1000 PCR).  Prepare one 
spin column and three 2 ml collection tubes per sample.  Label just the spin column 
with the DMPL unique identifying number.   For each sample prepare final spin 
collection tube by taking a 1.5 ml microcentrifuge tube and cutting off the cap end.  
Do not label any of the collection tubes.  
 
4. Remove sample tubes from centrifuge.  For each blood specimen, open the tube, 
pipet out the plasma , and discard.  Carefully remove the buffy coat cells and place 
into appropriately labeled 1.5 ml screw-cap microcentrifuge tubes.  Add at least an 
equal volume of Buffer EL.   Invert the tube several times until all red cells are 
lysed (sample becomes translucent).   
 
5. For body fluid samples, pipet excess supernatant leaving approximately 200 ul 
residual supernatant in tube.  Proceed to step #7. 
 
6. Centrifuge microcentrifuge tubes for 30 seconds at full speed.  Decant the 
supernatant carefully.  Add sufficient saline to bring the volume left in the sample 
tube to 200ul.  Vortex the tube containing the remaining cells and saline, making 
sure to break up any pellet, prior to continuing with the next step.  
 
7. Perform the following steps to each sample individually.  Add 25ul Proteinase K 
solution to the sample tube and mix well with sample.  Add 200 ul of Buffer AL to 
the sample and immediately mix thoroughly by pulse vortexing for at least 15 
seconds to break up any pellet.   
 
8. Incubate tubes at 560 C for 10 minutes.  Remove from water bath and briefly 
centrifuge to bring all liquid to the bottom.  
 
9. Add 200 ul of absolute ethanol to the sample and mix thoroughly by vortexing.  It is 
normal for a fibrous, white precipitate to form inside the sample mixture.  Briefly 
centrifuge to bring all liquid to the bottom.  
 
10. Place the appropriately labeled QIAamp spin column in a 2 ml collection tube.  
Carefully transfer the entire contents of the sample tube to the spin column 
including any fibrous precipitate that may have formed with the EtOH addition. 
Close the cap on the column.  When all the samples have been processed, place the 
tubes in the microcentrifuge and centrifuge at full speed for 2 minutes until all 
mixtures have passed through the columns.  
 
11. Place each QIAamp spin column in a clean 2 ml collection tube and discard the 
tube containing the filtrate.  Carefully open each QIAamp spin column and add 500 
ul of Buffer AW1.  Close the cap on the column.  When all the samples have buffer 
AW1 and are capped, place the tubes in the microcentrifuge and centrifuge at full 
speed for 2 minutes until the wash solution has passed through all the columns.  
 
12. Place each QIAamp spin column in a clean 2 ml collection tube and discard the 
tube containing the filtrate.  Carefully open each QIAamp spin column and add 500 
ul of Buffer AW2.  Close the cap on the column.  When all the samples have buffer 
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AW2 and are capped, place the tubes in the microcentrifuge and centrifuge at full 
speed for 3 minutes until the wash solution has passed through all the columns. 
 
13. Place the QIAamp spin columns in clean 1.5 ml microcentrifuge tubes originally 
prepared in step 3 and discard the collection tube containing the filtrate.  Add 
reagent water (50 ul for body fluids, 100 ul for blood) to the QIAamp spin column.  
Incubate at room temperature for 5 minutes.  Place the tubes in the microcentrifuge 
and centrifuge at full speed for 2 minutes.  This step elutes the DNA from the 
column. 
 
14. Remove the spin column from the 1.5 ml microcentrifuge collection tube and 
transfer the eluate into the second uniquely labeled 1.5 ml screw capped 
microcentrifuge tube from step 3.  Repeat step #13 and combine eluates. 
 
15. For body fluids that had no visible pellet upon initial centrifugation, the eluate may 
be concentrated by placing the microcentrifuge tube containing the eluate open in a 
heated vacuum oven for 5 minutes.  Evaporate the eluate to approximately 50 ul 
remaining in the tube.  Proceed with PCR analysis. 
 
DNA SAMPLE PREPARATION (Qiagen tissue method) 
 
1. All samples for PCR are labeled with the DMBL ID #.  If sample is fresh frozen 
tissue, place in PCR screw cap tube and proceed to step #8.  If sample is paraffin 
embedded tissue, add 950 ul of xylene to PCR screw cap tube containing the 
paraffin embedded tissue.  Vortex vigorously to dissolve the paraffin.  
 
2. Centrifuge for 2 minutes at maximum speed in Fisher Microcentrifuge to pellet 
tissue. 
 
3. Aspirate xylene using micropipette and repeat steps 1 (except using 500 ul of 
xylene) and 2. Aspirate xylene 
 
4. Add 500ul of absolute ethanol.  Vortex vigorously to remove xylene. 
 
5. Centrifuge for 2 minutes to pellet tissue.  Decant the ethanol. 
 
6. Repeat steps 4 & 5.  Decant the ethanol. 
 
7. Gently dislodge tissue pellet from bottom of tube by inverting or with clean pipet 
tip press pellet onto side of tube.  Dry the tissue pellet in a warm vacuum oven until 
completely dry (approx. 15 min.).   
 
8. Resuspend the tissue pellet in ATL buffer depending on size of tissue pellet.  Add 
180 ul ATL buffer for small pellets, 360ul buffer for larger pellets.  Add 25 ul of 
proteinase K per 180 ul ATL buffer and vortex.   
 
9. Screw cap on tightly and incubate with, shaking at, 560C in a water bath, vortexing 
every 15-20 minutes until tissue is completely dissolved.  Incubate overnight with 
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shaking.  If necessary, add more Proteinase K.  Overnight incubation is absolutely 
essential for paraffin-embedded tissue specimens. 
 
10. Remove tubes from shaking water bath and centrifuge briefly to remove drops from 
inside of tube. 
 
11. Add 200 ul of Buffer AL (per 180 ul of buffer ATL added to the sample) and mix 
by pulse vortexing.  Incubate at 70
0
C for 10 minute.  Briefly centrifuge the tubes to 
remove drops from inside of tube. 
 
12. Add 200 ul of absolute ethanol to the sample and mix thoroughly by vortexing.  It is 
normal for a fibrous, white precipitate to form inside the sample mixture.  Briefly 
centrifuge to bring all liquid to the bottom.  
 
13. Place the appropriately labeled QIAamp spin column in a 2 ml collection tube.  
Carefully transfer the entire contents of the sample tube to the spin column 
including any fibrous precipitate that may have formed with the EtOH addition. 
Close the cap on the column.  When all the samples have been processed, place the 
tubes in the microcentrifuge and centrifuge at full speed for 2 minutes until all 
mixtures have passed through the columns.  
 
14. Place each QIAamp spin column in a clean 2 ml collection tube and discard the 
tube containing the filtrate.  Carefully open each QIAamp spin column and add 500 
ul of Buffer AW1.  Close the cap on the column.  When all the samples have buffer 
AW1 and are capped, place the tubes in the microcentrifuge and centrifuge at full 
speed for 2 minutes until the wash solution has passed through all the columns.  
 
15. Place each QIAamp spin column in a clean 2 ml collection tube and discard the 
tube containing the filtrate.  Carefully open each QIAamp spin column and add 500 
ul of Buffer AW2.  Close the cap on the column.  When all the samples have buffer 
AW2 and are capped, place the tubes in the microcentrifuge and centrifuge at full 
speed for 3 minutes until the wash solution has passed through all the columns. 
 
16. Place the QIAamp spin columns in clean 1.5 ml microcentrifuge tubes originally 
prepared in step 3 and discard the collection tube containing the filtrate.  Add 50 ul 
reagent water, to the QIAamp spin column.  Incubate at room temperature for 5 
minutes.  Place the tubes in the microcentrifuge and centrifuge at full speed for 2 
minutes.  This step elutes the DNA from the column. 
 
17. Remove the spin column from the 1.5 ml microcentrifuge collection tube and 
transfer the eluate into the second uniquely labeled 1.5 ml screw capped 
microcentrifuge tube from step 3.  Repeat step #13 and combine eluates. 
 
18. For tissues that had minimal or no visible pellet upon initial centrifugation, the 
eluate may be concentrated by placing the microcentrifuge tube containing the 
eluate open in a heated vacuum oven for 5 minutes.  Evaporate the eluate to 
approximately 50 ul remaining in the tube.  Proceed with PCR analysis. 
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T CELL MULTIPLEX PCR TESTING 
 
1. Remove the appropriate T Cell Gamma Gene Rearrangement Assay kit master mix 
reagents (tubes T1 and T2) and Size Ladder (SL) master mix reagent and allow to 
thaw in the PCR reagent preparation area.  Remove Kit Negative (Human 
Polyclonal DNA) and Kit Positive control  (Clonal T Cell DNA JURKAT) and 
allow to thaw in the PCR set up area.  
 
2. Prepare T PCR run log and calculate amount of each master mix required to assay 
all controls and patient samples.  Each run must include a No Template Control 
(NTC), a Negative Control (KITNEG) and a Positive Control (KITPOS).  Each 
sample or control requires 25 ul of master mix reagent.  Each sample or control 
requires 0.15 ul of Amplitaq Gold DNA polymerase. 
 
3. Prepare working master mixes in the reagent preparation hood by adding Amplitaq 
Gold enzyme.   For each Master mix reaction, add appropriate stock master mix 
reagent and Amplitaq Gold to labeled working master mix tube and mix well.  Spin 
briefly.  Aliquot 25 ul working master mix per PCR tube color-coded for each 
master mix (T1=Yellow/Brown, T2=Purple, Red= SL) and cap tubes.   
 
4. Add 2.5 ul PCR water to NTC (no template control) control tubes (T1 and T2).  
Add 2.5 ul Kit positive control to the positive control tubes.   Add 2.5 ul Kit 
Negative (Human Polyclonal DNA) control to the Negative control tubes (T1 and 
T2).  Add 2.5 ul of each patient sample to the appropriate master mix tubes as in the 
run log T1, T2, and SL).  Note, the Size Ladder control reaction is run only on 
patient samples. 
 
5. Place tubes in the 9600 Thermal cycler or the 9700 Thermal cylcer to amplify.  The 
9600 is set to run on Method 87.  This method consists of a hold file #80, a cycling 
file #86 and two more hold files #81, and #9.  File 80 runs first as follows: 95
0
C for 
7 min.  This file is followed by file 86 which runs as follows:  94
0
C for 30 seconds, 
55
0
C for 30 seconds, 72
0
C for 60 seconds for 35 cycles.  After the last cycle in file 
#83, the first hold file # 81 holds samples at 72
0
C for 10 minutes and the final hold 
file  #9 holds the samples at 4
0
C until the STOP button is pressed.   The 9700 
Thermal cylcer is set to run the 3100-T-gamma file.  It has the same cycling 
parameters as the Method file #87 in the 9600. 
 
6. When cycling time is over, remove samples from thermal cycler.  You can proceed 
to the next step or store MicroAmp tubes refrigerated until used.  Samples can be 
stored refrigerated for 2 weeks before use in the detection step. 
 
7. Thaw one or more HI-DI Formamide aliquots  (1 ml) and add 40 ul of GENESCAN 
400HD(ROX) size standard to each if not aliquoted together prior to freezing.   Mix 
thoroughly. 
 
8. Prepare one yellow 500 ulmicrocentrifuge tube for each T1 PCR reaction patient or 
control sample tube and label them accordingly. Prepare one purple 500 
ulmicrocentrifuge tube for each T2 PCR reaction patient or control sample tube and 
number them accordingly.  Add 10ul of HI-DI ROX mixture to each tube.  Prepare 
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one red 500 ulmicrocentrifuge tube for each T  PCR patient SL amplification tube 
and add 10ul of HI-DI/ROX mixture to each tube. 
 
9. Add 1 ul of each amplification reaction product for the patient or control to the 
color-coded, labeled tube containing the 10ul of Hi-Di/ROX.  Add 1 ulof  the SL 
reaction for each patient to the color-coded, labeled tube containing 10ul of HI-
DI/ROX mixture. 
 
10. Place tubes in 950C heating block for 2 minutes.  Remove tubes from the heat block 
and immediately place in an ice bath for 5 minutes. 
 
11. Prepare a Plate loading record for the 3100-Avant.  Place either a 96-well or 384-
well plate in the appropriate base and load 10ul of each sample or control as 
indicated in the Plate Record.  
 
12. Prepare fresh 3100 running buffer by adding 2.5 ml GENETIC ANALYZER 
BUFFER (10X) reagent and dilute to 25 ml in a graduated cylinder.  Mix by 
inverting.  It is now ready for use. 
 
13. The 3100-Avant is a 4 capillary instrument and performs 4 injections at one time, 
therefore, all 4 wells of the 'quad' injected must be filled.  Use water or Hi-Di 
Formamide to fill any wells of a 'quad' that will not be used in the run. 
 
14. Cover the plate with the appropriate Plate Septa and top with the Plate Retainer.  
Plate is now ready for loading into 3100-Avant instrument.   
 
15. To load the plate press the 'Tray" button on the front of the 3100-Avant instrument.  
Do not open the doors until the tray cycles and stops.  Open the door and place 
plate in bay 'B' with the notched end facing the rear of the instrument. The tray is 
now loaded into the instrument. 
 
16. Remove the Anode Buffer Reservoir jar and remove old running buffer.  Rinse with 
distilled water.  Add 10 ml of fresh running buffer and replace gently.  Remove 
Cathode Buffer Reservoir, remove Reservoir Septa and pour out old running buffer.  
Rinse with distilled water.  Add 15 ml of fresh running buffer, replace septa and 
replace Cathode buffer reservoir in tray assembly.  Close 3100-Avant doors.  
Instrument is now ready to run.   
 
17. Prior to running a plate on the 3100-Avant, a record of samples to be run must be 
entered into the software.  This is called a Plate Record.  To create Plate Record in 
the 3100-Avant, enter Foundation Data collection software and select PLATE 
MANAGER.   Click on NEW and enter plate name-date in the New Plate Dialog 
Box. Add description if desired.  For Application, choose GeneMapper DMP-01, 
choose appropriate plate type (96 or 384 well), enter Owner and Operator as 
appropriate and click OK.   
 
18. The PLATE EDITOR screen appears next.  Enter specimen ID under the SAMPLE 
NAME box for the correct WELL # as loaded in the plate loading record.   Add 
comment for sample if desired.   
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19. Once all samples are entered into the Plate Record, go to SAMPLE TYPE and 
choose 'Sample' from the drop down menu.  Next go to the SIZE STANDARD 
column, and choose 'GS(400)HD-ROX' as the size standard.  Go to the PANEL 
column and choose 'None'.  Go to the ANALYSIS METHOD column and choose 
'ServiceFrag'.  Go to RESULTS GROUP and choose the appropriate results group 
(i.e. 'Alex results group').  Go to the INSTRUMENT PROTOCOL column and 
choose 'IGH4-29-04'.   Select all the SAMPLE TYPE, SIZE STANDARD, 
PANEL, ANALYSIS METHOD, RESULTS GROUP, and INSTRUMENT 
PROTOCOL columns corresponding to the samples and controls entered in the 
Plate Record.  When so selected, these should appear in blue.  Kit the keys 'Control 
D' to automatically auto-enter the information in all the columns.    
 
20. Click on OK to save the Plate Record.  Use the EDIT button to modify the plate 
record if necessary. 
 
21. Next go to RUN SCHEDULER and double click to open options.  Click on 'FIND 
ALL' and select the correct plate record (it should say 'pending').  Click on the 
image of the instrument tray bay 'B' (which should be yellow) to link the plate in 
the bay to the selected plate record.  The image of bay 'B' will turn green when the 
run record is linked.  In a few seconds, the RUN button (like a PLAY button on a 
tape machine) will become active and turn green.   
 
22. Click on the RUN button to start run.  The following on-screen message will appear 
on the computer screen, 'You are about to start processing plates. OK'.  Click on 
OK to initiate run on 3100-Avant. 
 
23. Go to the RUN SCHEDULER and select RUN VIEW.  Find the run numbers for 
the injections in the plate record being processed.  Note the run numbers on the 
Plate Loading Record for future use in retrieving data in GeneMapper. 
 
24. The instrument function and parameters may be monitored by using the 
INSTRUMENT STATUS screen. 
 
25. Each injection 'quad' takes approximately 35-40 minutes to process.  The 
instrument may be allowed to function during the day or overnight unattended. 
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DATA REDUCTION USING GENEMAPPER SOFTWARE 
 
1. Go to the GeneMapper Program Icon on the desktop and double click to load the 
program.  Enter USER ID and PASSWORD.  From the Project Manager Screen, go 
to the File menu and select ADD SAMPLES TO PROJECT.  Select the appropriate 
data run files and click on ADD TO LIST.  The run files are transferred to the right 
side of the screen.  Click on ADD AND ANALYZE and give project the correct 
name including the run type and date run.  Then click on OK.   
 
2. The GeneMapper program automatically analyzes the run files using a sizing 
function based on the GS(400)HD-ROX size standard included in each sample.   
 
3. If the program encounters a problem with the sizing standard table, it will flag the 
sample with a 'Low Quality' flag (red ball) in the sizing quality (SQ) column.  
Samples with the 'Low Quality' flag are placed at the top of the sample list.  To 
correctly size the sample, go the ANALYSIS menu and click on SIZE MATCH 
EDITOR.  In the Size Match Editor window, click on OVERIDE SQ and click on 
OK.  The sample is then flagged with a blue X in the 'SQI' column.  
 
4. Do the above to all samples with the 'Low Quality' flag.  These samples must now 
be re-analyzed by GeneMapper.  To re-analyze, go the ANALYSIS menu and click 
on ANALYZE.  These samples are now ready for viewing. 
 
5. To view individual run data, select a sample by highlighting it.  Go the ANALYSIS 
menu and click on DISPLAY PLOTS.  This opens the Sample Plots window.   
 
6. For the T PCR, the PANES drop down should be on 2, then click on the "Separate 
Dyes" button.  This displays all of the peaks detected for the 2 colors used in the 
assay.   Master mix T1 is displayed in Black so turn off the colors Blue and Green.  
Master mix T2 is displayed in Green so turn off the colors Blue and Yellow.   In 
both the T1 and T2 the ROX size standard is displayed in red.  The display will 
show all of the peaks detected for the 2 colors used in the assay.   Proceed to  #9. 
 
7. For the Size Ladder control (SL) reactions, use only 2 panes and turn off the green 
and yellow color graphs on the display by clicking on the color buttons.   
 
8. The Size Ladder control (SL) reaction produces 6 peaks of the following sizes in 
normal human DNA samples with sufficient quantity and quality of DNA:  89bp, 
96bp, 200bp, 300bp, 400bp and 600bp.  Using the 400 ROX standard, the 600bp 
size, if present, is seen as 588bp because it is out of the dynamic range of the 
standard curve. 
 
9. Each master mix (T1 and T2) has two size ranges (in bp) where product peaks are 
considered to be significant.  For master mix T1, the valid size ranges are 55 to 
85bp and 155-185bp.  For master mix T2, the valid size ranges are 200 to 235bp 
and 235-270bp.  The T2 multiplex master mix generates the products as two 
distinct size ranges of products and they should not be viewed as a continuum 
within the 200-270 range.  A clonal sample will frequently generate a clonal 
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product in each of these size ranges.  When products are generated in both of these 
size ranges the difference in size of these peaks is approximately 32 base pairs. 
 
10. Analyze the NTC and Negative controls first.  The NTC should give no major 
peaks in the size ranges of interest for any master mix.   The Negative Control 
should show uneven, spiky but  gaussian-like distributions in the valid size ranges.  
 
11. The Positive control should show the control peak sizes listed by the manufacturer.  
These sizes are valid up to +/- 5bp.   
 
12. If the controls are correct, then analyze each patient sample. 
 
13. To save the analysis for review on another computer or to archive, it is necessary to 
save an image of the graphs in the sample plot window.  The same procedure is 
used for the T PCR and the Size Ladder control reaction. 
 
14. In the Sample Plot window, select the correct number of panes and split the dyes.  
Click on the keys Control 'G' to display only the selected sample peaks.  In each 
electrophoretogram of T PCR, select any peaks that are of interest in the valid size 
range for each reaction.  To be considered of interest, peaks found in the valid size 
range of a master mix reaction (T1 and T2) must be at least 3X the median peak 
height of the gaussian distribution of the range. Select no peaks if none are found in 
the valid size ranges of interest.   
 
15.  For the Size Ladder control reaction, only the expected size blue peaks are 
selected.   Select no peaks if none are present where expected.   
 
16. Click on F11 to open Capture Express software window.  Select CAPTURE 
RECTANGULAR AREA to begin capture.  Left click on mouse to begin area 
selection.  Left click again to end capture.  Select SAVE AS JPEG and then click 
on SAVE.  Name image file with correct name and save in appropriate folder.  
Click on DONE to end capture. 
 
17. Save all images for the run by transferring them to a CD using the CD writer.   
 
18. Create results log for run.  Include all peaks of interest for each patient. 
 
F. RESULTS 
 
Expected control results 
The NTC should give no significant, major peaks in the size ranges of interest for any 
master mix.   The Negative Control should show gaussian-like distributions in the valid 
size ranges. The Positive control should show the control peak sizes listed by the 
manufacturer.  These sizes are valid up to +/- 5bp.    
 
Reportable Range 
Samples that contain a clonal population (Positive) in the T1 reaction, should show a 
distinct peak or peaks in the valid size ranges of 55 to 85bp and 155-185bp.  Samples 
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that contain a clonal population (Positive) in the T2 reaction, should show a distinct 
peak or peaks in the valid size ranges of 200 to 235bp and 235-270bp. Samples 
containing polyclonal populations (Negative) should appear as gaussian-like 
distributions in the valid size ranges for each T multiplex PCR reaction. 
 
Normal Values   
Normal samples should contain polyclonal lymphocytic populations and should appear 
as gaussian-like distributions in the valid size ranges for each T multiplex PCR 
reaction.  This is considered a Negative result. 
 
 
Critical Values 
There are no critical values associated with Multiplex PCR T Cell Gamma Gene 
Rearrangement Detection testing. 
 
 
Analytic Interferences 
Analytic interferences in PCR testing occur frequently.  Certain fixative solutions yield 
DNA samples that are not compatible with PCR analysis, specifically B-5 fixative.  
Samples that do not amplify the adequate number of peaks in the Size Ladder control 
reaction may contain interfering substances that do not allow the proper functioning of 
the Taq polymerase enzyme.  If the Size Ladder control reaction does not show the 
appropriate product larger than the upper limit of the valid size range for a reaction, the 
sample result is considered invalid and an answer of No Result is given (see below). 
 
 
Final results are interpreted by the pathologist as follows: 
Negative for T cell clonal peaks, positive for a T cell clonal peaks, or no result when 
the size Ladder control reaction does not show the appropriate size peaks. 
 
G. LIMITATIONS 
 
This Multiplex PCR method detects approximately 90% of T Cell gene rearrangements.  
Failure to detect some rearrangements might be attributable to insufficient homology 
between the T gamma V-region primer sequences and the T gamma V-region gene 
segment found in the rearranged DNA in question.  The assay cannot reliably detect 
less than 1 positive cell per 100 normal cells. 
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ANNEXURE XII (A) 
 
PROFORMA 
 
 
Name:                      Age:  Sex:  S.No. 
 
Address:    Occupation: 
 
 
Presenting Complaint: 
 
 Pruritus   Yes/No 
 
 Skin lesions   Yes/No 
 
 Others    Yes/No 
 
Duration of symptoms (in months) 
 
 Pruritus    
 
 Skin lesions    
 
 Others     
 
Site of involvement- Face/trunk/upper limb/lower limb/genitalia/scalp/palms/soles 
 
Systemic symptoms: Yes/No 
 
    No   Yes  Duration 
Fever 
 
Weight loss 
 
Cough 
 
Pedal edema 
 
Night sweats 
 
Others 
 
Any H/O drug intake-      systemic/topical/native medications 
 
Any immunosuppressants: 
 
Last dose: 
 
 
Examination 
 
 Type of skin lesions: Papules/macules/patch/Erythroderma/ 
                                              Purpuric/tumors/nodules/bullae/ulcer 
 
 Size of involvement: Face/upper limb/lower limb/trunk/palms/ 
              Soles/genitalia/scalp  
 
 Extent of involvement: 
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      Total 
Sites    Yes  No  Sites of involvement 
 
Face 
 
Upper limb 
 
Lower limb 
 
Trunk 
 
Genitalia 
 
Mucosa 
 
GS: Temperature   Pallor 
 
Systemic examination   Yes  No   Size 
 
Lymph node 
 
Cervical 
 
Axillary 
 
Inguinal 
 
Abdomen 
 
Liver 
 
Spleen 
 
Ascites 
 
 
Investigations 
 
1. Haemoglobin 
 
2. TC 
 
3. DC 
 
4. Platelet count 
 
5. ESR 
 
6. Sezary cells 
 
7. Urine 
 
M/E 
 
Albumin 
 
CXR 
 
8. Bilirubin 
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SGOT 
 
SGPT 
 
ALK POS 
 
LDH 
 
9. Serum Creatinine 
 
10. Serum Immune electroporesis 
 
11. HbsAg 
 
12. VDRL 
 
13. HIV 
 
14. HCV 
 
15. Biopsy 
 
a. Liver 
 
b. Lymph node 
 
c. Bone marrow 
 
d. Skin 
 
i) Epidermotropsim 
 
ii) Density of infiltrate 
 
iii) Cellular atypia 
 
iv) Reticular fibroplasia of papillary dermis 
 
v) Intraepidermal atypical lymphocytes 
 
vi) Lymphocytic infiltrate without inflammatory features 
 
vii) No. of elastic cells 
 
viii) No. of mitoses MM 
 
ix) Cellular density (No. of mononuclear cells/10mm) 
 
x) Presence or absence of eosinophilia 
 
xi) Follicular mucinosis 
 
e) Immunophenotype 
 
f) TCR gamma gene rearrangement – Monoclonal/Polyclonal/ Not done 
 
Ultrasound- 
 
Imaging (CT scan, MRI, PET scan)- 
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ANNEXURE XII (B) 
KEY TO MASTER CHART 
 
Variable   variable name      Code  
 
idno      Unique ID                         
name      Name of the patient              
age       Age of the patient                
agdia     Age at diagnosis                  
sex       Sex          [Male=1, Female=2] 
Hnum      Hospital number                   
State     State                             
occ       Occupation                        
pcomp     Presenting complaint 
pru       Pruritus   [0=absent, 1=present] 
sles      Skin lesions  [0=absent, 1=present] 
oth       Others  [0=absent, 1=present] 
dur       duration(in months) 
prud      Pruritus   [0-420 months] 
slesd     Skin lesions  [0-420 months] 
othd      Others   [0-420 months] 
ssym      Systemic symptoms   [0=absent, 1=present]                                          
fev       Fever   [0=absent, 1=present] 
wlos      Weight loss  [0=absent, 1=present] 
cou       Cough   [0=absent, 1=present] 
pedem     Pedaledema  [0=absent, 1=present] 
nsw       Night sweat [0=absent, 1=present] 
othss     Others      [0=absent, 1=present] 
ptre      Past treatment   [0=no, 1=yes] 
imms      Immunosuppressants   [0=no, 1=yes] 
tsles       Type of skin lesions 
pap         Papules   [0=absent, 1=present] 
hyoma       Macules   [0=absent, 1=present] 
pat         Patch     [0=absent, 1=present] 
pla         Plaques   [0=absent, 1=present] 
pur         Purpura   [0=absent, 1=present] 
poi         Poikiloderma  [0=absent, 1=present] 
nod         Nodules   [0=absent, 1=present] 
tum         Tumors    [0=absent, 1=present] 
bul         Bullae    [0=absent, 1=present] 
ulc         Ulcer     [0=absent, 1=present] 
ery         Erythroderma [0=absent, 1=present] 
soi         site of involvement 
fac         Head and neck  [0=absent, 1=present] 
tru         Trunk       [0=absent, 1=present] 
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ulim        Upper limbs [0=absent, 1=present] 
llim        Lower limbs [0=absent, 1=present] 
gen         Genitalia   [0=absent, 1=present] 
pal         Palms       [0=absent, 1=present] 
sol         Soles       [0=absent, 1=present] 
muc         Mucosa      [0=absent, 1=present] 
eoi         Extent of involvement [0=not applicable, 1=1-10%, 2=11-30%, 3=31-
50%, 4=51-80%, 5=81-100%] 
plor        Pallor      [0=absent, 1=present]                                         
lnod        Lymph node  [0=absent, 1=present] 
cer         Cervical lymph node [0=absent, 1=present] 
axi         Axillary lymph node [0=absent, 1=present] 
ing         Inguinal lymph node [0=absent, 1=present] 
liv         Liver enlargement   [0=absent, 1=present] 
spl         Spleen enlargement  [0=absent, 1=present] 
asc         Ascites             [0=absent, 1=present] 
inves       Investigations 
hb          Haemoglobin                                      
wbc         Total WBC  
neu         Neutrophils    
lym         Lymphocytes    
mon         Monocytes     
eos         Eosinophils    
bas         Basophils     
mye         Myelocytes 
memy        Metamyelocytes  
atyl        Atypical lymphocytes [0-absent, 1-present] 
plts        Platelets  
esr         ESR    
urin        Urine   [0=abnormal, 1=normal] 
alb         S.albumin  
bil         S.Bilirubin   
sgot        Aspartate transaminases   
sgpt        Alanine transaminases     
alkp        Alkaline phosphatase      
ldh         Lactate dehydrogenase   
creat       Serum creatinine        
hepb        Hepatitis B   [0=negative, 1=positive] 
hiv         HIV      [0=non reactive, 1=reactive] 
hepc        Hepatitis C    [0=negative, 1=positive] 
vdr         VDRL     [0=non reactive, 1=reactive] 
ana         ANA      [0=negative, 1=positive] 
ebvp        EBV PCR  [0=negative, 1=positive] 
htlv        HTLV-1 antibody  [0=negative, 1=positive] 
sbio        Skin biopsy 
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epi         Epidermotropism    [0=absent, 1=present] 
pmic        Pautrier microabscess [0=absent, 1=present] 
lymt        Lymphocytes tagging at DEJ  [0=absent, 1 present] 
papd        Thickening of papillary dermis [0=absent, 1=present] 
alym        Atypical lymphoid infiltrate [0=absent, 1=present] 
lct         Large cell transformation  [0=absent, 1=present] 
infmm       Inflammatory infiltrates   [0=absent, 1=mild, 2=moderate, 3=dense] 
lich        Lichenoid band like infiltrates   [0=absent, 1=present] 
sder        Superficial dermal [0=absent, 1=present] 
mder        Mid dermal         [0=absent, 1=present] 
dder        Deep reticular dermal    [0=absent, 1=present] 
scut        Subcutis      [0=absent, 1=present] 
lob         Lobular       [0=absent, 1=present] 
sep         Septal        [0=absent, 1=present] 
pvas        Perivascular  [0=absent, 1=present] 
ints        Interstitial  [0=absent, 1=present] 
pfol        Perifollicular [0=absent, 1=present]  
padn        Periadnexal    [0=absent, 1=present] 
pneu        Perineural     [0=absent, 1=present] 
adir        Adipocyte rimming of lymphocytes [0=absent, 1=present] 
minf        Mixed inflammation  [0=absent, 1=present]   
mit         Mitoses   [0=absent, 1=present]   
muci        mucin deposits [0=absent, 1=present]   
haep        Haemophagocytosis    [0=absent, 1=present]   
fatn        Fat necrosis  [0=absent, 1=present]   
fmuc        Follicular mucinosis   [0=absent, 1=present]                              
angin       Angioinvasion          [0=absent, 1=present]   
ihc         Immunohistochemistry 
cd3         CD3         [0=negative, 1=positive] 
cd20        CD20        [0=negative, 1=positive] 
cd30        CD30        [0=negative, 1=positive] 
mib         MIB1 index [0=1-10%, 1=11-30%, 2=31-50%, 3=51-80%, 4= >80%]   
cd4         CD4     [0=negative, 1=positive] 
cd8         CD8     [0=negative, 1=positive] 
cd4c8       CD4 CD8 ratio  [0-not known, 1-CD4>CD8, 2-CD8>CD4, 3-equivocal] 
cd5         CD5        [0=negative, 1=positive] 
cd7         CD7        [0=negative, 1=positive] 
cd45        CD45RO     [0=negative, 1=positive] 
grb         Granzyme B  [0=negative, 1=positive] 
cd56        CD56        [0=negative, 1=positive] 
cd43        CD43        [0=negative, 1=positive] 
cd79a       CD79a       [0=negative, 1=positive] 
tia         TIA 1       [0=negative, 1=positive] 
ebv         EBV LMP 1   [0=negative, 1=positive] 
cd10        CD10        [0=negative, 1=positive] 
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bc2         Bcl-2       [0=negative, 1=positive] 
cd23        CD23        [0=negative, 1=positive] 
alk1        ALK         [0=negative, 1=positive] 
cd138       CD138       [0=negative, 1=positive] 
tcrg        TCR gene rearrangement [0=not applicable, 1=monoclonal, 
2=polyclonal] 
xra         X ray [0=no extracutaneous involvement, 1=extracutaneous 
involvement, 9=not done] 
usg         Ultrasound [0=no extracutaneous involvement, 1=extracutaneous 
involvement, 9=not done]  
cts         CT scan    [0=no extracutaneous involvement, 1=extracutaneous 
involvement, 9=not done] 
mri         MRI scan   [0=no extracutaneous involvement, 1=extracutaneous 
involvement, 9=not done] 
pet         PET scan   [0=no extracutaneous involvement, 1=extracutaneous 
involvement, 9=not done] 
bmar        Bone marrow biopsy [0=no evidence of lymphoma, 1=evidence of 
lymphoma present, 9=not done]                                  
lyno        Lymph node biopsy  [0=no evidence of lymphoma, 1=evidence of 
lymphoma present, 9=not done] 
orgb        Extracutaneous Organ biopsy  [0=no evidence of lymphoma, 
1=evidence of lymphoma present, 9=not done] 
ext         Extracutaneous involvement  [0=absent, 1=present] 
aged        Age at diagnosis  [0-99 years] 
durd        Duration before first diagnosis   [0-400 months] 
msd         Months since diagnosis    [0-400 months] 
trtr        Treatment received     [0-not known, 1-Chemotherapy, 2-PUVA, 3-
Topical steroids, 4-Others] 
stgd        Stage of description  [0=Prior to therapy, 1=recurrence or 
relapse, 2-disease persistent, 3-Improved/cured] 
cat         Category of lymphoma   [0-NA, 1-primary CTCL, 2-secondary CTCL, 3-
primary CBCL, 4-secondary CBCL, 5-precursor neoplasm] 
diag        Diagnosis     [1-MF, 2-CD30 LPD, 3-SPTCL, 4-NKTL, 5-PTCLNOS, 6-
MZBCL, 7-FCL, 8-DLBCLL, 9-DLBCLO, 10-ILBCL, 11-Blastic NKL] 
mfdia       Criteria of Mycosis fungoides  [0-Other dermatoses, 1-MF cannot be 
excluded, 2-possibility of MF, 3-consistent with Mycosis fungoides]                   
mf          Mycosis fungoides subtype    [0-NA, 1-Classical MF, 2-PR, 3-
Folliculotropic MF, 4-GSS, 5-Adult TCL, 6-Sezary syndrome] 
cd30lp      CD30 LPD   [0-NA, 1-LyP, 2-ALCL] 
ptcl        PTCLNOS    [0-NA, 1-Aggress epiderm CD8 TCL, 2-cut alpha/delta 
TCL, 3-small/medium pleomorphic TCL] 
mtstg       T staging MF  [0-NA, 1-T1a, 2-T1b, 3-T2a,4-T2b, 5-T3, 6-T4] 
mfnst       N staging MF  [0-N0, 1-N1, 2-N2, 3-N3, 4-Nx] 
mfmst       M staging MF  [0-M0, 1-M1, 9-NA] 
mfbst       B staging MF  [0-B0, 1-B1, 2-B2, 9-NA] 
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othstg      Staging other than MF   [0-NA, 1-done] 
tstg        T staging   [0-T0, 1-T1a, 2-T1b, 3-T2a, 4-T2b, 5-T2c, 6-T3a, 7-
T3b] 
nstg        N staging   [0-N0, 1-N1, 2-N2, 3-N3, 9=Nx] 
mstg        M staging   [0-M0, 1-M1, 9=status not known] 
mfstg       Final staging  [0-NA, 1-IA, 2-IB, 3-II, 4-IIB, 5-III, 6-IIIA, 7-
IIIB, 8-IVA1, 9-IVA2, 10-IVB] 
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ANNEXURE XII (C) 
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1 63 58 1 Bihar 1 1 0 1 180 
 
0 
2 55 54 2 Tamilnadu 0 1 0 
 
24 
 
0 
3 29 29 2 Tamilnadu 0 1 0 
 
6 
 
0 
4 62 60 2 Jharkhand 1 1 0 6 6 
 
0 
5 22 22 2 Tamilnadu 0 1 1 
 
8 0.3 1 
6 14 14 1 Arunachal Pradesh 1 1 1 12 12 12 1 
7 70 70 1 West Bengal 1 1 0 84 120 
 
0 
8 55 52 1 Jharkhand 1 1 0 120 120 
 
0 
9 44 43 2 Kerala 1 1 0 360 360 
 
0 
10 59 58 2 Bangladesh 0 1 1 0 2 1 0 
11 43 43 1 Jharkhand 0 1 0 
 
84 
 
0 
12 32 30 2 Mizoram 1 1 0 180 180 
 
0 
13 27 27 2 Tamilnadu 1 1 0 18 18 
 
0 
14 44 44 1 Tamilnadu 0 1 0 
 
24 
 
0 
15 22 22 1 West Bengal 1 1 0 6 6 
 
0 
16 2 2 2 Chhattisgarh 1 1 0 2 12 
 
0 
17 41 41 1 Tamilnadu 0 1 0 
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0 
18 53 53 1 Andhra Pradesh 0 1 0 
 
60 
 
0 
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0 
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0 
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1 
22 33 33 2 Tamilnadu 0 1 1 
 
1 2 1 
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1 
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36 
 
0 
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0 
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48 4 0 
36 42 42 1 Tamilnadu 0 1 1 
 
36 24 0 
37 59 59 1 Andhra Pradesh 1 1 0 30 30 
 
0 
38 12 12 1 Tamilnadu 0 1 0 
 
6 
 
0 
39 50 49 2 Jharkhand 1 1 1 24 24 12 1 
40 17 17 2 Karnataka 0 1 1 
 
6 6 1 
41 64 59 2 Kerala 1 1 1 180 180 154 0 
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1 
         
               
      
1 
        
               
               
               
    
1 1 1 
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1 1 
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1 1 
 
1 
        
    
1 
          
               
               
               
      
1 
    
1 
   
               
 
1 1 
 
1 
          
               
      
1 
        1 1 
    
1 
    
0 
   
    
1 1 
          
cd3 cd20 cd30 mib cd4 cd8 cd4c8 cd5 cd7 cd45 grb cd56 
1 
   
1 1 
  
0 
   1 
   
1 0 
 
0 0 
   0 0 1 1 
        1 0 0 2 1 1 1 
    
0 
1 0 
 
2 1 1 
     
0 
1 0 1 
  
1 
  
0 
 
1 1 
1 0 1 3 1 1 1 
 
0 
   1 
   
1 1 1 
 
0 
   1 0 1 2 1 0 
  
1 
   1 0 1 2 1 0 
  
0 
   0 0 1 
         1 
   
1 1 1 
 
0 
   1 
   
1 1 1 
 
0 
   1 
 
1 1 1 0 
  
0 
   1 0 1 1 
        1 0 1 
 
1 1 1 
 
0 
   1 
   
1 0 
  
0 
   1 
   
1 1 1 
 
0 
   1 0 1 1 1 0 1 
     1 
   
1 1 2 
 
0 
   1 
 
0 3 1 0 1 
 
0 
   0 0 
          1 
 
0 
 
1 1 1 
 
0 
   1 0 1 2 1 1 2 0 0 
 
1 1 
1 0 0 3 1 1 2 
   
1 0 
1 0 
 
3 0 1 2 
   
1 0 
1 
  
2 1 1 2 
   
1 0 
1 
 
0 1 1 1 1 
 
0 
   1 
   
1 1 1 
 
0 
   0 0 1 4 
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1 
 
0 3 1 1 1 
 
0 
 
0 0 
1 
  
0 1 0 
  
0 
  
0 
1 
   
1 1 1 
 
0 
   1 0 1 3 1 
       1 
 
0 1 1 1 1 
 
0 
   1 0 1 3 1 0 
  
0 
  
0 
1 
   
1 0 
  
0 
   1 
   
1 1 3 
 
0 
   1 0 
  
1 1 1 
 
0 
   1 
 
1 2 1 0 
      1 
  
1 1 1 1 
 
0 
   1 0 0 1 1 0 1 
 
0 
   1 
  
2 0 1 
    
1 
 1 0 1 
         1 
   
1 1 1 
 
0 
   1 
   
1 1 
  
0 
   1 
   
1 1 1 
 
0 
   1 0 1 0 1 0 
      1 
   
1 1 2 
 
0 
   1 1 0 0 
        1 
   
1 0 
  
0 
   1 0 0 3 1 0 
  
1 
  
0 
1 
 
0 4 1 1 1 
 
0 
 
0 0 
1 0 
 
2 1 0 
       
cd43 cd79a tia ebv cd10 bc2 cd23 alk1 cd138 cd123 
          
          
          
          
          
  
1 1 
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0 
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0 
  
          
          
   
1 
    
1 
 
          
  
1 
       
  
1 
       
  
1 
       
  
1 
       
          
          1 0 
     
0 
  
  
0 
       
          
          
       
0 
  
          
          
          
          
          
       
0 
  
          
          
          
       
0 
  
          
          
          
          
          
        
0 
 
          
          0 
 
0 0 
      
           
tcrg xra usg cts mri pet bmar lyno orgb ext aged durd msd trtr 
2 0 9 9 9 9 9 9 
 
0 51 84 53 2 
1 0 0 9 9 9 9 9 
 
0 53 7 19 2 
 
0 
 
9 9 9 9 9 
 
0 28 6 
  
 
0 0 9 9 9 0 0 
 
0 59 6 18 1 
2 0 0 9 9 9 0 
  
0 21 2 5 3 
 
1 1 1 9 9 0 0 1 1 13 12 
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0 0 9 9 9 9 9 
 
0 60 120 
  1 1 0 1 0 0 9 9 9 0 42 120 40 2 
   
1 9 9 0 9 
 
0 18 300 16 4 
 
0 0 9 9 9 1 9 
 
1 58 1 7 1 
 
0 9 9 9 9 9 9 
 
0 38 60 
  1 0 0 9 9 9 9 9 
 
0 12 220 24 2 
1 0 0 9 9 9 9 9 
 
0 25 18 
  
 
0 0 9 9 9 9 9 
 
0 43 9 
  
 
9 9 9 9 9 9 9 
 
0 21 12 
  
 
0 9 9 9 9 9 9 
 
0 1 12 
  2 0 0 0 9 9 9 9 
 
0 26 180 
  
  
9 9 9 9 9 9 
 
0 48 60 
  
 
0 9 9 9 9 0 9 
 
0 65 24 45 1 
 
0 9 9 9 9 9 9 
 
0 4 24 14 3 
 
0 9 9 9 1 1 0 
 
1 50 60 13 1 
 
0 1 9 9 9 1 
  
1 33 1 
  1 0 0 9 9 9 1 9 
 
0 42 12 
  
 
0 0 9 9 9 9 9 
 
0 10 204 6 2 
 
0 0 0 9 0 0 
  
0 26 84 
  
 
0 
 
0 0 9 0 
 
0 0 49 0.5 
  
 
0 0 0 9 9 0 9 
 
0 18 6 
  2 0 0 9 9 9 9 9 
 
0 5 96 
  1 0 0 9 9 9 9 9 
 
0 24 72 
  
 
1 1 1 1 1 0 9 1 1 45 0.5 6 1 
 
0 0 
 
0 9 0 
  
0 40 5 
  
  
0 9 9 9 0 1 
 
1 20 72 
  
 
0 0 9 9 9 9 9 
 
0 66 96 
  
 
0 0 9 0 9 0 9 9 0 40 12 1 
 
 
0 0 9 9 9 0 9 9 0 58 48 10 1 
1 0 0 9 9 9 0 9 
 
0 39 36 
  2 
  
0 0 9 9 9 
 
0 56 18 4 2 
 
0 9 9 9 9 9 
  
0 12 6 
  
 
0 0 9 9 9 0 9 
 
0 47 24 10 2 
 
9 0 9 9 9 9 9 
 
0 16 6 
  
 
0 0 9 9 9 9 9 
 
0 53 72 53 1 
 
0 0 9 9 9 0 9 
 
0 76 6 
  
  
0 
   
0 9 
 
0 19 8 43 1 
 
0 0 9 9 9 0 9 
 
0 39 4 65 1 
1 9 9 9 9 9 9 9 
 
0 13 12 
  2 9 9 9 9 9 0 0 
 
0 26 24 
  
 
0 0 9 9 9 9 9 
 
0 18 180 6 
 
  
1 
   
1 
  
1 54 12 12 4 
1 0 
 
0 
     
0 51 72 64 2 
 
0 0 0 
  
1 9 
 
1 65 6 68 4 
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1 0 0 9 9 9 0 9 
 
0 72 108 18 2 
 
1 0 1 
  
0 1 9 1 17 180 
  
 
0 
 
9 9 9 0 0 0 0 52 3 
  
 
0 0 0 9 9 1 
 
0 0 6 400 48 4 
 
stgd cat diag mfdia mf cd30lp lyp mtstg mfnst mfmst mfbst othstg tstg nstg mstg mfstg 
2 1 1 1 
   
3 0 0 0 
    
2 
2 1 1 3 1 
  
3 0 0 0 
    
2 
0 1 2 
  
1 
     
1 5 0 0 2 
3 1 3 
        
1 7 1 0 4 
2 1 3 
         
6 9 0 4 
0 2 4 
        
1 7 3 1 10 
0 1 1 3 1 
  
5 0 0 0 
    
4 
3 1 1 
 
1 
  
3 0 0 0 
    
2 
2 1 1 2 1 
  
5 4 0 0 
    
4 
1 2 2 
  
2 
     
1 7 1 0 4 
0 1 2 
  
1 0 
     
7 0 0 4 
3 1 1 2 1 
  
3 0 0 0 
    
2 
 
1 1 1 1 
  
4 0 0 0 
    
2 
0 1 2 
  
1 2 
     
1 0 0 1 
0 1 2 
  
1 1 
     
4 0 0 2 
0 1 2 
  
1 
      
7 0 0 4 
0 1 1 1 
   
3 0 0 0 
    
2 
 
1 1 3 1 
  
3 0 0 0 
    
2 
1 1 2 
  
2 
      
7 9 0 4 
2 1 1 1 
   
3 0 0 0 
    
2 
1 1 1 3 1 
  
6 1 0 1 
    
7 
 
4 12 
         
6 9 1 
 0 1 1 1 1 
  
5 4 9 1 
    
4 
1 1 2 
  
1 4 
     
7 0 0 4 
0 1 3 
         
7 0 0 4 
0 1 3 
         
4 0 9 
 0 1 3 
         
7 0 0 4 
 
1 1 1 
   
3 4 0 0 
    
2 
0 1 1 1 1 
  
3 0 0 0 
    
2 
1 2 2 
  
2 
     
1 6 1 1 
 0 1 5 
         
7 0 0 
 0 1 1 3 1 
  
6 3 0 0 
    
9 
0 1 1 2 1 
  
3 0 0 0 
    
2 
0 1 2 
  
2 
     
1 4 9 0 
 1 1 1 
 
1 
  
5 0 0 0 
    
4 
0 1 2 
  
1 2 
    
1 3 0 0 4 
3 1 1 1 1 
  
4 0 0 0 
    
2 
 
1 1 1 
   
2 0 0 0 
    
1 
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2 1 1 3 1 
  
4 0 0 0 
    
2 
 
1 2 
  
1 0 
     
6 0 0 4 
1 1 1 3 1 
  
4 0 0 0 
    
2 
0 1 5 
         
7 0 0 4 
1 1 3 
         
6 0 0 2 
1 1 2 
  
2 
      
3 0 0 2 
0 1 1 1 1 
  
3 0 0 0 
    
2 
0 1 1 3 1 
  
3 0 0 0 
    
2 
0 1 1 2 1 
  
3 0 0 0 
    
2 
2 2 5 
         
7 9 0 
 3 1 1 2 1 
  
3 0 0 0 
    
2 
1 3 9 
         
4 0 1 10 
3 1 1 3 1 
  
1 0 0 0 
    
1 
0 2 5 
        
1 7 3 0 9 
0 1 5 
         
1 0 0 1 
2 1 1 3 1 
  
4 0 0 1 
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